var docs;if (!docs) docs =[]; docs["51"]={"5100":"<p><b>Title</b> CycloSPORINE (Systemic) / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased incidence of nephrotoxic effects of cyclosporine if amphotericin B is initiated or the dose is increased. Newer amphotericin formulations (ie, lipid complex, liposomal, cholesteryl sulfate complex) should be safer options than the conventional amphotericin formulation.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> A study in 47 bone marrow transplant patients showed a twofold to threefold increase in serum creatinine concentrations within 5 days in 80% of patients receiving both cyclosporine and amphotericin B; whereas only 38% of the patients receiving cyclosporine without amphotericin B showed a doubling of serum creatinine within 14-30 days.<sup>1</sup> Other concomitant medications affecting renal function being received in these patients likely had an impact on the data. Both products possess nephrotoxic potential, and whether the effects of combined therapy are additive, synergistic, or otherwise is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kennedy MS, Deeg HJ, Siegel M, et al, “Acute Renal Toxicity With Combined Use of Amphotericin B and Cyclosporine After Marrow Transplantation,” <i>Transplantation</i>, 1983, 35(3):211-5.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5101":"<p><b>Title</b> CycloSPORINE (Systemic) / Androgens</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential severity of this interaction, consideration should be given to avoiding the concomitant use of androgens and cyclosporine. Monitor serum cyclosporine concentrations, and for signs and symptoms of renal and hepatic toxicity, in patients receiving concomitant androgens and cyclosporine. Cyclosporine dosage reductions may be necessary.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Danazol*, Fluoxymesterone, Mesterolone, MethylTESTOSTERone*, Nandrolone, Oxandrolone, Oxymetholone, Testosterone</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum cyclosporine concentrations were increased two to threefold in a 15-year-old female within about 2 weeks of initiating danazol (200 mg twice daily).<sup>1</sup> This occurred in spite of a 29% reduction in cyclosporine dosage. Similar cases have been reported.<sup>2,3</sup> Methyltestosterone has been reported to cause significant increases in serum cyclosporine concentrations, accompanied by increases in serum creatinine, bilirubin, and ALT.<sup>4</sup> The mechanism of these interactions is unknown. They may be related to decreased hepatic metabolism of cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ross WB, Roberts D, Griffin PJ, et al, “Cyclosporine Interaction With Danazol and Norethisterone,” <i>Lancet</i>, 1986, i:330.</p>\n<p>2. Blatt J, Howrie D, Orlando S, et al, “Interaction Between Cyclosporine and Danazol in a Pediatric Patient,” <i>J Ped Hematol/Oncol</i>, 1996, 18:95.</p>\n<p>3. Koneru B, Hartner C, Iwatsuki S, et al, “Effect of Danazol on Cyclosporine Pharmacokinetics,” <i>Transplantation</i>, 1988, 45:1001.</p>\n<p>4. Moller BB and Ekelund B, “Toxicity of Cyclosporine During Treatment With Androgens,” <i>N Engl J Med</i>, 1985, 313:1416.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5102":"<p><b>Title</b> CycloSPORINE (Systemic) / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No additional action required beyond standard monitoring of renal function and serum potassium that accompanies routine cyclosporine and angiotensin-converting enzyme inhibitor use.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Acute renal failure developed in 4 cyclosporine-treated kidney-transplant patients within several days to weeks of initiating enalapril therapy.<sup>1,2</sup> In all cases, rejection and renal artery stenosis were ruled out, and renal function improved after discontinuation of enalapril and cyclosporine dose reduction. Loop diuretic therapy was coprescribed to all patients and may have contributed to some of the effects.<sup>3</sup> <br><br>In contrast, numerous clinical trials have evaluated the use of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension in patients receiving cyclosporine.<sup>4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Some trials report small decreases in renal function<sup>4,15</sup> or increases in hyperkalemia<sup>4,7,9,11</sup> when ACE inhibitor therapy was compared with other antihypertensive therapy. However, most trials report no change in renal function,<sup>5,7,8,11,12,13,14,16</sup> and a number of studies describe a decrease in proteinuria with ACE inhibitor use.<sup>4,6,9</sup> Treatment guidelines for the management of hypertension in kidney transplant recipients suggest the use of an ACE inhibitor over other antihypertensive therapy in the presence of proteinuria, although the effect on patient and/or graft survival is unknonwn.<sup>18</sup> <br><br>It is proposed that the possible afferent arteriole vasoconstriction by cyclosporine combined with the efferent arteriole dilation by an ACE inhibitor may result in a marked reduction in renal blood flow leading to acute kidney injury. However, the majority of clinical trial evidence suggests that these agents can be safely combined. Monitoring of renal function and serum potassium should still be performed, as is routinely done with either agent alone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Murray BM, Venuto RC, Kohli R, Cunningham EE. Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine. <i>Am J Kidney Dis</i>. 1990;16(1):66-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2368707\">[PubMed 2368707]</a></p>\n<p>2. Garcia TM, da Costa JA, Costa RS, Ferraz AS. Acute tubular renal necrosis in kidney transplant patients treated with enalapril. <i>Ren Fail</i>. 1994;16(3):419-423. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8059025\">[PubMed 8059025]</a></p>\n<p>3. Funck-Brentano C, Chatellier G, and Alexandre JM. Reversible renal failure after combined treatment with enalapril and furosemide in a patient with congestive heart failure. <i>Br Heart J</i>. 1986;55(6):596-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3013264\">[PubMed 3013264]</a></p>\n<p>4. Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. <i>Clin Transplant</i>. 2007;21(2):277-284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17425758\">[PubMed 17425758]</a></p>\n<p>5. Suwelack B, Kobelt V, Erfmann M, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. <i>Transpl Int</i>. 2003;16(5):313-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12759722\">[PubMed 12759722]</a></p>\n<p>6. Martienz-Castelao A, Hueso M, Sanz V, et al. Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. <i>Transplant Proc</i>. 2002;34(1):403-406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11959345\">[PubMed 11959345]</a></p>\n<p>7. Midtvedt K, Ihlen H, Hartmann A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. <i>Transplantation</i>. 2001;72(1):107-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11468543\">[PubMed 11468543]</a></p>\n<p>8. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. <i>Nephrol Dial Transplant</i>. 2001;16(5):1034-1037. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11328912\">[PubMed 11328912]</a></p>\n<p>9. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. <i>Kidney Int Suppl</i>. 1998;68:S130-S134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9839297\">[PubMed 9839297]</a></p>\n<p>10. Grekas D, Dioudis C, Kalevrosoglou I, Alivanis P, Derveniotis V, Tourkantonis A. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors. <i>Kidney Int Suppl</i>. 1996;55:S97-S100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8743523\">[PubMed 8743523]</a></p>\n<p>11. Brozena SC, Johnson MR, Ventura H, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trial. <i>J Am Coll Cardiol</i>. 1996;27(7):1707-1712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8636558\">[PubMed 8636558]</a></p>\n<p>12. Hannedouche TP, Natov S, Boitard C, Lacour B, Grunfeld JP. Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes. <i>Nephrol Dial Transplant</i>. 1996;11(4):673-678. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8671857\">[PubMed 8671857]</a></p>\n<p>13. Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated allograft recipients. <i>Hypertension</i>. 1995;26(3):436-444. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7649579\">[PubMed 7649579]</a></p>\n<p>14. van der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? <i>Hypertension</i>. 1995;25(1):77-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7843758\">[PubMed 7843758]</a></p>\n<p>15. Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. <i>J Am Soc Nephrol</i>. 1993;3(9):1570-1574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8507812\">[PubMed 8507812]</a></p>\n<p>16. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. <i>Kidney Int</i>. 1993;43(2):419-425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8382753\">[PubMed 8382753]</a></p>\n<p>17. Hartmann A, Schwietzer G, Stratmann D, Kaltenbach M, Kober G. Effects of nitrendipine and lisinopril on blood pressure and sodium excretion in ciclosporin-associated hypertension after heart transplantation. <i>Cardiology</i>. 1993;83(3):141-149. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8281528\">[PubMed 8281528]</a></p>\n<p>18. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009;9(suppl 3):S1-S155. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19845597\">[PubMed 19845597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5103":"<p><b>Title</b> CycloSPORINE (Systemic) / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nephrotoxic effects if cyclosporine and an aminoglycoside are used concomitantly.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic)*, Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concomitant administration of cyclosporine, gentamicin, and lincomycin in renal transplant patients showed a significantly greater incidence of nephrotoxicity than when the cyclosporine was coadministered with ampicillin, ceftazidime, and lincomycin (67% versus 5%).<sup>1</sup> This data has been upheld in other cyclosporine patient reports using gentamicin and tobramycin.<sup>2,3</sup> Animal studies further support this interaction.<sup>4</sup> The mechanism of this interaction is unknown, but may be related to additive or synergistic nephrotoxic effects of the individual agents. Careful monitoring of the patient's renal function (as well as serum concentrations of both cyclosporine and aminoglycosides) can help manage potential toxicity.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Termeer A, Hoitsma AJ, and Koene RA, “Severe Nephrotoxicity Caused by the Combined Use of Gentamicin and Cyclosporine in Renal Allograft Recipients,” <i>Transplantation</i>, 1986, 42(2):220-1.</p>\n<p>2. Hows JM, Palmer S, Want S, et al, “Serum Levels of Cyclosporin A and Nephrotoxicity in Bone Marrow Transplant Patients,” <i>Lancet</i>, 1981, 2(8238):145-6.</p>\n<p>3. Morales JM, Andres A, Prieto C, et al, “Reversible Acute Renal Toxicity by Toxic Synergic Effect Between Gentamicin and Cyclosporine,” <i>Clin Nephrol</i>, 1988, 29(5):272.</p>\n<p>4. Whiting PH and Simpson JG, “The Enhancement of Cyclosporine A-Induced Nephrotoxicity by Gentamicin,” <i>Biochem Pharmacol</i>, 1983, 32(13):2025-8.</p>\n<p>5. Chandrasekar PH and Cronin SM, “Nephrotoxicity in Bone Marrow Transplant Recipients Receiving Aminoglycoside Alone,” <i>J Antimicrob Chemother</i>, 1991, 27(6):845-9.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5105":"<p><b>Title</b> CycloSPORINE (Systemic) / Sulfonamide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if a sulfonamide derivative is initiated/dose increased, or increased serum concentrations/effects if a sulfonamide derivative is discontinued/dose decreased. Monitor for increased incidence of nephrotoxicity during concomitant therapy.</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE*, Sulfadoxine, Sulfamethoxazole*, SulfiSOXAZOLE</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum cyclosporine concentrations were decreased to undetectable values, associated with heart transplant rejection, in a patient within 7 days of initiating IV sulfadimidine (2 mg 4 times/day) and trimethoprim (300-500 mg twice daily).<sup>1</sup> Switching the antibiotic therapy to oral was accompanied by a near normalization of serum cyclosporine concentrations. The same authors report similar events with 4 other patients.<sup>2</sup> Oral sulfadiazine was reported to increase the serum concentrations of cyclosporine in 3 heart transplant patients.<sup>3</sup> In contrast, a 132-patient study showed no pharmacokinetic effects on cyclosporine by co-trimoxazole.<sup>4</sup> Some reports have described an increase in serum creatinine during concomitant use of cyclosporine and a sulfonamide or trimethoprim.<sup>5,6,7</sup> The mechanism of these various effects is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wallwork J, McGregor CG, Wells FC, et al, “Cyclosporine and Intravenous Sulphadimidine and Trimethoprim Therapy,” <i>Lancet</i>, 1983, i:336-7.</p>\n<p>2. Jones DK, Hakim M, Wallwork J, et al, “Serious Interaction Between Cyclosporine A and Sulphadimidine,” <i>Br Med J</i>, 1986, 292:728-9.</p>\n<p>3. Spes CH, Angermann CE, Stempfle HU, et al, “Sulfadiazine Therapy for Toxoplasmosis in Heart Transplant Recipients Decreases Cyclosporine Concentration,” <i>Clin Investig</i>, 1992, 70(9):752-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1450627\">[PubMed 1450627]</a></p>\n<p>4. Maki DG, Fox BC, Kuntz J, et al, “A Prospective, Randomized, Double-Blind Study of Trimethoprim-Sulphamethoxazole for Prophylaxis of Infection in Renal Transplantation. Side Effects of Trimethoprim-Sulphamethoxazole Interaction With Cyclosporine,” <i>J Lab Clin Med</i>, 1992, 119:11-24.</p>\n<p>5. Ringden O, Myrenfors P, Klintmalm G, et al, “Nephrotoxicity by Co-trimoxazole and Cyclosporine in Transplanted Patients,” <i>Lancet</i>, 1984, i:1016-7.</p>\n<p>6. Thompson JF, Chalmers DH, Hunnisett AG, et al, “Nephrotoxicity of Trimethoprim and Co-trimoxazole in Renal Allograft Recipients Treated With Cyclosporine,” <i>Transplantation</i>, 1983, 36:204-6.</p>\n<p>7. Nyberg G, Gabel H, Althoff P, et al, “Adverse Effect of Trimethoprim on Kidney Function in Renal Transplant Patients,” <i>Lancet</i>, 1984, i:394-5.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5106":"<p><b>Title</b> Sulfonylureas / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may diminish the therapeutic effect of Sulfonylureas. Sulfonylureas may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for increased concentrations/effects of cyclosporine and reduced therapeutic impact of sulfonylurea antidiabetic agents during concomitant therapy.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> In a retrospective review of records from 6 renal transplant recipients, serum concentrations of cyclosporine were on average 57% higher after patients began treatment with glyburide.<sup>1</sup> However, the methodology used to assess cyclosporine concentrations before and during glyburide treatment, including blood draw timing, are not described. Another report describes the need to decrease the cyclosporine dose by 20% to 30% in 2 patients following the addition of glipizide to their therapeutic regimens.<sup>2</sup> However, a clinical study of 11 renal transplant patients found no effect on cyclosporine maximum concentration, minimum concentration, or AUC when glipizide was added to stable cyclosporine regimens.<sup>3</sup> <br><br>In addition to possible pharmacokinetic interactions, some animal data suggest that cyclosporine and sulfonylurea antidiabetic agents may have opposing effects on glucose/glycogen metabolism and insulin/glucagon regulation,<sup>4,5,6</sup> but studies in humans have not been pursued.<br><br>The mechanism of any possible pharmacokinetic interaction between these agents is unknown. An in vitro study suggested that glyburide inhibited P-glycoprotein, a transporter involved in cyclosporine disposition, but the clinical importance of such inhibition has not been established.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Islam SI, Masuda QN, Bolaji OO, et al, “Possible Interaction Between Cyclosporine and Glibenclamide in Post-Transplant Diabetic Patients,” <i>Ther Drug Monit</i>, 1996, 18:624-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8885130\">[PubMed 8885130]</a></p>\n<p>2. Chidester PD and Connito DJ, “Interaction Between Glipizide and Cyclosporine: Report of Two Cases,” <i>Transplant Proc</i>, 1993, 25:2136-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8470294\">[PubMed 8470294]</a></p>\n<p>3. Sagedal S, Asberg A, Hartmann A, et al, “Glipizide Treatment of Post-Transplant Diabetes Does Not Interfere With Cyclosporine Pharmacokinetics in Renal Allograft Recipients,” <i>Clin Transplant</i>, 1998, 12(6):553-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9850449\">[PubMed 9850449]</a></p>\n<p>4. Bartlett ST, Gillison SL and Curry DL, “Cyclosporine Inhibition of Insulin Secretion: Effect of Tolbutamide and Extracellular Calcium Concentration,” <i>Transplant Proc</i>, 1990, 22(2):749-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2183445\">[PubMed 2183445]</a></p>\n<p>5. Hopps V, Galione A, Vetri P, et al, “Glybenclamide and Cyclosporine A: An Interaction on Glucose Metabolism,” <i>Transplant Proc</i>, 1988, 20(3 Suppl 3):979-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3133859\">[PubMed 3133859]</a></p>\n<p>6. Pollock SH, Reichbaum MI, Collier BH, et al, “Inhibitory Effect of Cyclosporine A on the Activity of Oral Hypoglycemic Agents in Rats,” <i>J Pharmacol Exp Ther</i>, 1991, 258(1):8-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1906541\">[PubMed 1906541]</a></p>\n<p>7. Golstein PE, Boom A, van Geffel J, et al, “P-Glycoprotein Inhibition by Glibenclamide and Related Compounds,” <i>Pflugers Arch</i>, 1999, 437(5):652-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10087141\">[PubMed 10087141]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5107":"<p><b>Title</b> CycloSPORINE (Systemic) / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Empiric reductions in cyclosporine dosage appear warranted with the use of ketoconazole and voriconazole. Reductions in the range of 50% to 80% have been suggested, with subsequent close monitoring of cyclosporine concentrations to further define dose requirement. It is likely that a dosage adjustment will also be needed if cyclosporine is used with other azole antifungals; minimally, close monitoring of cyclosporine serum concentrations will be necessary whenever starting, stopping, or adjusting therapy with an azole antifungal. Monitor for toxic effects of cyclosporine with concomitant use of these products.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Itraconazole*, Ketoconazole (Systemic)*, Posaconazole*, Voriconazole*<br><b>Exceptions</b> Fluconazole, Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum cyclosporine concentrations have been reported to increase as much as tenfold in transplant patients following the initiation of oral ketoconazole.<sup>1,2,3</sup> In some of these cases, patient cyclosporine dosages were empirically reduced by as much as 85% to account for this interaction. These changes have been implemented, at times, to exploit the interaction for its cost-saving effects.<sup>4</sup> In a randomized, double-blind, placebo-controlled study in kidney transplant recipients who were receiving cyclosporine, the addition of voriconazole resulted in a 1.7-fold increase in cyclosporine AUC and a nearly 2.5-fold increase in minimum plasma cyclosporine concentration (no significant change in maximum plasma concentration).<sup>5</sup> Additionally, more adverse events were reported with the voriconazole-cyclosporine combination than with placebo-cyclosporine. Lower, but still significant, increases in serum cyclosporine concentrations (two to threefold) have been reported in conjunction with itraconazole therapy.<sup>6,7,8</sup> A 65% increase in cyclosporine concentrations has been reported with IV miconazole.<sup>9</sup> Additionally, a 35% increase in cyclosporine concentrations requiring cyclosporine dosage reductions up to 29% by day 14 of therapy were reported with concomitant posaconazole use.<sup>10,11,12</sup> Posaconazole prescribing information recommends a 25% decrease in cyclosporine dose with the initiation of posaconazole;<sup>11</sup> although careful monitoring without empiric dose adjustment has also been suggested.<sup>12</sup> <br><br>These antifungals are known inhibitors of CYP3A4,<sup>13</sup> which is involved in the metabolism of cyclosporine. Additionally, these antifungals are substrates of the drug transporter p-glycoprotein, and at least ketoconazole and itraconazole are also inhibitors of p-glycoprotein activity,<sup>13</sup> which is important considering that p-glycoprotein transports cyclosporine and is an important determinant of its absorption, distribution, and elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. First MR, Schroeder TJ, Weiskittel P, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. <i>Lancet</i>. 1989;2(8673):1198-1201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2572912\">[PubMed 2572912]</a></p>\n<p>2. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. <i>Transplantation</i>. 1991;51(2):365-370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1994529\">[PubMed 1994529]</a></p>\n<p>3. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. <i>Transplantation</i>. 1993;55(5):1000-1004. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8497871\">[PubMed 8497871]</a></p>\n<p>4. el-Husseini A, el-Basuony F, Mahmoud I, et al. Co-administration of cyclosporine and ketoconazole in idiopathic childhood nephrosis. <i>Pediatr Nephrol</i>. 2004;19(9):976-981. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15241676\">[PubMed 15241676]</a></p>\n<p>5. Romero AJ, Le Pogamp P, Nilsson LG, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. <i>Clin Pharmacol Ther</i>. 2002;71(4):226-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11956505\">[PubMed 11956505]</a></p>\n<p>6. Kwan JT, Foxall PJ, Davidson DG, et al. Interaction of cyclosporin and itraconazole. <i>Lancet</i>. 1987;2(8553):282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2886752\">[PubMed 2886752]</a></p>\n<p>7. Trenk D, Brett W, Jahnchen E, et al. Time course of cyclosporin: itraconazole interaction. <i>Lancet</i>. 1987;2(8571):1335-1336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2890938\">[PubMed 2890938]</a></p>\n<p>8. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. <i>Ann Intern Med</i>. 1990;113(4):327-329. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2165371\">[PubMed 2165371]</a> </p>\n<p>9. Horton CM, Freeman CD, Nolan PE, et al. Cyclosporine interactions with miconazole and other azole-antimycotics: a case report and review of the literature. <i>J Heart Lung Transplant</i>. 1992;11(6):1127-1132. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1457436\">[PubMed 1457436]</a> </p>\n<p>10. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. <i>Pharmacotherapy</i>. 2007;27(6):825-834. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17542765\">[PubMed 17542765]</a></p>\n<p>11. Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck and Co., Inc; September 2016.</p>\n<p>12. Sanchez-Ortega I, Vazquez L, Montes C, et al. Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. <i>Antimicrob Agents Chemother</i>. 2012;56(12):6422-6424. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23027192\">[PubMed 23027192]</a></p>\n<p>13. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. <i>Pharmacotherapy</i>. 2006;26(12):1730-1744. [Pub Med 17125435]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5108":"<p><b>Title</b> Fibric Acid Derivatives / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risks for renal dysfunction and decreased cyclosporine concentrations, careful consideration of the risks and benefits should be undertaken prior to use of this combination. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary.</p>\n<div>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> Several mostly observational or uncontrolled studies of fibrates post-transplant (almost exclusively cardiac transplant; 1 study included pooled analysis with renal and cadiac transplant) patients receiving cyclosporine have described decreased cyclosporine concentrations following initiation of fibrate therapy.<sup>1,2,3,4</sup> Fenofibrate,<sup>1,2</sup> gemfibrozil,<sup>3</sup> and bezafibrate<sup>4</sup> have all been implicated in such reports. The decrease in cyclosporine concentations have generally been modest, averaging between 17% and 27%, though larger individual decreases have been reported. In contrast to these reports, several reports from mostly post-kidney transplant patients have concluded that fibrate therapy does not significantly alter cyclosporine concentrations.<sup>1,5,6,7,8,9</sup> In one report of 11 renal transplant patients on both fenofibrate and cyclosporine, a decrease in cyclosporine concentration was observed in 8/11 patients (by 2-59%), but the overall change in mean cyclosporine concentrations was only a nonsignificant 9% decrease (range of +42% to -59%).<sup>1</sup> Further, 2 controlled clinical studies (one with gemfibrozil in kidney transplant recipients<sup>5</sup> and one with fenofibrate in heart transplant recipients<sup>6</sup>) have failed to find any evidence of a significant pharmacokinetic interaction between fibrates and cyclosporine. In addition to these reports of no interaction, one case report even describes a substantial increase in cyclosporine concentrations in a post-kidney transplant patient following the addition bezafibrate.<sup>10</sup><br><br>The mechanism and significance of this possible interaction are unclear. The narrow therapeutic index of cyclosporine and the association of possible acute organ rejection with decreased cyclosporine concentrations<sup>2</sup> imply a certain clinical significance to this possible interaction, particularly in heart transplant patients. Though the specific mechanism of this interaction is not known, possible explanations have included decreased cyclosporine binding to blood lipids and decreased bioavailability.<sup>11,12</sup><br><br>Several controlled and uncontrolled studies of patients receiving cyclosporine have noted reversible renal dysfunction associated with initiation of fibrate therapy.<sup>1,2,4,6,7,8,9</sup> Reported mean increases in serum creatinine have varied from 10% to 88%, and increased creatinines were noted within about 1 week to several months after the addition of fibrate therapy. Of note, gemfibrozil appears to be much less likely to be associated with renal dysfunction than the other fibrates.<sup>6,8</sup> Whether or not such reports of nephrotoxicity are the result of an interaction between a fibrate and cyclosporine (potentially nephrotoxic on its own) is uncertain, despite warnings to this effect. Of note, renal dysfunction associated with the fibrates independent of cyclosporine use has been reported.<sup>1,13</sup> A review of several fibrate studies evaluating renal function reported serum creatinine increases associated with fibrate use in both post-transplant and non-transplant patients and in both cyclosporine recipients and non-cyclosporine recipients.<sup>1</sup> This review describes a range of serum creatinine increases of 8-18% for fenofibrate and 8-40% for bezafibrate, with gemfibrozil being free from any consistent effect on serum creatinine.<br><br>The mechanism for fibrate-related increases in serum creatinine is not clear. Fibrates have been associated with both directly toxic effects on the kidney as well as mostly functional changes (vs. directly toxic/structural effects).<sup>9,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Broeders N, Knoop C, Antoine M, et al, “Fibrate-Induced Increase in Blood Urea and Creatinine: Is Gemfibrozil the Only Innocuous Agent?,” <i>Nephrol Dial Transplant</i>, 2000, 15:1993-9.</p>\n<p>2. Boissonnat P, Salen P, Guidollet J, et al, “The Long-Term Effects of the Lipid-Lowering Agent Fenofibrate in Hyperlipidemic Heart Transplant Recipients,” <i>Transplantation</i>, 1994, 58:245-7.</p>\n<p>3. Fehrman-Ekholm I, Jogestrand T, Angelin B, “Decreased Cyclosporine Levels During Gemfibrozil Treatment of Hyperlipidemia After Kidney Transplantation,” <i>Nephron</i>, 1996, 72(3):483.</p>\n<p>4. Barbir M, Hunt B, Kushwaha S, et al, “Maxepa Versus Bezafibrate in Hyperlipidemic Cardiac Transplant Recipients,” <i>Am J Cardiol</i>, 1992, 70(20):1596-601.</p>\n<p>5. Pisanti N, Stanziale P, Imperatore P, et al, “Lack of Effect of Gemfibrozil on Cyclosporine Blood Concentrations in Kidney-Transplanted Patients,” <i>Am J Nephrol</i>, 1998, 18(3):199-203.</p>\n<p>6. de Lorgeril M, Boissonnat P, Bizollon CA, et al, “Pharmacokinetics of Cyclosporine in Hyperlipidaemic Long-Term Survivors of Heart Transplantation. Lack of Interaction with the Lipid-Lowering Agent, Fenofibrate,” <i>Eur J Clin Pharmacol</i>, 1992, 43:161-5.</p>\n<p>7. Lipscombe J, Lewis GF, Cattran D, et al, “Deterioration in Renal Function Associated with Fibrate Therapy,” <i>Clin Nephrol</i>, 2001, 55:39-44.</p>\n<p>8. Devuyst O, Goffin E, Pirson Y, et al, “Creatinine Rise after Fibrate Therapy in Renal Graft Recipients,” <i>Lancet</i>, 1993, 341:840.</p>\n<p>9. Angeles C, Lane BP, Miller F, et al, “Fenofibrate-Associated Reversible Acute Allograft Dysfunction in 3 Renal Transplant Recipients: Biopsy Evidence of Tubular Toxicity,” <i>Am J Kidney Dis</i>, 2004, 44(3):543-50.</p>\n<p>10. Hirai M, Tatuso E, Sakurai M, et al, “Elevated Blood Concentrations of Cyclosporine and Kidney Failure After Bezafibrate in Renal Graft Recipient,” <i>Ann Pharmacother</i>, 1996, 30(7-8):883-4.</p>\n<p>11. de Lorgeril M, Boissonnat P, Salen P, et al, “Fenofibrate, Probucol, and Other Lipid-Lowering Treatments in Heart Transplant Recipients,” <i>J Heart Lung Transplant</i>, 1996, 15:539-40.</p>\n<p>12. Massy ZA, Guijarro C, Kasiske BL, “Effect of Fenofibrates in Heart Transplant Patients,” <i>Transplantation</i>, 1995, 59:451-2.</p>\n<p>13. Prescribing information. TriLipix (fenofibric acid). North Chicago, IL: Abbott Laboratories, 12/2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5110":"<p><b>Title</b> Protease Inhibitors / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Protease Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduced cyclosporine and protease inhibitor doses may be necessary to achieve desired plasma concentration and to minimize the occurrence of concentration-dependent toxicity. Monitor patients using concomitant therapy closely, including plasma concentrations (when appropriate). Of note, this interaction may impact cyclosporine concentration monitoring such that 2 hour-post-dose (C2) concentrations may be altered disproportionately more than trough (C0) concentrations.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir*, Lopinavir*, Nelfinavir, Ritonavir*, Saquinavir, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One case series describes the initiation of ritonavir-boosted protease inhibitor therapy in 3 patients receiving cyclosporine as part of a post-liver transplant immunosuppressive regimen.<sup>1</sup> Two patients received lopinavir/ritonavir, and one received indinavir/ritonavir (after initially experiencing adverse effects on lopinavir/ritonavir). Addition of protease inhibitor therapy necessitated a decrease in cyclosporine dose to 5-20% of baseline in order to maintain therapeutic trough concentrations. Cyclosporine absorption appeared to be particularly sensitive to the interaction as peak concentrations essentially disappeared following protease inhibitor initiation, resulting in a relatively flat or constant concentration throughout the dosing interval. Similarly, protease inhibitor concentrations were greater than expected in these patients, suggesting that cyclosporine was interacting with these agents as well. Dose reductions of both lopinavir and indinavir were necessary to achieve therapeutic concentrations.<br><br>The principal mechanism of both probable interactions is likely inhibition of drug metabolism. Both cyclosporine and the protease inhibitors are primarily metabolized by CYP3A, and most protease inhibitors are potent inhibitors of CYP3A, as is cyclosporine.<sup>2,3</sup> This mechanism only partly explains the observed interaction, however, as it does not account for the apparent decrease in cyclosporine absorption. Protease inhibitor-mediated induction of the intestinal p-glycoprotein could at least partly explain this aspect, and at least some protease inhibitors have been shown to be potent inducers of p-glycoprotein.<sup>4,5</sup> However, the precise roles of CYP3A, p-glycoprotein, and other metabolic enzymes/transporters remains to be determined.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vogel M, Voigt E, Michaelis HC, et al, “Management of Drug-to-Drug Interactions between Cyclosporine a and the Protease-Inhibitor Lopinavir/Ritonavir in Liver-Transplanted Hiv-Infected Patients,” <i>Liver Transpl</i>, 2004, 10:939-44.</p>\n<p>2. Granfors MT, Wang JS, Kajosaari LI, et al, “Differential Inhibition of Cytochrome P450 3a4, 3a5 and 3a7 by Five Human Immunodeficiency Virus (Hiv) Protease Inhibitors in Vitro,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98:79-85.</p>\n<p>3. Masuda S,Inui K, “An up-Date Review on Individualized Dosage Adjustment of Calcineurin Inhibitors in Organ Transplant Patients,” <i>Pharmacol Ther</i>, 2006, 112:184-98.</p>\n<p>4. Kageyama M, Namiki H, Fukushima H, et al, “Effect of Chronic Administration of Ritonavir on Function of Cytochrome P450 3a and P-Glycoprotein in Rats,” <i>Biol Pharm Bull</i>, 2005, 28:130-7.</p>\n<p>5. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 10/2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5111":"<p><b>Title</b> CycloSPORINE (Systemic) / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may increase the metabolism of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if a barbiturate is initiated/dose increased, or increased serum concentrations/effects if a barbiturate is discontinued/dose decreased.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital*, Primidone, Secobarbital, Thiopental</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of cyclosporine was increased from 3.8 mL/min/kg to 12.6 mL/min/kg in a pediatric patient while taking phenobarbital.<sup>1</sup> Another pediatric patient was unable to attain adequate serum cyclosporine concentrations (even at doses of 18 mg/kg/day) while also receiving phenobarbital until the dose was reduced from 100 mg/day to 25 mg/day.<sup>2</sup> Barbiturates are known inducers of CYP isoenzymes, including CYP3A4 for which cyclosporine is a substrate. Such induction would increase the metabolism of the cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Burckart GJ, Venkataramanan R, Starz T, et al, “Cyclosporine Clearance in Children Following Organ Transplantation,” <i>J Clin Pharmacol</i>, 1984, 24:412.</p>\n<p>2. Carstensen H, Jacobsen N, and Dieperink H, “Interaction Between Cyclosporine A and Phenobarbitone,” <i>Br J Clin Pharmacol</i>, 1986, 21:550-1.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5112":"<p><b>Title</b> CycloSPORINE (Systemic) / Bosentan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the use of bosentan and systemic cyclosporine in combination. This combination is listed as contraindicated by bosentan US prescribing information.</p> \n<p><b>Discussion</b> In a clinical study summarized in cyclosporine US prescribing information, coadministration of bosentan (250 mg to 1000 mg every 12 hours) decreased the dose-adjusted cyclosporine (dosed to maintain a serum concentration or 200 ng/mL to 250 ng/mL) maximum concentration, minimum concentration (Cmin), and AUC by approximately 30%, 60%, and 50%, respectively, in healthy volunteers.<sup>1,2</sup> Coadministration with cyclosporine increased the dose-adjusted bosentan Cmin on days 1 and 8 of concomitant dosing by approximately 21 and 2 fold, respectively.<sup>1,2</sup> Consistent with these findings, US bosentan prescribing information states that bosentan Cmin was increased around 30 fold on the first day of cyclosporine coadministration, compared to 3-4 fold increases in exposure at steady state, and that cyclosporine concentrations decreased by approximately 50% during bosentan coadministration.<sup>3</sup> In a published study of healthy volunteers, an average 35% increase in cyclosporine dose during bosentan coadministraiton was sufficient to maintain similar cyclosporine Cmin and AUC compared to cyclosporine dosed alone, and bosentan concentrations were approximately doubled after 7 days of concomitant dosing.<sup>4</sup> Lastly, a case report describes a one-year-old infant who had persistent subtherapeutic cyclosporine concentrations (20 ng/mL to 80 ng/mL) despite escalating cyclosporine doses (up to 7 mg/kg/day) while taking bosentan.<sup>5</sup> Following bosentan discontinuation, therapeutic cyclosporine concentrations (120 ng/mL to 160 ng/mL) were achieved with a reduced dose of cyclosporine (3 mg/kg/day).<sup>5</sup><br><br>The suspected primary mechanisms of these interactions are bosentan induction of CYP3A4 mediated cyclosporine metabolism, and cyclosporine inhibition of CYP3A4 mediated bosentan metabolism and active hepatic bosentan uptake (eg, via organic anionic transport proteins).<sup>1,2,3,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sandimmune (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2013.</p>\n<p>2. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2013.</p>\n<p>3. Binet I, Wallnofer A, Weber C, Jones R, Thiel G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. <i>Kidney Int</i>. 2000;57(1):224-231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10620203\">[PubMed 10620203]</a></p>\n<p>4. Tracleer (bosentan) [prescribing information]. South San Fracisco, CA: Actelion Pharmaceuticals US Inc; October 2016.</p>\n<p>5. Masarwa R, Shamriz O, Zilkha A, et al. Bosentan-induced reduction in cyclosporine-A levels: a rare interaction in an infant with osteopetrosis and severe pulmonary hypertension. <i>J Pediatr Hematol Oncol</i>. 2015;37(7):573-574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26274036\">[PubMed 26274036]</a></p>\n<p>6. Treiber A, Schneiter R, Delahaye S, Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. <i>J Pharmacol Exp Ther</i>. 2004;308(3):1121-1129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14617681\">[PubMed 14617681]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5113":"<p><b>Title</b> CycloSPORINE (Systemic) / Bromocriptine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Bromocriptine may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Cyclosporine prescribing information lists bromocriptine as an agent that can increase serum concentrations of cyclosporine.<sup>1</sup> However, several studies looking at the combination of bromocriptine and cyclosporine found minimal or negligible changes in serum cyclosporine levels.<sup>2,3,4</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</p>\n<p>2. Carrier M, Wild J, Pelletier C, Copeland J. Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantation. <i>Ann Thorac Surg</i>. 1990;49(1);129-132. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2297260\">[PubMed 2297260]</a></p>\n<p>3. Dougados M, Duchesne L, Amor B. Bromocriptine and cyclosporin A therapy combination therapy in rheumatoid arthritis. <i>Arthritis Rheum</i>. 1988;31(10):1333-1334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3178914\">[PubMed 3178914]</a></p>\n<p>4. Yongjin J, ZiLin F, Zhenmei B. Bromocriptine as an adjuvant to cyclosporine immunosuppression after renal transplantation. <i>Transplant Proc</i>. 1997;29(1-2):297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9123004\">[PubMed 9123004]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5114":"<p><b>Title</b> Calcium Channel Blockers (Dihydropyridine) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased cyclosporine concentrations and effects if combined with dihydropyridine calcium channel blockers. Cyclosporine dose reductions may be necessary. Also monitor for increased calcium channel blocker effects (eg, decreases in blood pressure, peripheral edema) during concomitant use. Patients receiving nifedipine may be at elevated risk of gingival hyperplasia. Avoid nifedipine in patients with cyclosporine-associated gingival hyperplasia.</p>\n<div>\n <p><b>Calcium Channel Blockers (Dihydropyridine) Interacting Members</b> AmLODIPine*, Barnidipine, Benidipine, Cilnidipine, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine*, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A variety of studies and reports describe increases in cyclosporine serum concentrations with the addition of nicardipine,<sup>1,2,3,4,5,6,7,8</sup> amlodipine,<sup>1,9,10,11,12,13</sup> nifedipine,<sup>14</sup> and nisoldipine<sup>15</sup>. <br><br>In contrast, other studies have found that amlodipine,<sup>16</sup> felodipine,<sup>17,18</sup> isradipine,<sup>19,20,21</sup> nifedipine,<sup>22,23,24,25</sup> lacidipine,<sup>1,26</sup> and nitrendipine.<sup>27</sup> have little to no effect on the serum concentrations of cyclosporine. <br><br>In addition to increases in cyclosporine concentrations, cyclosporine has been shown to increase the AUC and maximum serum concentration of felodipine 58% and 151%, respectively,<sup>17</sup> and enhance the edema and flushing associated with amlodipine.<sup>28</sup> <br><br>The mechanism by which dihydropyridine calcium channel blockers (CCBs) increase cyclosporine concentrations is likely due to fact that many dihydropyridine CCBs weakly inhibit CYP3A4, an enzyme responsible for cyclosporine metabolism. Cyclosporine increases dihydropyridine CCB concentrations and effects also by inhibition of CYP3A4, an enzyme responsible for dihydropyridine CCB metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. <i>Ann Pharmacother</i>. 2014;48(12):1580-1584. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25280976\">[PubMed 25280976]</a></p>\n<p>2. Duvoux C, Cherqui D, Di Martino V, et al. Nicardipine as antihypertensive therapy in liver transplant recipients: results of long-term use. <i>Hepatology</i>. 1997;25(2):430-433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9021959\">[PubMed 9021959]</a></p>\n<p>3. Guan D, Wang R, Lu J, Wang M, Xu C. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. <i>Transplant Proc</i>. 1996;28(3):1311-1312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8658673\">[PubMed 8658673]</a></p>\n<p>4. Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF, Cledes J. Nicardipine increases cyclosporin blood levels. <i>Lancet</i>. 1986;1(8495):1447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872552\">[PubMed 2872552]</a></p>\n<p>5. Cantarovich M, Hiesse C, Lockiec F, Charpentier B, Fries D. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. <i>Clin Nephrol</i>. 1987;28(4):190-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3319309\">[PubMed 3319309]</a></p>\n<p>6. Deray G, Aupetit B, Martinez F, et al. Ciclosporin-nicardipine interaction. <i>Am J Nephrol</i>. 1989;9(4):349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2817022\">[PubMed 2817022]</a></p>\n<p>7. Kessler M, Netter P, Renoult E, et al. Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients. <i>Eur J Clin Pharmacol</i>. 1989;36(6):637-638. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2673796\">[PubMed 2673796]</a></p>\n<p>8. Todd P, Garioch JJ, Rademaker M, Thomson J. Nicardipine interacts with cyclosporin. <i>Br J Dermatol</i>. 1989;121(6):820. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2611131\">[PubMed 2611131]</a></p>\n<p>9. Cai J, Huang Z, Yang G, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. <i> Am J Cardiovasc Drugs</i>. 2011;11(6):401-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22149319\">[PubMed 22149319]</a></p>\n<p>10. Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. <i>Clin Transplant</i>. 2007;21(2):277-284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17425758\">[PubMed 17425758]</a></p>\n<p>11. Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. <i>Transplantation</i>. 2003;76(5):865-868. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14501869\">[PubMed 14501869]</a></p>\n<p>12. McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. <i>Clin Nephrol</i>. 1997;48(5):336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9403222\">[PubMed 9403222]</a></p>\n<p>13. Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. <i>J Am Soc Nephrol</i>. 1996;7(6):831-835. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8793790\">[PubMed 8793790]</a></p>\n<p>14. Crocker JF, Renton KW, LeVatte TL, McLellan DH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. <i>Pediatr Nephrol</i>. 1994;8(4):408-411. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7947026\">[PubMed 7947026]</a></p>\n<p>15. Fourtounas C, Kopelias I, Kiriaki D, Agroyannis B. Increased cyclosporine blood levels after nisoldipine administration in a renal transplant recipient. <i>Transpl Int</i>. 2002;15(11):586-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12461666\">[PubMed 12461666]</a></p>\n<p>16. Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. <i>Hypertension</i>. 1994;24(3):297-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8082935\">[PubMed 8082935]</a></p>\n<p>17. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. <i>Eur J Clin Pharmacol</i>. 1996;50(3):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737760\">[PubMed 8737760]</a></p>\n<p>18. Cohen DJ, Teng SN, Appel GB. Influence of oral felodipine on serum cyclosporine concentrations. <i>Clin Transplant</i>. 1994;8(6):541-545. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7865916\">[PubMed 7865916]</a></p>\n<p>19. Vernillet L, Bourbigot B, Codet JP, Le Saux L, Moal MC, Morin JF. Lack of effect of isradipine on cyclosporin pharmacokinetics. <i>Fundam Clin Pharmacol</i>. 1992;6(8-9):367-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1292968\">[PubMed 1292968]</a></p>\n<p>20. Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg KJ. Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. <i>Ther Drug Monit</i>. 1991;13(6):490-495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1837629\">[PubMed 1837629]</a></p>\n<p>21. Martinez F, Pirson Y, Wallemacq P, van Ypersele de Strihou C. No clinically significant interaction between ciclosporin and isradipine. <i>Nephron</i>. 1991;59(4):658-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1837336\">[PubMed 1837336]</a></p>\n<p>22. Legault L, Ogilvie RI, Cardella CJ, Leenen FH. Calcium antagonists in heart transplant recipients: effects on cardiac and renal function and cyclosporine pharmacokinetics. <i>Can J Cardiol</i>. 1993;9(5):398-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8348391\">[PubMed 8348391]</a></p>\n<p>23. Howard RL, Shapiro JI, Babcock S, Chan L. The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients. <i>Ren Fail</i>. 1990;12(2):89-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2236731\">[PubMed 2236731]</a></p>\n<p>24. Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV, Kasiske BL. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. <i>Ther Drug Monit</i>. 1990;12(4):321-328. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2396304\">[PubMed 2396304]</a></p>\n<p>25. Roy LF, East DS, Browning FM, et al. Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidney-transplant patients. <i>Clin Pharmacol Ther</i>. 1989;46(6):657-667. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2689045\">[PubMed 2689045]</a></p>\n<p>26. Kuypers DR, Neumayer HH, Fritsche L, et al; Lacidipine Study Group. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. <i>Transplantation</i>. 2004;78(8):1204-1211. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502721\">[PubMed 15502721]</a></p>\n<p>27. Copur MS, Tasdemir I, Turgan C, Yasavul U, Caglar S. Effects of nitrendipine on blood pressure and blood ciclosporin A level in patients with posttransplant hypertension. <i>Nephron</i>. 1989;52(3):227-230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2662047\">[PubMed 2662047]</a></p>\n<p>28. von Vigier RO, Fossali E, Edefonti A, Vogt B, Bianchetti MG. Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers. <i>Br J Clin Pharmacol</i>. 2002;54(3):334-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12236856\">[PubMed 12236856]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5115":"<p><b>Title</b> Calcium Channel Blockers (Nondihydropyridine) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor serum cyclosporine concentrations if diltiazem or verapamil are initiated/dose increased, or decreased serum cyclosporine concentrations if diltiazem or verapamil is discontinued/dose decreased. During coadministration of cyclosporine and calcium channel blockers, monitor for decreases in blood pressure.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem*, Verapamil*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A variety of studies demonstrate changes in both cyclosporine and calcium channel blocker serum concentrations during concomitant therapy. Apparently due to significant inhibitory effects on CYP3A4, diltiazem,<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18</sup> nicardipine,<sup>19,20,21,22,23</sup> and verapamil<sup>4,13,24,25,26,27,28</sup> appear to exert the greatest effect on cyclosporine, with serum cyclosporine concentrations being increased up to threefold. As such, significant reductions in cyclosporine dosage is needed which results in a therapy cost savings of as much as 40% yearly.<sup>5,6,29,30</sup> Increases in serum creatinine have been infrequently reported. In fact, some studies have reported reduced incidence of renal toxicity and/or organ rejection, in spite of increased cyclosporine concentrations, suggesting a protective effect of the calcium channel blocker on the kidney.<sup>8,9,11,24,31</sup> Other calcium channel blockers studied do not affect CYP3A4, and thus show little to no effect on the serum concentrations of cyclosporine. These include: Amlodipine,<sup>32,33</sup> felodipine,<sup>34,35,36</sup> isradipine,<sup>37,38</sup> nifedipine,<sup>4,19,31,39,40</sup> and nitrendipine.<sup>41</sup> In addition to these effects, cyclosporine, as an inhibitor of CYP3A4, tends to increase serum concentrations of all of these calcium channel blockers, potentially resulting in small decreases in blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pochet JM and Pirson Y, “Cyclosporine-Diltiazem Interaction,” <i>Lancet</i>, 1986, i:979.</p>\n<p>2. Grino JM, Sabate I, Castelao AM, et al, “Influence of Diltiazem on Cyclosporine Clearance,” <i>Lancet</i>, 1986, i:1387.</p>\n<p>3. Sabate I, Grino JM, Castelao AM, et al, “Cyclosporine-Diltiazem Interaction: Comparison of Cyclosporine Levels Measured With Two Monoclonal Antibodies,” <i>Transplant Proc</i>, 1989, 21:1460-1.</p>\n<p>4. Campistol JM, Oppenheimer F, Vilardell J, et al, “Interaction Between Cyclosporine and Diltiazem in Renal Transplant Patients,” <i>Nephron</i>, 1991, 57:241-2.</p>\n<p>5. Valantine H, Keogh A, McIntosh N, et al, “Cost Containment. Coadministration of Diltiazem With Cyclosporine Following Cardiac Transplant,” <i>J Heart Transplant</i>, 1990, 9:68.</p>\n<p>6. Bourge RC, Kirkin JK, Naftel DC, et al, “Diltiazem-Cyclosporine Interaction in Cardiac Transplant Recipients; Impact on Cyclosporine Dose and Medication Costs,” <i>Am J Med</i>, 1991, 90:402-4.</p>\n<p>7. Brockmoller J, Neumayer HH, Wagner K, et al, “Pharmacokinetic Interaction Between Cyclosporine and Diltiazem,” <i>Eur J Clin Pharmacol</i>, 1990, 38:237-42.</p>\n<p>8. Wagner K, Albrecht S, Neumayer HM, “Prevention of Post-transplant Acute Tubular Necrosis by the Calcium Antagonist Diltiazem: A Prospective Randomized Study,” <i>Am J Nephrol</i>, 1987, 7:287-91.</p>\n<p>9. McCauley J, Ptachcinski RJ, and Shapiro R, “The Cyclosporine-Sparing Effects of Diltiazem in Renal Transplantation,” <i>Transplant Proc</i>, 1989, 21:3955-7.</p>\n<p>10. Shennib H and Auger JL, “Diltiazem Improves Cyclosporine Dosage in Cystic Fibrosis Lung Transplant Recipients,” <i>J Heart Lung Transplant</i>, 1994, 13:292-6.</p>\n<p>11. MacDonald P, Keogh A, Connell J, et al, “Diltiazem Coadministration Reduces Cyclosporine Toxicity After Heart Transplantation: A Prospective Randomized Study,” <i>Transplant Proc</i>, 1992, 24:2259-62.</p>\n<p>12. Masri MA, Shakuntaia V, Shanwaz M, et al, “Pharmacokinetics of Cyclosporine in Renal Transplant Patients on Diltiazem,” <i>Transplant Proc</i>, 1994, 26:1921.</p>\n<p>13. Sketris IS, Methot ME, Nicol D, et al, “Effect of Calcium-Channel Blockers on Cyclosporine Clearance and Use in Renal Transplant Patients,” <i>Ann Pharmacother</i>, 1994, 28:1227-31.</p>\n<p>14. Bleck JS, Thiesemann C, Kliem V, et al, “Diltiazem Increases Blood Concentrations of Cyclized Cyclosporine Metabolites Resulting in Different Cyclosporine Metabolite Patterns in Stable Male and Female Renal Allograft Recipients,” <i>Br J Clin Pharmacol</i>, 1996, 41:551-6.</p>\n<p>15. Morris RG and Jones TE, “Diltiazem Disposition and Metabolism in Recipients of Renal Transplants,” <i>Ther Drug Monit</i>, 1998, 20:365-70.</p>\n<p>16. Jones TE, Morris RG, and Mathew TH, “Formulation of Diltiazem Affects Cyclosporine-Sparing Activity,” <i>Eur J Clin Pharmacol</i>, 1997, 52:55-8.</p>\n<p>17. Jones TE, Morris RG, and Mathew TH, “Diltiazem-Cyclosporine Pharmacokinetic Interaction - Dose-Response Relationship,” <i>Br J Clin Pharmacol</i>, 1997, 44:499-504.</p>\n<p>18. Sharma A, Bell L, Drolet D, et al, “Cyclosporine (CSA) Neoral Kinetics in Children Treated With Diltiazem,” <i>J Am Soc Nephrol</i>, 1996, 7:1923.</p>\n<p>19. Bourbigot B, Guiserix J, Airiau J, et al, “Nicardipine Increases Cyclosporine Blood Levels,” <i>Lancet</i>, 1986, i:1447.</p>\n<p>20. Cantarovich M, Hiesse C, Lockiec F, et al, “Confirmation of the Interaction Between Cyclosporine and the Calcium Channel Blocker Nicardipine in Renal Transplant Patients,” <i>Clin Nephrol</i>, 1987, 28:190-3.</p>\n<p>21. Deray G, Aupetit B, Martinez F, et al, “Cyclosporine-Nicardipine Interaction,” <i>Am J Nephrol</i>, 1989, 9:349.</p>\n<p>22. Kessler M, Netter P, Renoult E, et al, “Influence of Nicardipine on Renal Function and Plasma Cyclosporine in Renal Transplant Patients,” <i>Eur J Clin Pharmacol</i>, 1989, 36:637-8.</p>\n<p>23. Todd P, Garioch JJ, Rademaker M, et al, “Nicardipine Interacts With Cyclosporine,” <i>Br J Dermatol</i>, 1989, 121:820.</p>\n<p>24. Dawidson I, Rooth P, Fry WR, et al, “Prevention of Acute Cyclosporine Induced Renal Blood Flow Inhibition and Improved Immunosuppression With Verapamil,” <i>Transplantation</i>, 1989, 48:575-80.</p>\n<p>25. Lindholm A and Henricsson S, “Verapamil Inhibits Cyclosporine Metabolism,” <i>Lancet</i>, 1987, i:1262-3.</p>\n<p>26. Hampton EM, Stewart CF, Herrod GH, et al, “Augmentation of <i>in vitro</i> Immunosuppressive Effects of Cyclosporine by Verapamil,” <i>Clin Pharmacol Ther</i>, 1987, 41:169.</p>\n<p>27. Robson RA, Fraenkel M, Barratt LF, et al, “Cyclosporine-Verapamil Interaction,” <i>Br J Clin Pharmacol</i>, 1988, 25:402-3.</p>\n<p>28. Angermann CE, Spes CH, Anthuber M, et al, “Verapamil Increases Cyclosporine - A Blood Trough Levels in Cardiac Recipients,” <i>J Am Coll Cardiol</i>, 1988, 11:206A.</p>\n<p>29. Smith CL, Hampton EM, Pederson JA, et al, “Influence of Diltiazem on the Pharmacokinetics and Dose/Cost Relationships of Cyclosporine in Renal Transplant Patients,” <i>J Am Soc Nephrol</i>, 1991, 2:816.</p>\n<p>30. Kumana CR, Tong MK, Li CS, et al, “Diltiazem Co-Treatment in Renal Transplant Patients Receiving Microemulsion Cyclosporin,” <i>Br J Clin Pharmacol</i>, 2003, 56(6):670-8.</p>\n<p>31. Wahner K, Philipp TH, Heinemeyer G, et al, “Interaction of Cyclosporine and Calcium Antagonists,” <i>Transplant Proc</i>, 1989, 21:1453-6.</p>\n<p>32. Toupance O, Lavaud S, Canivet E, et al, “Antihypertensive Effect of Amlodipine and Lack of Interference With Cyclosporine Metabolism in Renal Transplant Recipients,” <i>Hypertension</i>, 1994, 24:297-300.</p>\n<p>33. Pesevento TE, Jones PA, Julian BA, et al, “Amlodipine Increases Cyclosporine Levels in Hypertensive Renal Transplant Patients: Results of Prospective Study,” <i>J Amer Soc Nephrol</i>, 1996, 7:831-5.</p>\n<p>34. Cohen DJ, Teng SN, Valeri A, et al, “Influence of Oral Felodipine on Serum Cyclosporine Concentrations in Renal Transplant Patients,” <i>J Am Soc Nephrol</i>, 1993, 4:929.</p>\n<p>35. Madsen JK, Jensen JD, Jensen LW, et al, “Pharmacokinetic Interaction Between Cyclosporine and the Dihydropyridine Calcium Antagonist Felodipine,” <i>Eur J Clin Pharmacol</i>, 1996, 50:203-8.</p>\n<p>36. Madsen JK, Kronerup HJ, Sorensen SS, et al, “Cyclosporine Nephrotoxicity Can Be Counteracted by a Calcium Antagonist (Felodipine) in Acute and Short-Term Studies,” <i>J Am Soc Nephrol</i>, 1995, 6:1102.</p>\n<p>37. Endresen L, Bergan S, Holdaas H, et al, “Lack of Effect of the Calcium Antagonist Isradipine on Cyclosporine Pharmacokinetics in Renal Transplant Patients,” <i>Ther Drug Monit</i>, 1991, 13:490-5.</p>\n<p>38. Martinez F, Pirson Y, Wallemacq P, et al, “No Clinically Significant Interaction Between Cyclosporine and Isradipine,” <i>Nephron</i>, 1991, 59:658-9.</p>\n<p>39. McNally P, Mistry N, Idle J, et al, “Calcium Channel Blockers and Cyclosporine Metabolism,” <i>Transplantation</i>, 1989, 48:1071.</p>\n<p>40. Rossi SJ, Hariharan S, Schroeder TJ, et al, “Cyclosporine Dosing and Blood Levels in Renal Transplants Receiving Procardia XL,” <i>Clin Pharmacol Ther</i>, 1993, 53:238.</p>\n<p>41. Copur MS, Tasdemir I, Turgan C, et al, “Effects of Nitrendipine on Blood Pressure and Blood Cyclosporine A Level in Patients With Post-transplant Hypertension,” <i>Nephron</i>, 1989, 52:227-30.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5116":"<p><b>Title</b> CycloSPORINE (Systemic) / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor frequently for decreased serum concentrations and therapeutic effects of cyclosporine if carbamazepine is initiated/dose increased, or increased serum concentrations/effects if carbamazepine is discontinued/dose decreased. Increased cyclosporine doses will likely be needed to maintain adequate serum concentrations.</p> \n<p><b>Discussion</b> In a study conducted in pediatric renal transplant patients, cyclosporine clearance was 2.6-fold higher in 3 patients who received cyclosporine and carbamazepine (16.4 to 20.8 mg/kg/day) compared with the cyclosporine clearance in 3 patients who received cyclosporine alone.<sup>1</sup> Cyclosporine trough concentrations were 65% lower in the carbamazepine group (57 ng/mL vs 162 ng/mL) despite receiving a cyclosporine dose that was 50% higher than those who received cyclosporine alone (16.2 mg/kg/day vs 10.8 mg/kg/day).<sup>1</sup> Two additional case reports also describe decreased serum concentrations and subtherapeutic levels of cyclosporine with the coadministration of carbamazepine.<sup>2,3</sup> <br><br>The mechanism of this interaction is likely related to the ability of carbamazepine to induce CYP3A4 , an enzyme responsible for cyclosporine metabolism.<sup>1,2,3,4,5</sup> Limited cyclosporine metabolite data also suggest that the interaction may also be due to decreased cyclosporine absorption.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cooney GF, Mochon M, Kaiser B, Dunn SP, Goldsmith B. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. <i>Pharmacotherapy</i>. 1995;15(3):353-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7667170\">[PubMed 7667170]</a></p>\n<p>2. Soto Alvarez J, Sacristan Del Castillo A, Alsar Ortiz MJ. Effect of carbamazepine on ciclosporin blood level. <i>Nephron</i>. 1991;58(2):235-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1865983\">[PubMed 1865983]</a></p>\n<p>3. Schofield OM, Camp RD, Levene GM. Cyclosporin A in psoriasis: interaction with carbamazepine. <i>Br J Dermatol</i>. 1990;122(3):425-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2322504\">[PubMed 2322504]</a></p>\n<p>4. Sandimmune (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.</p>\n<p>5. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5119":"<p><b>Title</b> CycloSPORINE (Systemic) / Carvedilol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Carvedilol may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Cyclosporine doses may need to be reduced in patients on cyclosporine who are started on carvedilol (or with increasing carvedilol dose). Studies have reported that average cyclosporine dose reductions were 10-20% but that there were considerable interpatient variability. Cyclosporine concentrations should be monitored closely with any adjustment to carvedilol dosing (including starting or stopping therapy).</p> \n<p><b>Discussion</b> In one study of 21 renal transplant patients receiving cyclosporine the addition of carvedilol (6.25mg initially, titrated up 50mg according to blood pressure response) resulted in increased cyclosporine concentrations that necessitated dose reductions.<sup>1</sup> By 90 days the average cyclosporine dose was 20% lower than at baseline, but the authors note that there was considerable patient-to-patient variability in the magnitude of this interaction. A retrospective analysis of cardiac transplant patients receiving cyclosporine found that the addition of metoprolol (n=20) for blood pressure control resulted in no consistent change in cyclosporine concentrations (decreased in 12 patients; increased in 8 patients) or dose requirement, while the addition of carvedilol (n=12) was associated with a significant increase in cyclosporine concentrations and a significant decrease in cyclosporine dose requirement (average of 10% lower).<sup>2</sup> The mechanism of this interaction is likely carvedilol-mediated inhibition of p-glycoprotein. Carvedilol is a p-glycoprotein substrate and has been shown to inhibit p-glycoprotein activity.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kaijser M, Johnsson C, Zezina L, et al, “Elevation of Cyclosporin A Blood Levels During Carvedilol Treatment in Renal Transplant Patients,” <i>Clin Transplant</i>, 1997, 11(6):577-81.</p>\n<p>2. Bader FM, Hagan ME, Crompton JA, et al, “The Effect of Beta-Blocker Use on Cyclosporine Level in Cardiac Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2005, 24(12):2144-7.</p>\n<p>3. Bachmakov I, Werner U, Endress B, et al, “Characterization of Beta-Adrenoceptor Antagonists as Substrates and Inhibitors of the Drug Transporter P-glycoprotein,” <i>Fundam Clin Pharmacol</i>, 2006, 20(3):273-82.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5120":"<p><b>Title</b> Caspofungin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Weigh the potential benefits of caspofungin therapy against a possible elevated risk of hepatotoxicity in patients receiving cyclosporine. Monitor liver function tests and re-evaluate the potential risks and benefits of treatment in patients with abnormal results. Based on limited clinical evidence, transient mild elevations in transaminase concentrations are relatively common with this combination.</p> \n<p><b>Discussion</b> Prescribing information for caspofungin describes a retrospective study in which 40 immunocompromised patients (37 transplant recipients) were treated with cyclosporine and caspofungin concomitantly for a median of 17.5 days (range 1 to 290 days).<sup>1</sup> Fourteen of these patients developed elevated transaminase elevations greater than 5 times the upper limit of normal (ULN) values or greater than 3 times baseline during or within the 2 weeks following concomitant treatment. Five cases were deemed possibly related to concomitant treatment. In clinical studies, 3 of 4 patients who received caspofungin (70 mg/day days 1 to 10) with cyclosporine (3 mg/kg every 12 hours for 2 doses starting day 10) developed ALT concentrations 2 to 3 times ULN, and 2 of 8 healthy subjects given caspofungin (70 mg daily days 3 to 13) with cyclosporine (4 mg/kg days 1 and 12) developed ALT elevations less than 2 times ULN. Cyclosporine at the doses described was estimated to increase caspofungin exposure (approximately 35% increase in caspofungin AUC). Caspofungin did not affect cyclosporine pharmacokinetics in this study, nor did it appear to have an impact on cyclosporine concentrations in a in a retrospective review of patients receiving concomitant therapy.<sup>1,2</sup> <br> <br>Several case reports describe patients treated with caspofungin and cyclosporine concomitantly, without clinically important signs or symptoms of hepatotoxicity.<sup>3,4,5,6</sup> Additionally, a number of retrospective reviews have been conducted.<sup>7,8,9,10,11,12</sup> To summarize, during concomitant treatment: 3 of 8 patients transplant recipients treated for aspergillosis experienced AST or ALT elevations above 3 times ULN;<sup>7</sup> one of 19 patients treated for febrile neutropenia developed hepatotoxicity (no further detail given);<sup>8</sup> none of 14 bone marrow transplant recipients (multiple indications) experienced clinically significant transaminase elevations;<sup>9</sup>; median transaminase concentrations in 20 bone marrow transplant recipients remained near the ULN, although there were several patients with significant elevations at some point during treatment;<sup>10</sup> seven of 7 liver transplant recipients experienced substantial decreases in circulating transaminase concentrations;<sup>11</sup> and two of 40 patients with varying cyclosporine indications discontinued concomitant treatment due to hepatotoxicity involving substantial elevation of AST, alkaline phosphatase, and bilirubin.<sup>12</sup> <br><br>The mechanism of this potential drug interaction is unknown. Elevated transaminase concentrations may result from additive hepatotoxicity of the agents, increased exposure to caspofungin, or both. It appears from published studies that many patients experience transient mild transaminase elevations during concomitant treatment, with serious hepatic complications being much less common. Unfortunately, interpretability of study findings is quite limited due to the retrospective designs, small sample sizes, and presumably irregular monitoring involved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cancidas (caspofungin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; April 2016.</p>\n<p>2. Sanz-Rodriguez C, Arranz R, Cisneros JM, et al. Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics. <i>Swiss Med Wkly</i>. 2005;135(43-44):658-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16380854\">[PubMed 16380854]</a></p>\n<p>3. Anttila VJ, Piilonen A, Valtonen M. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. <i>Scand J Infect Dis</i>. 2003;35(11-12):893-894. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14723374\">[PubMed 14723374]</a></p>\n<p>4. Veroux M, Macarone M, Fiamingo P, et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. <i>Transplant Proc</i>. 2006;38(4):1037-1039. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16757256\">[PubMed 16757256]</a></p>\n<p>5. Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. <i>Eur J Haematol</i>. 2005;75(3):227-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16104879\">[PubMed 16104879]</a></p>\n<p>6. Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. <i>J Heart Lung Transplant</i>. 2008;27(1):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18187079\">[PubMed 18187079]</a></p>\n<p>7. Morrissey CO, Slavin MA, O'Reilly MA, et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. <i>Mycoses</i>. 2007;50 Suppl 1:24-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17394607\">[PubMed 17394607]</a></p>\n<p>8. Koo A, Sung L, Allen U, et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. <i>Pediatr Infect Dis J</i>. 2007;26(9):854-856. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721388\">[PubMed 17721388]</a></p>\n<p>9. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. <i>Bone Marrow Transplant</i>. 2004;34(1):13-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15122312\">[PubMed 15122312]</a></p>\n<p>10. Christopeit M, Eikam M, Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. <i>Mycoses</i>. 2008;51 Suppl 1:19-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18471157\">[PubMed 18471157]</a></p>\n<p>11. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. <i>Infection</i>. 2006;34(6):328-332. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17180587\">[PubMed 17180587]</a></p>\n<p>12. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. <i>Transpl Infect Dis</i>. 2004;6(3):110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569226\">[PubMed 15569226]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5122":"<p><b>Title</b> Citalopram / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Citalopram. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Mean serum cyclosporine concentrations remained essentially unchanged in 5 therapy-stable patients following several days of concomitant therapy with citalopram.<sup>1</sup> Effects of cyclosporine on citalopram pharmacokinetics were not studied. <br><br>Although there is no apparent impact of citalopram on cyclosporine concentrations, cyclosporine could theoretically increase concentrations of citalopram by inhibiting its CYP3A4 mediated metabolism. However, this effect has not been demonstrated clinically and the apparent lack effect of ketoconazole (a more potent CYP3A4 inhibitor than cyclosporine) on citalopram pharmacokinetics casts doubt on the clinical relevance of such an interaction.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Liston HL, Markowitz JS, Hunt N, et al, “Lack of Citalopram Effect on the Pharmacokinetics of Cyclosporine,” <i>Psychosomatics</i>, 2001, 42(4):370-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11496034\">[PubMed 11496034]</a></p>\n<p>2. Prescribing information. Celexa (citalopram). St. Louis, MO: Forest Pharmaceuticals, Inc., February 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5123":"<p><b>Title</b> DOXOrubicin (Conventional) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of doxorubicin (e.g., increased myelosuppression, serious neurotoxicity) if cyclosporine is initiated, the dose is increased, or the agent has been recently discontinued (the effects on doxorubicin may last for several days after discontinuation). Consider a doxorubicin dose reduction if clinically appropriate.</p> \n<p><b>Discussion</b> A case report describes the rapid development of coma (twice) and tonic clonic seizures in a patient following administration of a chemotherapy regimen that included doxorubicin.<sup>1</sup> The patient had been receiving cyclosporine until the time of chemotherapy initiation.<br><br>Doxorubicin AUC was increased by an average of 48% in 8 patients after initiating cyclosporine in an effort to reverse tumor drug-resistance.<sup>2</sup> Doxorubicinol (doxorubicin metabolite) concentrations were increased 443%. Myelotoxicity was greater in the cyclosporine-treated patients. Other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose-requirements with concurrent cyclosporine.<sup>3,4,5,6</sup><br><br>This interaction appears to result from both inhibition of doxorubicin transport by P-glycoprotein and inhibition of the CYP3A-mediated metabolism of doxorubicin. As a result of this dual mechanism, systemic doxorubicin concentrations increase and the distribution of doxorubicin, particularly into “protected” sites such as the brain, testes, etc., also increases. Several in vitro and animal studies support this dual interaction mechanism.<sup>7,8,9,10,11,12,13</sup> As a result of the effects of cyclosporine on doxorubicin efflux this combination has generated interest as a means of reversing tumor resistance to doxorubicin (and similar drugs).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Barbui T, Rambaldi A, Parenzan L, et al, “Neurological Symptoms and Coma Associated with Doxorubicin Administration During Chronic Cyclosporin Therapy,” <i>Lancet</i>, 1992, 339(8806):1421. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1350835\">[PubMed 1350835]</a></p>\n<p>2. Rushing DA, Raber SR, Rodvold KA, et al, “The Effects of Cyclosporine on the Pharmacokinetics of Doxorubicin in Patients with Small Cell Lung Cancer,” <i>Cancer</i>, 1994, 74(3):834-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>3. Erlichman C, Moore M, Thiessen JJ, et al, “Phase I Pharmacokinetic Study of Cyclosporin A Combined with Doxorubicin,” <i>Cancer Res</i>, 1993, 53(20):4837-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>4. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, et al, “Increased Intracellular Concentrations of Doxorubicin in Resistant Lymphoma Cells In Vivo by Concomitant Therapy with Verapamil and Cyclosporin A,” <i>Eur J Haematol</i>, 1994, 52(5):276-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>5. Bartlett NL, Lum BL, Fisher GA, et al, “Phase I Trial of Doxorubicin with Cyclosporine as a Modulator of Multidrug Resistance,” <i>J Clin Oncol</i>, 1994, 12(4):835-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>6. Sonneveld P, Suciu S, Weijermans P,et al, “Cyclosporin A Combined with Vincristine, Doxorubicin and Dexamethasone (VAD) Compared with VAD Alone in Patients with Advanced Refractory Multiple Myeloma: An EORTC-HOVON Randomized Phase III Study (06914),” <i>Br J Haematol</i>, 2001, 115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>7. Perez V, Pierre A, Leonce S, et al, “Effect of Duration of Exposure to S9788, Cyclosporin A or Verapamil on Sensitivity of Multidrug Resistant Cells to Vincristine or Doxorubicin,” <i>Anticancer Res</i>, 1993, 13(4):985-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8352569\">[PubMed 8352569]</a></p>\n<p>8. Lee TW, Yang SW, Kim CM, et al, “Chemosensitization to Adriamycin by Cyclosporin A and Verapamil in Human Retinoblastoma Cell Lines,” <i>J Korean Med Sci</i>, 1993, 8(2):104-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8397925\">[PubMed 8397925]</a></p>\n<p>9. Colombo T, Zucchetti M, D'Incalci M, “Cyclosporin A Markedly Changes the Distribution of Doxorubicin in Mice and Rats,” <i>J Pharmacol Exp Ther</i>, 1994, 269(1):22-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8169829\">[PubMed 8169829]</a></p>\n<p>10. Van de Vrie W, Jonker AM, Marquet RL, et al, “The Chemosensitizer Cyclosporin A Enhances the Toxic Side-Effects of Doxorubicin in the Rat,” <i>J Cancer Res Clin Oncol</i>, 1994, 120(9):533-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7913932\">[PubMed 7913932]</a></p>\n<p>11. Massart C, Gibassier J, Raoul M, et al, “Cyclosporin A, Verapamil and S9788 Reverse Doxorubicin Resistance in a Human Medullary Thyroid Carcinoma Cell Line,” <i>Anticancer Drugs</i>, 1995, 6(1):135-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7756676\">[PubMed 7756676]</a></p>\n<p>12. Hughes CS, Vaden SL, Manaugh CA, et al, “Modulation of Doxorubicin Concentration by Cyclosporin A in Brain and Testicular Barrier Tissues Expressing P-glycoprotein in Rats,” <i>J Neurooncol</i>, 1998, 37(1):45-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9525837\">[PubMed 9525837]</a></p>\n<p>13. Saito T, Zhang ZJ, Tokuriki M, et al, “Doxorubicin Ototoxicity is Induced in Mice by Combination Treatment with Cyclosporin A,” <i>Acta Otolaryngol</i>, 2001, 121(7):787-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11718240\">[PubMed 11718240]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5124":"<p><b>Title</b> Dronedarone / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Dronedarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of cyclosporine with dronedarone is contraindicated according to dronedarone prescribing information.</p> \n<p><b>Discussion</b> Though often classified as a moderate CYP3A4 inhibitor, cyclosporine is listed as a strong CYP3A4 inhibitor (and thus as contraindicated with dronedarone) in dronedarone prescribing information.<sup>1</sup> Similarly, concurrent use of the moderate CYP3A4 inhibitor grapefruit juice is specifically contraindicated with dronedarone.<br><br>Administration of the moderate CYP3A4 inhibitor grapefruit juice was associated with mean 3-fold and 2.5-fold increases in dronedarone AUC and maximum serum concentration (Cmax), respectively.<sup>1</sup> Administration of multiple doses of the strong CYP3A4 inhibitor ketoconazole was associated with a mean 17-fold increase in dronedarone AUC and a mean 9-fold increase in dronedarone Cmax.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Multaq (dronedarone). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, June 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5125":"<p><b>Title</b> CycloSPORINE (Systemic) / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Estrogen Derivatives may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor serum cyclosporine concentrations, and for signs and symptoms of renal and hepatic toxicity, in patients receiving concomitant cyclosporine and estrogen derivatives. Cyclosporine dosage reductions may be necessary.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol*, Mestranol, Polyestradiol, Tibolone</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports. Serum trough cyclosporine concentrations increased approximately 2-fold in a patient receiving a combination oral contraceptive (levonorgestrel 150 mcg and ethinyl estradiol 30 mcg).<sup>1</sup> Signs and symptoms of hepatotoxicity (e.g., increased ALT, AST, bilirubin, and alkaline phosphatase, nausea, and vomiting) were apparent. These events were reproduced upon rechallenge. Another report supports these findings.<sup>2</sup> The mechanism of the increased cyclosporine concentrations is unclear, but might be related to an inhibition of hepatic drug metabolism. The mechanism of the hepatotoxicity is unknown but is likely related to the increased cyclosporine concentrations. Likewise, whether these events would occur with estrogen-only therapy (e.g., hormone replacement therapy) is unknown. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Deray G, Le Hoang P, Cacoub P, et al, “Oral Contraceptive Interaction With Cyclosporine,” <i>Lancet</i>, 1987, i:158-9.</p>\n<p>2. Maurer G, “Metabolism of Cyclosporine,” <i>Transplant Proc</i>, 1985, 17(Suppl 1):19.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5126":"<p><b>Title</b> Etoposide / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may decrease the metabolism of Etoposide. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, systemic cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.</p> \n<p><b>Discussion</b> The AUC (a measure of drug exposure) of etoposide (84 - 200 mg/m2 daily) was increased by 50% to 80% in 16 adult patients when coadministered with cyclosporine (plasma concentrations 297 - 5073 ng/mL).<sup>1</sup> The clearance of etoposide and the leukocyte nadir were both reduced. In a follow-up report, the authors concluded that the majority of the increased myelosuppression seen with cyclosporine coadministration was attributable to pharmacokinetic changes, and to a much lesser extent on a possible effect of cyclosporine itself in potentiating toxicity or enhancing penetration of bone marrow precursor cells, based on pharmacodynamic modeling.<sup>2</sup> <br><br>Another report (N=18 children) describes a 74% increase in etoposide AUC accompanied by increased effectiveness and toxicity of etoposide following the addition of high-dose cyclosporine (1359 - 4835 ng/mL in plasma).<sup>3</sup> The authors of this study and the authors of the original PK study in adults<sup>1</sup> both suggest a 50% dose reduction in etoposide in patients receiving high-dose cyclosporine. An additional study (N=38 children) that employed a preemptive 40% etoposide dose reduction with cyclosporine still showed a 47% average increase in etoposide AUC when cyclosporine was present (3000 - 5000 ng/mL in plasma), although between-subject variability was high.<sup>4</sup> <br><br>Cyclosporine likely increases etoposide concentrations in two main ways: it inhibits CYP3A4 which is a major metabolic pathway for etoposide; and it inhibits P-glycoprotein (P-gp) mediated transport of etoposide. The second effect, cyclosporine inhibition of P-gp, has also been investigated as a possible mechanism to overcome P-gp (often referred to as MDR1 in this context) mediated tumor resistance to etoposide <sup>3,5,6,7,8,9,10,11</sup> or to enhance CNS penetration of etoposide.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lum BL, Kaubisch S, Yahanda AM, et al, “Alteration of Etoposide Pharmacokinetics and Pharmacodynamics by Cyclosporine in a Phase I Trial to Modulate Multidrug Resistance,” <i>J Clin Oncol</i>, 1992, 10(10):1635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1403041\">[PubMed 1403041]</a></p>\n<p>2. Lum BL, Kaubisch S, Fisher GA, et al, “Effect of High-Dose Cyclosporine on Etoposide Pharmacodynamics in a Trial to Reverse P-Glycoprotein (MDR1 Gene) Mediated Drug Resistance,” <i>Cancer Chemother Pharmacol</i>, 2000, 45(4):305-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10755319\">[PubMed 10755319]</a></p>\n<p>3. Bisogno G, Cowie F, Boddy A, et al, “High-Dose Cyclosporine With Etoposide - Toxicity and Pharmacokinetic Interaction in Children With Solid Tumors,” <i>Br J Cancer</i>, 1998, 77:2304-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9649150\">[PubMed 9649150]</a></p>\n<p>4. Lacayo NJ, Lum BL, Becton DL, et al, “Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia,” <i>Leukemia</i>, 2002, 16(5):920-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11986955\">[PubMed 11986955]</a></p>\n<p>5. Yahanda AM, Alder KM, Fisher GA, et al, “Phase I Trial of Etoposide with Cyclosporine as a Modulator of Multidrug Resistance,” <i>J Clin Oncol</i>, 1992, 10(10):1624-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1403040\">[PubMed 1403040]</a></p>\n<p>6. Moore DF, Swan F, Yaj J, et al, “Cyclosporin plus Doxorubicin, Vincristine and Etoposide in the Treatment of Refractory Non-Hodgkin's Lymphoma: a Phase II Study,” <i>Clin Oncol (R Coll Radiol)</i>, 1995, 7(5):300-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8580055\">[PubMed 8580055]</a></p>\n<p>7. Maia RC, Carrico MK, Klumb CE, et al, “Clinical Approach to Circumvention of Multidrug Resistance in Refractory Leukemic Patients: Association of Cyclosporin A with Etoposide,” <i>J Exp Clin Cancer Res</i>, 1997, 16(4):419-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505216\">[PubMed 9505216]</a></p>\n<p>8. Tallman MS, Lee S, Sikic BI, et al, “Mitoxantrone, Etoposide, and Cytarabine plus Cyclosporine for Patients with Relapsed or Refractory Acute Myeloid Leukemia: an Eastern Cooperative Oncology Group Pilot Study,” <i>Cancer</i>, 85(2):358-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10023703\">[PubMed 10023703]</a></p>\n<p>9. Dahl GV, Lacayo NJ, Brophy N, et al, “Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients with Recurrent or Refractory Acute Myeloid Leukemia,” <i>J Clin Oncol</i>, 2000, 18(9):1867-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10784627\">[PubMed 10784627]</a></p>\n<p>10. Raschko JW, Synold TW, Chow W, et al, “A Phase I Study of Carboplatin and Etoposide Administered in Conjunction with Dipyridamole, Prochlorperazine and Cyclosporine A,” <i>Cancer Chemother Pharmacol</i>, 2000, 46(5):403-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11127945\">[PubMed 11127945]</a></p>\n<p>11. Davidson A, Dick G, Pritchard-Jones K, et al, “EVE/Cyclosporin (Etoposide, Vincristine, Epirubicin with High-Dose Cyclosporin)-Chemotherapy Selected for Multidrug Resistance Modulation,” <i>Eur J Cancer</i>, 2002, 38(18):2422-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12460787\">[PubMed 12460787]</a></p>\n<p>12. Greenberg ML, Fisher PG, Freeman C, et al, “Etoposide, Vincristine, and Cyclosporin A with Standard-Dose Radiation Therapy in Newly Diagnosed Diffuse Intrinsic Brainstem Gliomas: a Pediatric Oncology Group Phase I Study,” <i>Pediatr Blood Cancer</i>, 2005, 45(5):644-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16110498\">[PubMed 16110498]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5127":"<p><b>Title</b> Etoposide Phosphate / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Etoposide Phosphate. CycloSPORINE may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider empirically reducing the dose of etoposide phosphate in patients who are receiving or have recently received, cyclosporine. The authors of one report (involving intravenous etoposide) recommend reducing the etoposide dose by 50%;<sup>1</sup> however, another report described an increase in etoposide AUC of nearly 50% with cyclosporine coadministration, despite an empiric 40% decrease in etoposide dose.<sup>2</sup> In all cases, monitor closely for increased toxic effects of etoposide phosphate if cyclosporine is initiated or if the dose of cyclosporine is changed.</p> \n<p><b>Discussion</b> Etoposide phosphate is rapidly converted to etoposide by plasma phosphatases following administration; data regarding this potential drug interaction is based on reported interactions for etoposide.<br><br>The AUC of etoposide was increased by 50% to 80% in 16 patients when coadministered with cyclosporine.<sup>1</sup> The clearance of etoposide, and the leukocyte nadir, were both reduced. In a study of 38 children, cyclosporine administration with intravenous etoposide resulted in a 71% reduction in etoposide clearance and a 47% increase in etoposide AUC; these changes were observed despite an empiric 40% decrease in etoposide dose in the cyclosporine plus etoposide arm of the study.<sup>2</sup> In another study, both free (unbound) and total etoposide AUC were increased by more than 100% following intravenous etoposide plus cyclosporine (median concentration of 1,938 ug/mL) vs. etoposide alone.<sup>3</sup> This increase in etoposide exposure was also associated with a 12% greater decline in white blood count following etoposide plus cyclosporine. Another report describes an increase in effectiveness, and toxicity, of etoposide following the addition of high-dose cyclosporine.<sup>4</sup> These in vivo studies confirm the results of numerous <i>in vitro</i> and animal studies showing reduced etoposide clearance, greater etoposide concentrations, and enhanced etoposide activity with coadministration of cyclosporine.<br><br>The mechanism of this interaction is likely twofold. Etoposide is a substrate for, and cyclosporine an inhibitor of, both CYP3A4 isoenzymes and P-glycoprotein. The result would be a significant reduction in etoposide metabolism.<br><br>Since etoposide is subject to both renal and hepatic/biliary elimination, the degree to which changes in hepatic metabolism will be of clinical importance is unclear. For orally administered etoposide, there is evidence of appreciable first pass elimination, involving CYP3A4 and p-glycoprotein,<sup>5,6,7</sup> meaning that co-administration with an inhibitor or inducer of CYP3A4 and/or p-glycoprotein may lead to interactions that are more significant than those expected with intravenous etoposide products. Since etoposide phosphate is only available as an intravenous product, such considerations regarding CYP3A4 inducers and inhibitors are of particular importance when extrapolating etoposide drug interaction data. With regard to this potential cyclosporine-etoposide phosphate interaction, since the studies supporting the interaction used intravenous etoposide, the likelihood that a similar interaction could be observed with etoposide phosphate is high.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lum BL, Kaubisch S, Yahanda AM, et al, “Alteration of Etoposide Pharmacokinetics and Pharmacodynamics by Cyclosporine in a Phase I Trial to Modulate Multidrug Resistance,” <i>J Clin Oncol</i>, 1992, 10:1635-42.</p>\n<p>2. Lacayo NJ, Lum BL, Becton DL, et al, “Pharmacokinetic Interactions of Cyclosporine with Etoposide and Mitoxantrone in Children with Acute Myeloid Leukemia,” <i>Leukemia</i>, 2002, 16(5):920-7.</p>\n<p>3. Lum BL, Kaubisch S, Fisher GA, et al, “Effect of High-Dose Cyclosporine on Etoposide Pharmacodynamics in a Trial to Reverse P-Glycoprotein (MDR1 Gene) Mediated Drug Resistance,” <i>Cancer Chemother Pharmacol</i>, 2000, 45(4):305-11.</p>\n<p>4. Bisogno G, Cowie F, Boddy A, et al, “High-Dose Cyclosporine With Etoposide - Toxicity and Pharmacokinetic Interaction in Children With Solid Tumors,” <i>Br J Cancer</i>, 1998, 77:2304-9.</p>\n<p>5. Kawashiro T, Yamashita Z, Zhao XJ, et al, “A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes,” <i>J Pharmacol Exp Ther</i>, 1998, 286:1294-300.</p>\n<p>6. Leu BL, Huang JD, “Inhibition of Intestinal P-glycoprotein and Effects on Etoposide Absorption,” <i>Cancer Chemother Pharmacol</i>, 1995, 35:432-6.</p>\n<p>7. Lum BL, Kaubisch S, Yahanda AM, et al, “Alteration of Etoposide Pharmacokinetics and Pharmacodynamics by Cyclosporine in a Phase I Trial to Modulate Multidrug Resistance,” <i>J Clin Oncol</i>, 1992, 10:1635-42.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5128":"<p><b>Title</b> Everolimus / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Everolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When everolimus is used for treatment of renal cell carcinoma, everolimus prescribing information recommends avoiding concurrent use with cyclosporine, which is a moderate CYP3A4 inhibitor and an inhibitor of p-glycoprotein. However, when everolimus is used as a post-transplant immunosuppressant, it is often used with cyclosporine. With such concurrent use, lower cyclosporine doses and lower target serum cyclosporine concentrations must be used. Any changes in cyclosporine dose will likely result in changes in everolimus concentrations and may require everolimus dose adjustments. Close monitoring of both everolimus and cyclosporine serum concentrations is required with concurrent use.</p> \n<p><b>Discussion</b> Everolimus AUC increased considerably with two different formulations of cyclosporine when a single dose of everolimus (2mg) was combined a single dose of cyclosporine (74% increase with Sandimmune 300mg; 168% increase with Neoral 175mg) in a study of 24 healthy subjects.<sup>1</sup> Similarly, a study of 8 renal transplant recipients receiving everolimus plus tacrolimus found that everolimus exposure was 2.9-fold higher in a prior study using the combination of everolimus plus cyclosporine (n=47 renal transplant recipients) than that observed in their study of everolimus-tacrolimus.<sup>2</sup> In a study comparing immediate post-transplant cyclosporine initiation versus delayed cyclosporine initiation in renal transplant recipients (n=56) who were also being treated with everolimus, basiliximab, and corticosteroids, everolimus minimum plasma concentrations (Cmin) were 2.9-fold lower without concurrent cyclosporine (i.e., in the delayed initiation group).<sup>3</sup> Similarly, everolimus Cmin and AUC decreased by 45% and 48%, respectively, following a switch from cyclosporine to tacrolimus in a study of 6 cardiac transplant patients also receiving everolimus.<sup>4</sup><br><br>Studies examining the effects of everolimus on cyclosporine concentrations or dose-requirements have found no significant alteration in cyclosporine pharmacokinetics.<sup>5,6</sup><br><br>It appears that cyclosporine increases everolimus concentrations via inhibition of CYP3A4 and/or p-glycoprotein. Everolimus is a substrate for both CYP3A4 and p-glycoprotein.<sup>7</sup> Everolimus prescribing information recommendations vary according to specific product/indication.<sup>7,8</sup> When everolimus is used for treatment of renal cell carcinoma, everolimus (Afinitor brand product) prescribing information recommends avoiding concurrent use with strong or moderate CYP3A4 inhibitors as well as with p-glycoprotein inhibitors.<sup>7</sup> However, when everolimus (Zortress brand product) is used as a post-transplant immunosuppressant, it is often used with cyclosporine (and may be used with other CYP3A inhibitors).<sup>8</sup> With such concurrent use, lower cyclosporine doses and lower target serum cyclosporine concentrations must be used.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovarik JM, Kalbag J, Figueiredo J, et al, “Differential Influence of Two Cyclosporine Formulations on Everolimus Pharmacokinetics: A Clinically Relevant Pharmacokinetic Interaction,” <i>J Clin Pharmacol</i>, 2002, 42:95-9.</p>\n<p>2. Kovarik JM, Curtis JJ, Hricik DE, et al, “Differential Pharmacokinetic Interaction of Tacrolimus and Cyclosporine on Everolimus,” <i>Transplant Proc</i>, 2006, 38:3456-8.</p>\n<p>3. Kovarik JM, Dantal J, Civati G, et al, “Influence of Delayed Initiation of Cyclosporine on Everolimus Pharmacokinetics in De Novo Renal Transplant Patients,” <i>Am J Transplant</i>, 2003, 3:1576-80.</p>\n<p>4. Brandhorst G, Tenderich G, Zittermann A, et al, “Everolimus Exposure in Cardiac Transplant Recipients Is Influenced by Concomitant Calcineurin Inhibitor,” <i>Ther Drug Monit</i>, 2008, 30:113-6.</p>\n<p>5. Wang CH, Chou NK, Wu FL, et al, “Influence of Everolimus on Cyclosporine Neoral Pharmacokinetics in Chinese De Novo Cardiac Transplant Recipients,” <i>Transplant Proc</i>, 2006, 38:2032-4.</p>\n<p>6. Budde K, Lehne G, Winkler M, et al, “Influence of Everolimus on Steady-State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients,” <i>J Clin Pharmacol</i>, 2005, 45:781-91.</p>\n<p>7. Prescribing information. Afinitor (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, March 2009.</p>\n<p>8. Prescribing information. Zortress (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 03/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5129":"<p><b>Title</b> Ezetimibe / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of cyclosporine and ezetimibe if coadministered, especially in patients with severe renal impairment. A dosage adjustment for ezetimibe might be required.</p> \n<p><b>Discussion</b> Case report. The manufacturer reports that serum ezetimibe concentrations were increased twelvefold in a single renal transplant patient while also receiving several additional drugs, including cyclosporine.<sup>1</sup> The AUC of ezetimibe was increased 3.4-fold in 8 post-renal transplant patients (all with creatinine clearance &gt; 50 mL/min) receiving stable doses of cyclosporine (75 mg to 150 mg twice daily).<sup>1</sup> Another case report described a supratherapeutic response to ezetimibe (60% decrease in LDL cholesterol to 51 mg/dL while receiving 10 mg/day) in a heart transplant patient receiving cyclosporine.<sup>2</sup> Two months later, after decreasing the ezetimibe dose to 5 mg/day, the LDL remained at 57 mg/dL. The mechanism of this interacation is also unknown.<br><br>Additionally, the AUC of cyclosporine (100 mg single dose) was increased 15% in 12 normal subjects when administered on day 7 of an 8-day course of ezetimibe (20 mg daily).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zetia (ezetimibe). North Wales, PA: Merck/Schering Plough Pharmaceuticals, 2005.</p>\n<p>2. Koshman SL, Lalonde LD, Burton I, et al, “Supratherapeutic Response to Ezetimibe Administered with Cyclosporine,” <i>Ann Pharmacother</i>, 2005, 39(9):1561-5.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5130":"<p><b>Title</b> CycloSPORINE (Systemic) / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Closely monitor for increases in cyclosporine concentrations and serum creatinine with initiation/dose increase of fluconazole. Cyclosporine dose reduction may be necessary.</p> \n<p><b>Discussion</b> A number of case reports, retrospective reviews, and brief reports of clinical studies describe increases in serum cyclosporine concentrations, up to 2- to 3-fold, in patients receiving fluconazole.<sup>1,2,3,4,5,6,7</sup> Additionally, two controlled prospective clinical studies in patients have shown increases in average oral cyclosporine AUC (range 65-84%) and average trough concentration (115% in one study) with concomitant oral fluconazole (200 mg/day).<sup>8,9</sup> A similar study cited in fluconazole prescribing information showed a 92% average increase in AUC and 157% average increase in 24-hour trough cyclosporine concentration with fluconazole (200 mg/day for 14 days).<sup>10</sup><br><br>In contrast to studies using oral dosing, a study of allogeneic bone marrow transplant recipients showed a lower 21% increase in trough concentration and 21% decrease in clearance of cyclosporine (3 mg/kg/day continuous intravenous infusion) during concomitant intravenous fluconazole (400 mg/day).<sup>11</sup><br><br>The likely mechanism of the observed interaction is fluconazole inhibition of cyclosporine metabolism. Fluconazole inhibits CYP3A, the major pathway for cyclosporine metabolism, and two in vitro studies have demonstrated inhibition of cyclosporine metabolism in the presence of fluconazole.<sup>12,13</sup> While some clinical data suggest a reduced magnitude of drug interaction when fluconazole is administered intravenously, no direct comparison of the effects of oral vs. intravenous fluconazole has been conducted, and a small retrospective review suggested only a marginally greater magnitude of interaction with oral administration.<sup>14</sup> Further, the low magnitude of interaction demonstrated in the cited clinical study could be attributable to the intravenous administration of fluconazole, the intravenous administration of cyclosporine, the continuous infusion of cyclosporine, and other factors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Carleton BC, Graves NM, Matas AJ, et al, “Managing the Fluconazole and Cyclosporine Interaction: Results of a Double-Blind Randomized Pharmacokinetic and Safety Study,” <i>Pharmacotherapy</i>, 1990, 10:250.</p>\n<p>2. Graves NM, Matas AJ, Hilligoss DM, et al, “Fluconazole/Cyclosporine Interaction,” <i>Clin Pharmacol Ther</i>, 1990, 47:208.</p>\n<p>3. Sugar AM, Saunders C, Idelson BA, et al, “Interaction of Fluconazole and Cyclosporine,” <i>Ann Intern Med</i>, 1989, 110:844. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2540690\">[PubMed 2540690]</a></p>\n<p>4. Lopez-Gil JA, “Fluconazole-Cyclosporine Interaction: A Dose-Dependent Effect?” <i>Ann Pharmacother</i>, 1993, 27(4):427-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8477116\">[PubMed 8477116]</a></p>\n<p>5. Torregrosa V, De la Torre M, Campistol JM, et al, “Interaction of Fluconazole with Ciclosporin A,” <i>Nephron</i>, 1992, 60(1):125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1738408\">[PubMed 1738408]</a></p>\n<p>6. Sugar AM, Saunders C, Idelson BA, et al, “Interaction of Fluconazole and Cyclosporine,” <i>Ann Intern Med</i>, 1989, 110(10):844. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2540690\">[PubMed 2540690]</a></p>\n<p>7. Mathis AS, DiRenzo T, Friedman GS, et al, “Sex and Ethnicity May Chiefly Influence the Interaction of Fluconazole with Calcineurin Inhibitors,” <i>Transplantation</i>, 2001, 71(8):1069-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11374405\">[PubMed 11374405]</a></p>\n<p>8. Sud K, Singh B, Krishna VS, et al, “Unpredictable Cyclosporin--Fluconazole Interaction in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 1999, 14(7):1698-703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435879\">[PubMed 10435879]</a></p>\n<p>9. Canafax DM, Graves NM, Hilligoss DM, et al, “Interaction Between Cyclosporine and Fluconazole in Renal Allograft Recipients,” <i>Transplantation</i>, 1991, 51(5):1014-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2031258\">[PubMed 2031258]</a></p>\n<p>10. Prescribing information. Diflucan (fluconazole). New York, NY: Pfizer, Inc, April 2010.</p>\n<p>11. Osowski CL, Dix SP, Lin LS, et al, “Evaluation of the Drug Interaction Between Intravenous High-Dose Fluconazole and Cyclosporine or Tacrolimus in Bone Marrow Transplant Patients,” <i>Transplantation</i>, 1996, 61(8):1268-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8610430\">[PubMed 8610430]</a></p>\n<p>12. Omar G, Whiting PH, Hawksworth GM, et al, “Ketoconazole and Fluconazole Inhibition of the Metabolism of Cyclosporin A by Human Liver In Vitro,” <i>Ther Drug Monit</i>, 1997, 19(4):436-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9263386\">[PubMed 9263386]</a></p>\n<p>13. Back DJ and Tjia JF, “Comparative Effects of the Antimycotic Drugs Ketoconazole, Fluconazole, Itraconazole and Terbinafine on the Metabolism of Cyclosporin by Human Liver Microsomes,” <i>Br J Clin Pharmacol</i>, 1991, 32(5):624-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1659439\">[PubMed 1659439]</a></p>\n<p>14. Mihara A, Mori T, Aisa Y, et al, “Greater Impact of Oral Fluconazole on Drug Interaction with Intravenous Calcineurin Inhibitors as Compared with Intravenous Fluconazole,” <i>Eur J Clin Pharmacol</i>, 2008, 64(1):89-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17965855\">[PubMed 17965855]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5131":"<p><b>Title</b> CycloSPORINE (Systemic) / Grapefruit Juice</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is primarily limited to orally administered cyclosporine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the metabolism of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/effects of orally administered cyclosporine if grapefruit juice is initiated/dose increased, or the consumption schedule is changed, or decreased effects if grapefruit juice is discontinued/dose decreased. Advise patients to not alter their consumption pattern of grapefruit/grapefruit juice without consulting their healthcare provider.</p> \n<p><b>Discussion</b> Serum cyclosporine concentrations have been increased as much as 70% when coadministered with 6-8 ounces of grapefruit juice.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18</sup> The mechanism of this interaction is presumably related to the ability of grapefruit juice to inhibit CYP3A4 isoenzymes in the gastrointestinal tract, resulting in increased quantities of cyclosporine available for absorption. As expected, IV cyclosporine is not affected by grapefruit juice.<sup>4</sup> Further, orange juice does not appear to affect cyclosporine concentrations.<sup>3,4,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Edwards DJ, Ducharme MP, Provenzano R, et al, “Effect of Grapefruit Juice on Blood Concentrations of Cyclosporine,” <i>Clin Pharmacol Ther</i>, 1993, 53:237.</p>\n<p>2. Ducharme MP, Provenzano R, Dehoorne-Smith M, et al, “Trough Concentrations of Cyclosporine in Blood Following Administration With Grapefruit Juice,” <i>Br J Clin Pharm</i>, 1993, 36:457-9.</p>\n<p>3. Yee GC, Stanley DL, Ruiz J, et al, “Effect of Grapefruit Juice on Oral Cyclosporine Pharmacokinetics,” <i>Pharmacotherapy</i>, 1994, 14:377.</p>\n<p>4. Yee GC, Stanley DL, Pessa LJ, et al, “Effect of Grapefruit Juice on Blood Cyclosporine Concentration,” <i>Lancet</i>, 1995, 345:955-6.</p>\n<p>5. Yee GC, Adams VR, Pessa L, et al, “Comparison on One Versus Two Doses of Grapefruit Juice on Oral Cyclosporine Pharmacokinetics,” <i>Pharmacotherapy</i>, 1997, 17:1112.</p>\n<p>6. Ku YM, Min KE, and Flanigan MJ, “The Effect of Grapefruit Juice on Microemulsion Cyclosporine (Neoral) Pharmacokinetics in Healthy Volunteers,” <i>Pharmacotherapy</i>, 1998, 18:442.</p>\n<p>7. Proppe D, Visser K, Bartels R, et al, “Grapefruit Juice Selectively Modifies Cyclosporine A Metabolite Patterns in Renal Transplant Patients,” <i>Clin Pharmacol Ther</i>, 1996, 59:138.</p>\n<p>8. Min DI, Ku YM, Perry PJ, et al, “The Effect of Grapefruit Juice on Cyclosporine Pharmacokinetics in Renal Allograft Recipients,” <i>Pharmacotherapy</i>, 1996, 16:516.</p>\n<p>9. Edwards DJ, Woster PM, and Warbasse LH, “Effect of Grapefruit Juice and Seville Orange Juice on Cyclosporine Disposition,” <i>Clin Pharmacol Ther</i>, 1998, 63:149.</p>\n<p>10. Hollander AA, van Rooij J, Lentjes GW, et al, “The Effect of Grapefruit Juice on Cyclosporine and Prednisone Metabolism in Transplant Patients,” <i>Clin Pharmacol Ther</i>, 1995, 57:318-24.</p>\n<p>11. Mehrsai AR, Pourmand G, Mansour D, et al, “Effect of Grapefruit Juice on Serum Concentration of Cyclosporine in Iranian Renal Transplant Patients,” <i>Transplant Proc</i>, 2003, 35: 2739-41. [PMID 14612100]</p>\n<p>12. Hermann M, Asberg A, Reubsaet JL, et al, “Intake of Grapefruit Juice Alters the Metabolic Pattern of Cyclosporine A in Renal Transplant Recipients,” <i>Int J Clin Pharmacol Ther</i>, 2002, 40:451-6.[PMID 12395977] </p>\n<p>13. Bistrup C, Nielsen FT, Jeppesen UE, et al, “Effect of Grapefruit Juice on Sandimmune Neoral Absorption Among Stable Renal Allograft Recipients,” <i>Nephrol Dial Transplant</i>, 2001, 16:373-7. [PMID 11158415]</p>\n<p>14. Lee M, Min DI, Ku YM, et al, “Effect of Grapefruit Juice on Pharmacokinetics of Microemulsion Cyclosporine in African American Subjects Compared with Caucasian Subjects: Does Ethnic Difference Matter?” <i>J Clin Pharmacol</i>, 2001, 41:317-23.</p>\n<p>15. Brunner LJ, Pai KS, Munar MY, et al, “Effect of Grapfruit Juice on Cyclosporin A Pharmacokinetics in Pediatric Renal Transplant Patients,” <i>Pediatr Transplant</i>, 2000, 4:313-21.</p>\n<p>16. Brunner LJ, Munar MY, Vallian J, et al, “Interaction Between Cyclosporine and Grapefruit Juice requires Long-Term Ingestion in Stable Renal Transplant Recipients,” <i>Pharmacotherapy</i>, 1998, 18:23-9. [PMID 9469677]</p>\n<p>17. Ioannides-Demos LL, CHristophidis N, Ryan P, et al, “Dosing Implications of a Clinical Interaction Between Grapefruit Juice and Cyclosporine and Metabolite Concentrations in Patients with Autoimmune Diseases,” <i>J Rheumatol</i>, 1997, 24: 49-54. [PMID 9002010]</p>\n<p>18. Ducharme MP, Warbasse LH, and Edwards DJ, “Disposition of Intravenous and Oral Cyclosporine After Administration with Grapefruit Juice,” <i>Clin Pharmacol Ther</i>, 1995, 57: 485-91. [PMID 7768070]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5132":"<p><b>Title</b> CycloSPORINE (Systemic) / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Griseofulvin may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if griseofulvin is initiated/dose increased, or increased serum concentrations/effects if griseofulvin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Serum cyclosporine concentrations were decreased by approximately 45% in a patient within 2 weeks of initiating griseofulvin therapy (500 mg/day), in spite of a 70% increase in cyclosporine dosage.<sup>1</sup> The eventual discontinuation of the griseofulvin was accompanied by a fourfold increase in serum cyclosporine concentrations. <br><br>The most likely mechanism of this interaction is griseofulvin induction of CYP3A4 mediated cyclosporine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abu-Romeh SH and Rashed A, “Cyclosporine A and Griseofulvin: Another Drug Interaction,” <i>Nephron</i>, 1991, 58:237.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5133":"<p><b>Title</b> CycloSPORINE (Systemic) / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor serum cyclosporine concentrations if an H<sub>2</sub>-antagonist is initiated, discontinued, or the dose is changed.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> Data are inconsistent. Some reports implicate cimetidine and famotidine as increasing cyclosporine concentrations and/or decreasing cyclosporine clearance,<sup>1,2</sup> while other reports suggest that neither cimetidine, famotidine, nor ranitidine affect cyclosporine concentrations.<sup>3,4,5</sup> The mechanism of a possible interaction is unknown. Rises in serum creatinine have been observed in both kidney and heart transplant patients receiving cyclosporine following the addition of either cimetidine or ranitidine.<sup>6</sup> These rises have been reported from 37% to 62%, some of which are transient, and may be due to competition between the H<sub>2</sub>-antagonist and creatinine for secretion sites in the renal tubules (thus not reflecting drug-induced renal dysfunction).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine After Heart Transplantation: Experimental and Clinical Results,” <i>J Heart Lung Transplant</i>, 1993, 12(6 Pt 1):987-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8312324\">[PubMed 8312324]</a></p>\n<p>2. D'Souza MJ, Pollock SH, Solomon HM, “Cyclosporine-Cimetidine Interaction,” <i>Drug Metab Dispos</i>, 1988, 16(1):57-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2894956\">[PubMed 2894956]</a> </p>\n<p>3. Shaefer MS, Rossi SJ, McGuire TR, et al, “Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men,” <i>Ann Pharmacother</i>, 1995, 29(11):1088-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8573949\">[PubMed 8573949]</a></p>\n<p>4. Jadoul M and Hene RJ, “Ranitidine and the Cyclosporine Treated Recipient,” <i>Transplantation</i>, 1989, 48(2):359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2667215\">[PubMed 2667215]</a></p>\n<p>5. Tsang VT, Johnston A, Heritier F, et al, “Cyclosporine Pharmacokinetics in Heart-Lung Transplant Recipients With Cystic Fibrosis Effects of Pancreatic Enzymes and Ranitidine,” <i>Eur J Clin Pharmacol</i>, 1994, 46(3):261-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8070508\">[PubMed 8070508]</a></p>\n<p>6. Jarowenko MV, Van Buren CT, Kramer WG, et al, “Ranitidine, Cimetidine, and the Cyclosporine-Treated Recipient,” <i>Transplantation</i>, 1986, 42(3):311-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3529532\">[PubMed 3529532]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5134":"<p><b>Title</b> CycloSPORINE (Systemic) / Imatinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Imatinib may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cyclosporine serum concentrations and watch for signs/symptoms of toxicity when imatinib is initiated or discontinued in patients receiving cyclosporine.</p> \n<p><b>Discussion</b> Cyclosporine product labeling lists imatinib as an agent that can increase cyclosporine concentrations,<sup>1</sup> but there are a lack of published data regarding this potential interactions in humans. One study in rats reported an interaction between orally administered cyclosporine and imatinib (increased cyclosporine AUC, bioavailability, and maximum concentration), but the interaction was not apparent between intravenous cyclosporine and imatinib.<sup>2</sup> This discrepancy between oral and intravenous cyclosporine led the authors to conclude that imatinib increased the intestinal absorption of cyclosporine via a mechanism involving CYP3A and/or the drug transporters p-glycoprotein and/or breast cancer resistance protein (BCRP, ABCG2). In vitro evidence suggests imatinib is a substrate for and an inhibitor of p-glycoprotein,<sup>3</sup> which is an important determinant of cyclosporine disposition and elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product labeling. Neoral (cyclosporine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, August 2005.</p>\n<p>2. Kajita T, Higashi Y, Imamura M, et al, “Effect of Imatinib Mesilate on the Disposition Kinetics of Ciclosporin in Rats,” <i>J Pharm Pharmacol</i>, 2006, 58:997-1000.</p>\n<p>3. Hamada A, Miyano H, Watanabe H, et al, “Interaction of Imatinib Mesilate with Human P-Glycoprotein,” <i>J Pharmacol Exp Ther</i>, 2003, 307:824-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5135":"<p><b>Title</b> Imipenem / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the neurotoxic effect of Imipenem. Imipenem may decrease the serum concentration of CycloSPORINE (Systemic). Imipenem may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of neurotoxicity if cyclosporine and imipenem are used concomitantly. In addition, monitor for altered (increased or decreased) serum concentrations (and associated toxicities) of cyclosporine if imipenem is used concomitantly.</p> \n<p><b>Discussion</b> According to one published case report, a cyclosporine-treated patient developed disorientation, confusion, agitation, motor aphasia, and tremor within 20 minutes of receiving a second dose of imipenem/cilastatin (500 mg every 12 hours).<sup>1</sup> These adverse effects diminished over the next few days (in the absence of imipenem administration). Also of note, the patient's serum cyclosporine concentrations increased approximately 150% over the 4 days following the initial event. This report is in contrast with data from animal studies showing that pretreatment with or coadministration of imipenem/cilastatin was associated with a decrease in cyclosporine concentrations.<sup>2,3</sup> In one animal study, coadministration of imipenem/cilastatin with cyclosporine was associated with an average 35% reduction in cyclosporine minimum plasma concentrations (Cmin).<sup>2</sup> Additionally, animals receiving coadministered imipenem/cilastatin demonstrated less nephrotoxicity than animals receiving cyclosporine alone.<br><br>Though not designed to evaluate any potential pharmacokinetic interaction, a study of 166 bone marrow transplant patients found no differences in seizure rates between patients receiving concurrent cyclosporine and imipenem/cilastatin (n=45) and those receiving either cyclosporine alone (n=77) or imipenem/cilastatin alone (n=44).<sup>4</sup><br><br>The mechanism(s), as well as the cause-effect relationship, of any possible interaction(s) between cyclosporine and imipenem/cilastatin is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zazgornik J, Schein W, Heimberger K, et al, “Potentiation of Neurotoxic Side Effects by Coadministration of Imipenem to Cyclosporine Therapy in a Kidney Transplant Recipient, Synergism of Side Effects or Drug Interaction?” <i>Clin Nephrol</i>, 1986, 26:265-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3467883\">[PubMed 3467883]</a></p>\n<p>2. Mraz W, Sido B, Knedel M, et al, “Concomitant Immunosuppressive and Antibiotic Therapy--Reduction of Cyclosporine A Blood Levels Due to Treatment with Imipenem/Cilastatin,” <i>Transplant Proc</i>, 1987, 19(5):4017-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3478881\">[PubMed 3478881]</a></p>\n<p>3. Mraz W, Modic PK, Hammer C, “Impact of Imipenem/Cilastatin on Cyclosporine Metabolism and Excretion,” <i>Transplant Proc</i>, 1992, 24(5):1704-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1412804\">[PubMed 1412804]</a></p>\n<p>4. Turhal NS, “Cyclosporin A and Imipenem Associated Seizure Activity in Allogeneic Bone Marrow Transplantation Patients,” <i>J Chemother</i>, 1999, 11(5):410-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10632390\">[PubMed 10632390]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5137":"<p><b>Title</b> CycloSPORINE (Systemic) / Melphalan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Melphalan may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nephrotoxicity in cyclosporine-treated patients who receive melphalan.</p> \n<p><b>Discussion</b> Renal failure developed in 13 of 17 patients receiving concurrent cyclosporine (12.5 mg/kg/day) and melphalan (140-250 mg/m<sup>2</sup> as a single dose), compared with 0 of 7 patients receiving melphalan alone.<sup>1</sup> Renal toxicity is a common adverse effect of cyclosporine therapy, but not with melphalan. The incidence of toxicity in the concomitant therapy group would suggest the potential for melphalan to increase toxicity in cyclosporine-treated patients but requires additional study. Nonetheless, exercising caution with concomitant therapy appears warranted.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Morgenstern GR, Powles R, Robinson B, McElwain TJ. Cyclosporin interaction with ketoconazole and melphalan. <i>Lancet</i>. 1982;2(8311):1342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6128626\">[PubMed 6128626]</a></p>\n<p>2. Alkeran (melphalan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2011.</p>\n<p>3. Evomela (melphalan) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5138":"<p><b>Title</b> Methotrexate / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Combination therapy with these agents is occasionally indicated. If cyclosporine and methotrexate are used concurrently, increased monitoring for potential toxicities of each, including nephrotoxicity, hepatotoxicity, hypertension, nausea, vomiting, and mouth ulcers. Previous use of methotrexate may cause increased risk of cyclosporine toxicity, even in the absence of current methotrexate therapy, and, therefore, renal function and blood pressure should still be more closely monitored.</p> \n<p><b>Discussion</b> The AUC of methotrexate was increased by 26% when coadministered with cyclosporine (1.5 mg/kg every 12 hours for 14 days).<sup>1</sup> The concentration of its major metabolite (less active but more toxic) was reduced by approximately 80%. Concomitant administration of cyclosporine (5 mg/kg/day) and methotrexate (2.5 mg every 12 hours or 3 doses at weekly intervals) in 4 patients resulted in increased serum cyclosporine and methotrexate concentrations, as well as increased adverse effects (nausea, vomiting, oral ulcers, and increased serum creatinine, ALT, and AST).<sup>2</sup> In yet another study, increased serum cyclosporine and creatinine concentrations, and hypertension, were more evident in cyclosporine-treated patients if they had previously received methotrexate.<sup>3</sup> On the other hand, concomitant therapy using reduced doses of cyclosporine has been safely and effectively used in the treatment of graft-versus-host.<sup>4</sup> The administration of methotrexate (a hepatotoxic agent) or cyclosporine (a nephrotoxic agent) may predispose the patient to toxicity of the other agent. A firm mechanism of these interactions, however, is still unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fox R, Morgan S, Smith H, et al, “Treatment of RA Patients With Methotrexate (MTX) Plus Cyclosporine A (CSA) Leads to Elevation of Plasma MTX Levels and Decrease of 7 Hydroxymethotrexate (7-OH) Levels,” <i>Arthritis Rheum</i>, 1998, 41(Suppl 9):S138.</p>\n<p>2. Korstanje MJ, van Breda Vriesman CJ, and van de Staak WJ, “Cyclosporine and Methotrexate: A Dangerous Combination,” <i>J Am Acad Dermatol</i>, 1990, 23:320-1.</p>\n<p>3. Powles AV, Baker BS, Fry L, et al, “Cyclosporine Toxicity,” <i>Lancet</i>, 1990, 335:610.</p>\n<p>4. Stockschlaeder M, Storb R, Pepe M, et al, “A Pilot Study of Low Dose Cyclosporine for Graft-Versus-Host Prophylaxis in Marrow Transplantation,” <i>Br J Haematol</i>, 1991, 80:49-54.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5139":"<p><b>Title</b> CycloSPORINE (Systemic) / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metoclopramide may increase the absorption of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations of cyclosporine if metoclopramide is initiated/dose increased, or decreased effects if metoclopramide is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of cyclosporine was increased an average of 29% in 14 patients when administered concurrent with a single dose of metoclopramide.<sup>1</sup> The extent of effect of multiple doses of metoclopramide is unknown. The mechanism of this interaction is presumed to be due to the prokinetic effects of metoclopramide on the gastrointestinal tract, which result in a more rapid transport of cyclosporine to the small intestine (its place of absorption) reducing the opportunity for degradation by other metabolic mechanisms. The clinical impact of this interaction is unknown. It has been suggested that such an interaction might be exploited to save money in cyclosporine therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wadhwa NK, Schroeder TJ, O’Flaherty E, et al, “The Effect of Oral Metoclopramide on the Absorption of Cyclosporine,” <i>Transplant Proc</i>, 1987, 19:1730-3.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5141":"<p><b>Title</b> Mycophenolate / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Changes in mycophenolate dosing may be required depending on whether or not patients are also receiving cyclosporine. Monitor mycophenolate dosing and response to therapy particularly closely when adjusting concurrent cyclosporine (starting, stopping, or changing dose).</p> \n<p><b>Discussion</b> The Cyclosporine Avoidance Eliminates Serious Adverse Renal-toxicity (CAESAR) study randomized renal transplant patients taking mycophenolate mofetil (MMF) to receive standard dose cyclosporine, low dose cyclosporine, or complete cyclosporine withdrawl. Of the 536 randomized patients, 110 were evaluated in a pharmacokinetic substudy. After 12 months, the AUC of mycophenolic acid (MPA; active metabolite of mycophenolate) rose 45% and the MPA glucuronide conjugate (MPAG) decreased 26% in patients withdrawn from cyclosporine compared to those on standard dose.<sup>1</sup> One small study describes the effects of cyclosporine discontinuation on MPA and MPAG in 5 kidney transplant recipients.<sup>2</sup> Within 1 week of cyclosporine discontinuation, mean MPA AUC increased 31%, and mean MPA trough (pre-dose) concentrations increased 78%. Both remained slightly but non-significantly increased 6 months after cyclosporine discontinuation (approximately 10% and 20% increased vs. baseline, respectively). MPAG AUC (0-2 hr) and trough concentrations were significantly decreased 1 week after cyclosporine discontinuation. A retrospective analysis of pharmacokinetic data from 23 pediatric renal transplant recipients found evidence of a concentration-dependent effect of cyclosporine on MPA concentrations, reporting a significant negative association between cyclosporine AUC and MPA AUC.<sup>3</sup> In a study comparing MMF dose requirements and MPA pharmacokinetics among pediatric kidney transplant recipients, the average MMF dose requirement was 34% greater in patients receiving both cyclosporine and MMF (n=15) than in patients receiving MMF with no concurrent calcineurin inhibitor (n=13).<sup>4</sup> <br><br>Other studies of the cyclosporine-MMF interaction have compared cyclosporine to either tacrolimus, sirolimus or everolimus, reporting significantly decreased MPA AUC (approximately 25%-40% lower) and decreased trough MPA concentrations with cyclosporine, and increased concentrations and decreased total clearance of the MPAG metabolite.<sup>5,6,7,8,9,10,11</sup> One study of 24 renal transplant recipients maintained on cyclosporine or tacrolimus reported disparate results, showing that dose-normalized MPA concentrations were higher in cyclosporine-treated patients.<sup>12</sup> Of the 12 cyclosporine-treated patients, 10 were receiving ketoconazole, but it is not clear what effect, if any, this concurrent therapy had on these results.<br><br>Available data suggest the mechanism of this cyclosporine-MMF interaction is cyclosporine-mediated inhibition of biliary excretion of MPAG via the multidrug resistance-associated protein 2 (MRP2) transporter.<sup>13,14,15</sup> Such inhibition of MPAG biliary excretion leads to decreased enterohepatic recirculation, decreasing the “second MPA peak” observed in several pharmacokinetic studies.<sup>5,9,10,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuypers DR, Ekberg H, Grinyo J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporine in renal transplant recipients. <i>Clin Pharmacokinet</i>. 2009;48(5):329-341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19566116\">[PubMed 19566116]</a></p>\n<p>2. Shipkova M, Armstrong VW, Kuypers D, et al; MMF Creeping Creatinine Study Group. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. <i>Ther Drug Monit</i>. 2001;23(6):717-721. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11802109\">[PubMed 11802109]</a></p>\n<p>3. Filler G, Lepage N, Delisle B, Mai I. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. <i>Ther Drug Monit</i>. 2001;23(5):514-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11591896\">[PubMed 11591896]</a></p>\n<p>4. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. <i>Pediatr Nephrol</i>. 2000;14(2):100-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10684356\">[PubMed 10684356]</a></p>\n<p>5. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. <i>Am J Transplant</i>. 2005;5(12):2937-2944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16303008\">[PubMed 16303008]</a></p>\n<p>6. Picard N, Premaud A, Rousseau A, Le Meur Y, Marquet P. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. <i>Br J Clin Pharmacol</i>. 2006;62(4):477-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16995869\">[PubMed 16995869]</a></p>\n<p>7. Buchler M, Lebranchu Y, Beneton M, et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. <i>Clin Pharmacol Ther</i>. 2005;78(1):34-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16003290\">[PubMed 16003290]</a></p>\n<p>8. El Haggan W, Ficheux M, Debruyne D, et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. <i>Transplant Proc</i>. 2005;37(2):864-866. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15848558\">[PubMed 15848558]</a></p>\n<p>9. Kuriata-Kordek M, Boratynska M, Falkiewicz K, et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. <i>Transplant Proc</i>. 2003;35(6):2369-2371. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14529944\">[PubMed 14529944]</a></p>\n<p>10. Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. <i>Br J Clin Pharmacol</i>. 2005;60(3):249-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16120063\">[PubMed 16120063]</a></p>\n<p>11. Noreikaite A, Saint-Marcoux F, Marquet P, Kadusevicius E, Stankevicius E. Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: cross-sectional study. <i>Medicine (Baltimore)</i>. 2017;96(13):e6469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28353583\">[PubMed 28353583]</a></p>\n<p>12. Patel CG, Harmon M, Gohh RY, Akhlaghi F. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. <i>Ther Drug Monit</i>. 2007;29(1):87-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17304155\">[PubMed 17304155]</a></p>\n<p>13. Cellcept (mycophenolate mofetil) [prescribing information]. Nutley, NJ: Roche Laboratories Inc; December 2007.</p>\n<p>14. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. <i>Drug Metab Dispos</i>. 2006;34(2):261-266. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16272406\">[PubMed 16272406]</a></p>\n<p>15. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. <i>Am J Transplant</i>. 2005;5(5):987-994. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816878\">[PubMed 15816878]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5142":"<p><b>Title</b> CycloSPORINE (Systemic) / Nafcillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nafcillin may increase the metabolism of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations and effects of cyclosporine if nafcillin is initiated/dose increased, or increased concentrations/effects if nafcillin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Case report. Serum cyclosporine concentrations decreased by more than 70% after 7-9 days of nafcillin therapy (2 g every 6 hours) in a female patient on 2 separate occasions.<sup>1</sup> The incidence of renal toxicity was increased in a group of cyclosporine-treated patients when they received concomitant nafcillin therapy (times 1 week for prophylaxis against staphylococci), but serum cyclosporine concentrations were not noted to have increased.<sup>2</sup> Nafcillin appears to be an effective inducer of CYP3A4 enzymes of which cyclosporine is a substrate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Veremis SA, Maddux MS, Pollak R, et al, “Subtherapeutic Cyclosporine Concentrations During Nafcillin Therapy,” <i>Transplantation</i>, 1987, 43:913-5.</p>\n<p>2. Jahansouz F, Kriett JM, Smith CM, et al, “Potentiation of Cyclosporine Nephrotoxicity by Nafcillin in Lung Transplantation Patients,” <i>Transplantation</i>, 1993, 55:1045-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5143":"<p><b>Title</b> CycloSPORINE (Systemic) / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider using agents other than nonsteroidal anti-inflammatory agents (NSAIDs) to avoid the risk of this interaction. Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> A number of case reports and small clinical studies describe increases in serum creatinine concentrations and/or increases in blood pressure during concomitant therapy with cyclosporine and nonsteroidal anti-inflammatory agents (NSAIDs).<sup>1,2</sup> A study in healthy volunteers found a 37% decrease in glomerular filtration rate when indomethacin was added to cyclosporine.<sup>3</sup> Diclofenac, ketoprofen, mefenamic acid, naproxen, piroxicam, and sulindac administration have been reported to increase serum creatinine concentrations as much as 2-fold, sometimes occurring within 24 hours of starting therapy.<sup>2,4,5,6,7,8,9</sup> Reversible colitis has also been reported as a possible adverse effect of coadministration of cyclosporine and NSAIDs, and occurred in a patient on three separate occasions using three different regimens containing cyclosporine with either diclofenac or indomethacin.<sup>10</sup><br><br>Serum cyclosporine concentrations have increased by more than 2-fold with NSAID coadministration,<sup>2,9,11</sup> and diclofenac serum concentrations and AUC have increased approximately 2-fold during concomitant cyclosporine treatment.<sup>1,11,12,13</sup> These increases in serum concentrations have been associated with renal toxicity in some cases, but both drug concentration elevations and renal toxicity have also occurred independently. Conversely, the time to maximum serum concentration (t<sub>max</sub>) of cyclosporine was delayed when combined with dipyrone. However, this delay did not diminish serum concentrations or affect other pharmacokinetis parameters as the maximum serum concentration (C<sub>max</sub>), half-life, AUC, and serum trough concentrations (C<sub>min</sub>) of cyclosporine were unaffected by dipyrone.<sup>14</sup> The clinical significance of this is unknown.<br><br>The mechanism(s) for these effects has not been specifically investigated. It has been proposed that NSAID disruption of prostaglandin synthesis (especially in the kidney) may predispose patients to cyclosporine-induced renal toxicity, even in the absence of elevated cyclosporine concentrations<sup>1,11,15</sup>. Cyclosporine may inhibit CYP3A4 and/or 2C9 mediated diclofenac metabolism, particularly its first-pass metabolism. <sup>1,15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovarik JM, Mueller EA, Gerbeau C, Tarral A, Francheteau P, Guerret M. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. <i>J Clin Pharmacol</i>. 1997;37(4):336-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9115060\">[PubMed 9115060]</a></p>\n<p>2. Agar JW. Cyclosporin A and mefenamic acid in a renal transplant patient. <i>Aust N Z J Med</i>. 1991;21(5):784-785. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1759935\">[PubMed 1759935]</a></p>\n<p>3. Sturrock ND, Lang CC, Struthers AD. Indomethacin and cyclosporine together produce marked renal vasoconstriction in humans. <i>J Hypertens</i>. 1994;12:919-924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7814851\">[PubMed 7814851]</a></p>\n<p>4. Branthwaite JP, Nicholls A. Cyclosporine and diclofenac interaction in rheumatoid arthritis. <i>Lancet</i>. 1991;337(8735):252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1670893\">[PubMed 1670893]</a></p>\n<p>5. Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A. Enhancement of cyclosporine A nephrotoxicity by diclofenac. <i>Clin Nephrol</i>. 1987;27(4):213-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2953512\">[PubMed 2953512]</a></p>\n<p>6. Tugwell P, Ludwin D, Gent M, et al. Multiple cross-over study to examine the interaction between cyclosporine and nonsteroidal anti-inflammatory drugs. <i>Arthritis Rheum</i>. 1994;37(Suppl 9):S335. [Abstract]</p>\n<p>7. Ludwin D, Bennett KJ, Grace EM, et al. Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine. <i>Transplant Proc</i>. 1988;20(3)(Suppl 4):367-370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381299\">[PubMed 3381299]</a></p>\n<p>8. Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. <i>Am J Med</i>. 1992;93(4):396-402. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1415303\">[PubMed 1415303]</a></p>\n<p>9. Sesin GP, O’Keefe E, Roberto P. Sulindac-induced elevation of serum cyclosporine concentration. <i>Clin Pharm</i>. 1989;8(6):445-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2663332\">[PubMed 2663332]</a></p>\n<p>10. Constantopoulos A. Colitis induced by interaction of cyclosporine A and non-steroidal anti-inflammatory drugs. <i>Pediatr Int</i>. 1999;41(2):184-186. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10221025\">[PubMed 10221025]</a></p>\n<p>11. Harris KP, Jenkins D, Walls J. Nonsteroidal anti-inflammatory drugs and cyclosporine. A potentially serious adverse interaction. <i>Transplantation</i>. 1988;46(4):598-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3176159\">[PubMed 3176159]</a></p>\n<p>12. Kovarik JM, Kurki P, Mueller E, et al. Diclofenac combined with cyclosporine in treatment of refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. <i>J Rheumatol</i>. 1996;23:2033-2038. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8970037\">[PubMed 8970037]</a></p>\n<p>13. <i>Gengraf</i> (cyclosporine). [Prescribing information] North Chicago, IL: Abbott Laboratories, January 2010.</p>\n<p>14. Caraco Y, Zylber-Katz E, Fridlander M, Admon D, Levy M. The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. <i>Eur J Clin Pharmacol</i>. 1999;55(6):475-478. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10492062\">[PubMed 10492062]</a> </p>\n<p>15. Mueller EA, Kovarik JM, Koelle EU, Merdjan H, Johnston A, Hitzenberger G. Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. <i>J Clin Pharmacol</i>. 1993;33(10):936-943. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8227465\">[PubMed 8227465]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5144":"<p><b>Title</b> CycloSPORINE (Systemic) / Norfloxacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Norfloxacin may decrease the metabolism of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum cyclosporine concentrations if norfloxacin is initiated/dose increased, and decreased concentrations if norfloxacin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> An observational study revealed that pediatric renal transplant patients receiving norfloxacin required 40% lower daily doses of cyclosporine to maintain trough blood concentrations of 150-400 ng/mL compared to patients not receiving norfloxacin.<sup>1</sup> Norfloxacin likely inhibited the CYP3A4-mediated metabolism of cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McLellan RA, Drobitch RK, McLellan H, et al, “Norfloxacin Interferes With Cyclosporine Disposition in Pediatric Patients Undergoing Renal Transplantation,” <i>Clin Pharmacol Ther</i>, 1995, 58(3):322-7.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5145":"<p><b>Title</b> CycloSPORINE (Systemic) / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Omeprazole may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations closely when starting or stopping therapy with omeprazole.</p> \n<p><b>Discussion</b> Data regarding the effect of omeprazole on cyclosporine are inconsistent. One case report describes a clinically significant increase in cyclosporine concentrations associated with the onset of omeprazole.<sup>1</sup> A review of data from 163 heart transplant recipients similarly found that patients treated with omeprazole required relatively lower cyclosporine doses to achieve similar trough concentrations.<sup>2</sup> The clinical significance of this effect is uncertain. A series of experiments in rats by the same investigators likewise found that concurrent omeprazole decreased the cyclosporine dose/concentration ratio.<sup>2</sup><br><br>In contrast to those findings, several other reports conclude that there is no clinically significant interaction between omeprazole and cyclosporine. In one case report, the addition of omeprazole (20mg/d) to a patient receiving cyclosporine therapy did not result in any change in cyclosporine concentrations or dose requirement.<sup>3</sup> In a placebo-controlled study of 10 post-renal transplant patients receiving cyclosporine, two weeks of omeprazole (20mg/d) therapy was not associated with any significant changes in cyclosporine concentrations.<sup>4</sup> A study using rat livers similarly reported no evidence of an interaction between omeprazole and cyclosporine.<sup>5</sup> Also of note, two controlled studies with pantoprazole (which, similar to omeprazole, is an acid-reducing proton pump inhibitor, but possibly unlike omeprazole, is thought to have less of an inhibitory effect on individual cytochrome P450 enzymes) both reported no evidence of any interaction between pantoprazole and cyclosporine.<sup>6,7</sup><br><br>The mechanism for any possible interaction between omeprazole and cyclosporine is not certain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schouler L, Dumas F, Couzigou P, et al, “Omeprazole-Cyclosporin Interaction,” <i>Am J Gastroenterol</i>, 1991, 86(8):1097.</p>\n<p>2. Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine after Heart Transplantation: Experimental and Clinical Results,” <i>J Heart Lung Transplant</i>, 1993, 12:987-92.</p>\n<p>3. Castellote E, Bonet J, Lauzurica R, et al, “Does Interaction between Omeprazole and Cyclosporin Exist?,” <i>Nephron</i>, 1993, 65:478.</p>\n<p>4. Blohme I, Idstrom JP,Andersson T, “A Study of the Interaction between Omeprazole and Cyclosporine in Renal Transplant Patients,” <i>Br J Clin Pharmacol</i>, 1993, 35:156-60.</p>\n<p>5. Bar-Meir S, Bardan E, Ronen I, et al, “Cimetidine and Omeprazole Do Not Affect Cyclosporine Disposition by the Rat Liver,” <i>Eur J Drug Metab Pharmacokinet</i>, 1993, 18:355-8.</p>\n<p>6. Lorf T, Ramadori G, Ringe B, et al, “The Effect of Pantoprazole on Tacrolimus and Cyclosporin a Blood Concentration in Transplant Recipients,” <i>Eur J Clin Pharmacol</i>, 2000, 56:439-40.</p>\n<p>7. Lorf T, Ramadori G, Ringe B, et al, “Pantoprazole Does Not Affect Cyclosporin a Blood Concentration in Kidney-Transplant Patients,” <i>Eur J Clin Pharmacol</i>, 2000, 55:733-5.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5146":"<p><b>Title</b> CycloSPORINE (Systemic) / Orlistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of cyclosporine are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer orlistat at least 3 hours before or after oral cyclosporine. Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation.</p> \n<p><b>Discussion</b> A number of case reports describe reductions in cyclosporine serum/plasma concentrations during concomitant therapy with orlistat.<sup>1,2,3,4,5,6,7</sup> Trough concentrations have been reported to decrease by up to two-thirds or more, and these decreases have in some cases been associated with apparent cyclosporine therapeutic failure. Additionally, a clinical study in 30 healthy volunteers showed average 34% decreases in cyclosporine (50 mg with breakfast and dinner) AUC and maximum concentration, and a 27% decrease in trough concentration, with concomitant administration of orlistat (120 mg orally with breakfast, lunch, and dinner).<sup>8</sup> Administration of cyclosporine three hours after meals/orlistat rather than concurrently had a similar effect on cyclosporine trough concentrations.<br><br>The exact mechanism of this interaction is unknown. It appears that cyclosporine absorption may be impaired by orlistat treatment. Prescribing information for orlistat recommends separating orlistat doses at least 3 hours before or after cyclosporine to minimize this interaction.<sup>9</sup> Monitor cyclosporine concentrations closely for decreases during concomitant orlistat treatment, even with the recommended period of separation between doses.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nagele H, Petersen B, Bonacker U, et al, “Effect of Orlistat on Blood Cyclosporin Concentration in an Obese Heart Transplant Patient,” <i>Eur J Clin Pharmacol</i>, 1999, 55(9):667-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10638396\">[PubMed 10638396]</a></p>\n<p>2. Colman E and Fossler M, “Reduction in Blood Cyclosporine Concentrations by Orlistat,” <i>N Engl J Med</i>, 2000, 342:1141-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10766596\">[PubMed 10766596]</a></p>\n<p>3. Schnetzler B, Kondo-Oestreicher M, Vala D, et al, “Orlistat Decreases the Plasma Level of Cyclosporine and May Be Responsible for the Development of Acute Rejection Episodes,” <i>Transplantation</i>, 2000, 70(10):1540-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11118104\">[PubMed 11118104]</a></p>\n<p>4. Le Beller C, Bezie Y, Chabatte C, et al, “Co-Administration of Orlistat and Cyclosporine in a Heart Transplant Recipient,” <i>Transplantation</i>, 2000, 70(10):1541-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11118105\">[PubMed 11118105]</a></p>\n<p>5. Barbaro D, Orsini P, Pallini S, et al, “Obesity in Transplant Patients: Case Report Showing Interference of Orlistat with Absorption of Cyclosporine and Review of Literature,” <i>Endocr Pract</i>, 2002, 8(2):124-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11942778\">[PubMed 11942778]</a></p>\n<p>6. Errasti P, Garcia I, Lavilla J, et al, “Reduction in Blood Cyclosporine Concentration by Orlistat in Two Renal Transplant Patients,” <i>Transplant Proc</i>, 2002, 34(1):137-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11959223\">[PubMed 11959223]</a></p>\n<p>7. Evans S, Michael R, Wells H, et al, “Drug Interaction in a Renal Transplant Patient: Cyclosporin-Neoral and Orlistat,” <i>Am J Kidney Dis</i>, 2003, 41(2):493-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12552515\">[PubMed 12552515]</a></p>\n<p>8. Zhi J, Moore R, Kanitra L, et al, “Pharmacokinetic Evaluation of the Possible Interaction Between Selected Concomitant Medications and Orlistat at Steady State in Healthy Subjects,” <i>J Clin Pharmacol</i>, 2002, 42(9):1011-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12211217\">[PubMed 12211217]</a></p>\n<p>9. Prescribing information. Xenical (orlistat). South San Francisco, CA: Genentech USA, Inc., 1/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5147":"<p><b>Title</b> Pantoprazole / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) does not appear to affect serum concentration of Pantoprazole. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Two small clinical studies of transplant recipients reported no evidence of any clinically significant interaction between pantoprazole and cyclosporine.<sup>1,2</sup><br><br>These findings are somewhat in contrast to those with omeprazole, another proton pump inhibitor, where some reports have suggested an interaction with cyclosporine (i.e., increase cyclosporine concentrations),<sup>3,4</sup> while others have concluded that there is no significant omeprazole-cyclosporine interaction.<sup>5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lorf T, Ramadori G, Ringe B, et al, “The Effect of Pantoprazole on Tacrolimus and Cyclosporin A Blood Concentration in Transplant Recipients,” <i>Eur J Clin Pharmacol</i>, 2000, 56:439-40.</p>\n<p>2. Lorf T, Ramadori G, Ringe B, et al, “Pantoprazole Does Not Affect Cyclosporin a Blood Concentration in Kidney-Transplant Patients,” <i>Eur J Clin Pharmacol</i>, 2000, 55:733-5.</p>\n<p>3. Schouler L, Dumas F, Couzigou P, et al, “Omeprazole-Cyclosporin Interaction,” <i>Am J Gastroenterol</i>, 1991, 86(8):1097.</p>\n<p>4. Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine after Heart Transplantation: Experimental and Clinical Results,” <i>J Heart Lung Transplant</i>, 1993, 12:987-92.</p>\n<p>5. Castellote E, Bonet J, Lauzurica R, et al, “Does Interaction between Omeprazole and Cyclosporin Exist?,” <i>Nephron</i>, 1993, 65:478.</p>\n<p>6. Blohme I, Idstrom JP,Andersson T, “A Study of the Interaction between Omeprazole and Cyclosporine in Renal Transplant Patients,” <i>Br J Clin Pharmacol</i>, 1993, 35:156-60.</p>\n<p>7. Bar-Meir S, Bardan E, Ronen I, et al, “Cimetidine and Omeprazole Do Not Affect Cyclosporine Disposition by the Rat Liver,” <i>Eur J Drug Metab Pharmacokinet</i>, 1993, 18:355-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5148":"<p><b>Title</b> CycloSPORINE (Systemic) / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may increase the metabolism of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if phenytoin is initiated/dose increased, or increased serum concentrations/effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC and maximum serum concentration of cyclosporine (15 mg/kg single dose) were decreased by 47% and 37%, respectively, in 6 normal subjects while receiving phenytoin (300-400 mg/day).<sup>1</sup> Reductions in serum cyclosporine concentrations in conjunction with phenytoin administration have been elsewhere reported.<sup>2,3,4,5,6</sup> Phenytoin is a known inducer of CYP isoenzymes, including CYP3A4 for which cyclosporine is a substrate. Such induction would increase the metabolism of the cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Freeman DJ, Laupacis A, Keown PA, et al, “Evaluation of Cyclosporine-Phenytoin Interaction With Observations on Cyclosporine Metabolites,” <i>Br J Clin Pharmacol</i>, 1984, 18:887-93.</p>\n<p>2. Keown PA, Laupacis A, Carruthers G, et al, “Interaction Between Phenytoin and Cyclosporine Following Organ Transplantation,” <i>Transplantation</i>, 1984, 38:304-6.</p>\n<p>3. Keown PA, Stiller CR, Laupacis AL, et al, “The Effects and Side Effects of Cyclosporine: Relationship to Drug Pharmacokinetics,” <i>Transplant Proc</i>, 1982, 14:659-61.</p>\n<p>4. Grigg-Damberger MM, Costanzo-Nordin R, Kelly MA, et al, “Phenytoin May Compromise Efficacy of Cyclosporine Immunosuppression in Cardiac Transplant Patients,” <i>Epilepsia</i>, 1988, 29:693.</p>\n<p>5. Schmidt H, Naumann R, Jaschonek K, et al, “Drug Interaction Between Cyclosporine and Phenytoin in Allogeneic Bone Marrow Transplantation,” <i>Bone Marrow Transplant</i>, 1989, 4:212-3.</p>\n<p>6. Formea CM, Evans CG, and Karlix JL, “Altered Cytochrome P450 Metabolism of Calcineurin Inhibitors: Case Report and Review of the Literature,” <i>Pharmacotherapy</i>, 2005, 25(7):1021-9.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5149":"<p><b>Title</b> Pitavastatin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Pitavastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of pitavastatin with cyclosporine is contraindicated. Consider changing to a statin that is less sensitive to this interaction (e.g., pravastatin or fluvastatin) or to an alternative type of LDL-lowering medication.</p> \n<p><b>Discussion</b> Pitavastatin AUC and maximum serum concentration were each increased by an average of 4.6-fold and 6.6-fold, respectively, when a single dose of cyclosporine (2 mg/kg x1 on day 6) was administered with pitavastatin (2 mg daily x 6 days).<sup>1</sup><br><br>The specific mechanism for this apparent interaction is uncertain. Considering that pitavastatin disposition is largely dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>2,3,4,5,6</sup> and possibly on ABCG2 (BCRP),<sup>7</sup> and also somewhat dependent on glucuronidation by UGT1A3 and UGT2B7,<sup>8,9</sup> alterations in one or more of these processes by cyclopsorine may be at least somewhat responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Livalo (pitavastatin). Montgomery, AL: Kowa Pharmaceuticals America, Inc., February 2012.</p>\n<p>2. Chung JY, Cho JY, Yu KS, et al, “Effect of OATP1B1 (SLCO1B1) Variant Alleles on the Pharmacokinetics of Pitavastatin in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2005, 78:342-50.</p>\n<p>3. Deng JW, Song IS, Shin HJ, et al, “The Effect of SLCO1B1*15 on the Disposition of Pravastatin and Pitavastatin Is Substrate Dependent: The Contribution of Transporting Activity Changes by SLCO1B1*15,” <i>Pharmacogenet Genomics</i>, 2008, 18:424-33.</p>\n<p>4. Fujino H, Nakai D, Nakagomi R, et al, “Metabolic Stability and Uptake by Human Hepatocytes of Pitavastatin, a New Inhibitor of HMG-CoA Reductase,” <i>Arzneimittelforschung</i>, 2004, 54:382-8.</p>\n<p>5. Hirano M, Maeda K, Shitara Y, et al, “Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans,” <i>J Pharmacol Exp Ther</i>, 2004, 311:139-46.</p>\n<p>6. Ieiri I, Suwannakul S, Maeda K, et al, “SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2007, 82:541-7.</p>\n<p>7. Hirano M, Maeda K, Matsushima S, et al, “Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin,” <i>Mol Pharmacol</i>, 2005, 68:800-7.</p>\n<p>8. Fujino H, Yamada I, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Human UDP-Glucuronosyltransferase Enzymes Involved in Lactonization,” <i>Xenobiotica</i>, 2003, 33:27-41.</p>\n<p>9. Yamada I, Fujino H, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Similarities and Difference in the Metabolism of Pitavastatin in Monkeys and Humans,” <i>Xenobiotica</i>, 2003, 33:789-803.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5151":"<p><b>Title</b> CycloSPORINE (Systemic) / Progestins</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Progestins may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Progestins may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Due to the potential severity of this interaction, consideration should be given to using a method of contraception other than oral contraceptives. Monitor serum cyclosporine concentrations, and for signs and symptoms of renal and hepatic toxicity, in patients receiving concomitant cyclosporine and progestins. Cyclosporine dosage reductions may be necessary.</p>\n<div>\n <p><b>Progestins Interacting Members</b> Chlormadinone, Cyproterone, Desogestrel, Dienogest, Drospirenone, Dydrogesterone, Ethynodiol Diacetate, Etonogestrel, Gestodene, HYDROXYprogesterone Caproate, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Megestrol, Norelgestromin, Norethindrone, Norgestimate, Norgestrel, Progesterone</p>\n</div> \n<p><b>Discussion</b> Case reports. Serum trough cyclosporine concentrations increased approximately 2-fold in a patient while receiving a combination oral contraceptive (levonorgestrel 150 mcg and ethinyl estradiol 30 mcg).<sup>1</sup> Signs and symptoms of hepatotoxicity manifested (eg, increased ALT, AST, bilirubin, and alkaline phosphatase, nausea, and vomiting). These events were reproduced upon rechallenge. Another report supports these findings.<sup>2</sup> The mechanism of the increased cyclosporine concentrations is unclear, but might be related to an inhibition of hepatic drug metabolism. The mechanism of the hepatotoxicity is unknown. Likewise, whether these events would occur with progestin-only therapy is unknown. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Deray G, Le Hoang P, Cacoub P, et al, “Oral Contraceptive Interaction With Cyclosporine,” <i>Lancet</i>, 1987, i:158-9.</p>\n<p>2. Maurer G, “Metabolism of Cyclosporine,” <i>Transplant Proc</i>, 1985, 17(Suppl 1):19.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5152":"<p><b>Title</b> CycloSPORINE (Systemic) / Pyrazinamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrazinamide may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if pyrazinamide is initiated/dose increased, or increased serum concentrations/effects if pyrazinamide is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The serum concentration of cyclosporine was decreased approximately 40% in a patient within 2 days of initiating pyrazinamide therapy.<sup>1</sup> Increased pyrazinamide dosages were associated with increased cyclosporine need. The opposite was also true. The patient was also receiving prednisone, isoniazid, rifampicin, and ethambutol. Another report suggests that pyrazinamide may have added to the effects of rifampicin in reducing cyclosporine concentrations.<sup>1</sup> In contrast, pyrazinamide has been reported to not affect cyclosporine serum concentrations.<sup>2,3</sup> The mechanism of these potential interactions is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jimenez del Cerro LA and Rivera Hernandez F, “Effect of Pyrazinamide on Ciclosporin Levels,” <i>Nephron</i>, 1992, 62(1):113.</p>\n<p>2. Coward RA, Raftery AT, and Brown CB, “Cyclosporine and Antituberculous Therapy,” <i>Lancet</i>, 1985, i:1342-3.</p>\n<p>3. Aguado JM, Herrero JA, Gavalda J, et al, “Clinical Presentation and Outcome of Tuberculosis in Kidney, Liver, and Heart Transplant Recipients in Spain,” <i>Transplantation</i>, 1997, 63:1276-86.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5153":"<p><b>Title</b> CycloSPORINE (Systemic) / Quinupristin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Quinupristin may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cyclosporine if quinupristin/dalfopristin is initiated/dose increased, or decreased serum concentrations/effects if quinupristin/dalfopristin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of cyclosporine (300 mg single dose) was increased by 63% in 24 healthy volunteers when given following a 2-day course of quinupristin/dalfopristin (7.5 mg/kg every 8 hours).<sup>1</sup> A case report describes a serum cyclosporine increase of threefold within 3 days of initiating quinupristin/dalfopristin (300 mg every 8 hours).<sup>2</sup> <br><br>The likely primary mechanism of interaction between these agents is quinupristin/dalfopristin inhibition of CYP3A4 mediated cyclosporine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Synercid (quinupristin and dalfopristin). Bristol, TN: Monarch Pharmaceuticals Inc, August 2010.</p>\n<p>2. Stamatakis MK and Richards JG, “Interaction Between Quinupristin/Dalfopristin and Cyclosporine,” <i>Ann Pharmacother</i>, 1997, 31:576-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5154":"<p><b>Title</b> Repaglinide / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Repaglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects (eg, decreased blood glucose) in patients receiving repaglinide who initiate or increase the dose of cyclosporine. Limit the daily repaglinide dose to a maximum of 6 mg with concurrent use of cyclosporine.</p> \n<p><b>Discussion</b> The AUC of repaglinide (0.25 mg single dose) was increased nearly 2.5-fold in 12 healthy subjects when administered following 2 doses of cyclosporine (100 mg oral, spaced 12 hours apart).<sup>1</sup> Pharmacodynamic effects of this pharmacokinetic alteration were relatively insignificant in this study. However, both the repaglinide and cyclosporine doses used in this study were relatively small compared to doses used clinically. The likely mechanism of this apparent interaction is inhibition of both hepatic uptake of repaglinide via the OATP1B1 uptake transporter and its hepatic metabolism via CYP3A4, both processes that are inhibited by cyclosporine.<sup>1</sup><br><br>The U.S. repaglinide labeling recommends limiting the maximum daily repaglinide dose to no more than 6 mg with concurrent cyclosporine.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. <i>Clin Pharmacol Ther</i>. 2005;78(4):388-399. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198658\">[PubMed 16198658]</a></p>\n<p>2. Prandin (repaglinide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5155":"<p><b>Title</b> CycloSPORINE (Systemic) / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Due to the significance of the interaction with rifampin, consider using a different immunosuppressive therapy, or different antitubercular therapy. Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if a rifamycin derivative is initiated/dose increased, or increased serum concentrations/effects if a rifamycin derivative is discontinued/dose decreased. In order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin*, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The serum concentrations of cyclosporine can be reduced to grossly subtherapeutic values, permitting acute graft rejection, following the addition of rifampin therapy.<sup>1,2,3,4,5,6,7,8</sup> Such effects may take up to 2 weeks to manifest. Fourfold or higher increases in cyclosporine dosages may be required to maintain acceptable serum concentrations. Rifampin is a potent inducer of CYP3A4, and is likely the cause of these effects. Rifabutin and rifapentine are also CYP3A4 inducers. Limited evidence suggests a much less dramatic effect on cyclosporine serum concentrations by rifabutin.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Modry DL, Stinson EB, Oyer PE, et al, “Acute Rejection and Massive Cyclosporine Requirements in Heart Transplant Recipients Treated With Rifampin,” <i>Transplantation</i>, 1985, 39:313-4.</p>\n<p>2. Langhoff E and Madsen S, “Rapid Metabolism of Cyclosporine and Prednisone in Kidney Transplant Patients on Tuberculostatic Treatment,” <i>Lancet</i>, 1983, ii:1303.</p>\n<p>3. Cassidy MJ, Van Zyl-Smit R, Pascoe MD, et al, “Effect of Rifampicin on Cyclosporine A Blood Levels in a Renal Transplant Recipient,” <i>Nephron</i>, 1985, 41:207-8.</p>\n<p>4. Howard P, Bixler TJ, and Gill B, “Cyclosporine-Rifampin Drug Interaction,” <i>Drug Intell Clin Pharm</i>, 1985, 19:763-4.</p>\n<p>5. Offermann G, Keller F, and Molzahn M, “Low Cyclosporine A Blood Levels and Acute Graft Rejection in a Renal Transplant Recipient During Rifampin Treatment,” <i>Am J Nephrol</i>, 1985, 5:385-7.</p>\n<p>6. Daniels NJ, Dover JS, and Schachter RK, “Interaction Between Cyclosporine and Rifampicin,” <i>Lancet</i>, 1984, ii:639.</p>\n<p>7. Vandevelde C, Chang A, Andrews D, et al, “Rifampin and Ansamycin Interactions With Cyclosporine After Renal Transplantation,” <i>Pharmacotherapy</i>, 1991, 11:88-9.</p>\n<p>8. Zylber-Katz E, “Multiple Drug Interactions With Cyclosporine in a Heart Transplant Patient,” <i>Ann Pharmacother</i>, 1995, 29:127-31.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5156":"<p><b>Title</b> CycloSPORINE (Systemic) / Sirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED]. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral doses of sirolimus 4 hours after doses of cyclosporine. Monitor for toxic effects of sirolimus if administered concurrent with cyclosporine. Additionally, monitor for the development of calcineurin inhibitor-induced thrombotic microangiopathy.</p> \n<p><b>Discussion</b> The AUC and C<sub>max</sub> of oral sirolimus (10 mg) was significantly increased in 24 normal subjects when administered simultaneous with oral doses of cyclosporine [MODIFIED].<sup>1</sup> C<sub>max</sub> changes ranged from 116% to 512%, and AUC changes ranged from 148% to 230%. The changes were significantly lower when the sirolimus was administered 4 hours after the dose of cyclosporine [MODIFIED]. Trough serum sirolimus concentrations (0.5 - 3 mg/m<sup>2</sup>/day) increased 67% to 86% in 150 psoriasis patients when coadministered with cyclosporine oral solution (1.25 mg/kg/day).<sup>1</sup> Additionally, concurrent use may increase the risk of calcineurin inhibitor-induced thrombotic microangiopathy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune [package insert]. Philadelphia, PA: Wyeth-Ayerst Pharmaceuticals, Inc, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5158":"<p><b>Title</b> CycloSPORINE (Systemic) / Somatostatin Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor serum cyclosporine concentrations when patients concurrently receive a somatostatin analog. Increased cyclosporine doses may be required. The modified cyclosporine formulations may have a less substantial interaction with somatostatin analogs than what has been reported with other formulations.</p>\n<div>\n <p><b>Somatostatin Analogs Interacting Members</b> Lanreotide, Octreotide, Pasireotide, Somatostatin Acetate</p>\n</div> \n<p><b>Discussion</b> Case reports describe significant reductions in serum cyclosporine (orally administered, likely as non-modified formulation) concentrations following the initiation of octreotide therapy,<sup>1,2</sup> with associated concerns regarding reductions in therapeutic efficacy. One report provides evidence that intravenously administered cyclosporine was able to restore concentrations to the desired range.<br><br>Although these reports did not offer sufficient data to definitively explain the mechanism of this apparent interaction, it is likely that somatostatin analogs impair the absorption of cyclosporine, reducing plasma concentrations. The fact that intravenous cyclosporine appears not to be subject to this interaction supports this mechanism.<sup>1,3</sup> This interaction may also be formulation-specific, as the non-modified oral formulation of cyclosporine depends on bile acid secretion to aid its absorption.<sup>3,4</sup> However, somatostatin analogs substantially impair the release of bile acids,<sup>5,6</sup> a physiologic effect likely to have a significant impact on the absorption of that cyclosporine formulation. The modified (microemulsion) formulation of cyclosporine is less dependent on bile acids to aid its absorption and would be expected to have a less substantial interaction with somatostatin analogs, though specific data on the combination are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rosenberg L, Dafoe DC, Schwartz R, et al, “Administration of Somatostatin Analog (SMS 201-995) in the Treatment of a Fistula Occurring After Pancreas Transplantation,” <i>Transplantation</i>, 1987, 43:764-6.</p>\n<p>2. Landgraf R, Landgraf-Leurs MMC, Nusser J, et al, “Effect of Somatostatin Analogue (SMS 201-995) on Cyclosporine Levels,” <i>Transplantation</i>, 1987, 44:724-5.</p>\n<p>3. Naoumov NV, Tredger JM, Steward CM, et al, “Cyclosporin a Pharmacokinetics in Liver Transplant Recipients in Relation to Biliary T-Tube Clamping and Liver Dysfunction,” <i>Gut</i>, 1989, 30:391-6.</p>\n<p>4. Ericzon BG, Todo S, Lynch S, et al, “Role of Bile and Bile Salts on Cyclosporine Absorption in Dogs,” <i>Transplant Proc</i>, 1987, 19:1248-9.</p>\n<p>5. Drewe J, Sieber CC, Mottet C, et al, “Dose-Dependent Gastrointestinal Effects of the Somatostatin Analog Lanreotide in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 1999, 65:413-9.</p>\n<p>6. Lamrani A, Vidon N, Sogni P, et al, “Effects of Lanreotide, a Somatostatin Analogue, on Postprandial Gastric Functions and Biliopancreatic Secretions in Humans,” <i>Br J Clin Pharmacol</i>, 1997, 43:65-70.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5159":"<p><b>Title</b> CycloSPORINE (Systemic) / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to St. John's wort (SJW) in patients treated with cyclosporine. If the combination cannot be avoided, monitor for decreased serum concentrations/effects of cyclosporine following SJW initiation/dose increase, or increased serum concentrations/effects following SJW discontinuation/dose decrease.</p> \n<p><b>Discussion</b> Numerous case reports and series describe reduced serum concentrations and/or systemic effects of cyclosporine, including cases of acute rejection and graft loss, in transplant recipients taking St. John's wort (SJW).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14</sup> In a clinical study of 11 renal transplant recipients, addition of SJW (600 mg daily, Jarsin300 tablets, Lichtwer Pharma, Berlin, Germany) to stable cyclosporine therapy (1.9-4.2 mg/kg/day, dosed to achieve trough blood concentrations 100-150 ug/L) reduced the dose-adjusted cyclosporine maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 42%, 41%, and 45%, respectively.<sup>15</sup> Some or all of these pharmacokinetic variables (Cmax, Cmin, and AUC) increased significantly for 4 of 5 cyclosporine metabolites measured. Similar changes in cyclosporine pharmacokinetics were seen with the same SJW product in a second clinical study, although decreases in AUC, Cmax, and Cmin were much smaller (less than 15%) when greater than 98% of the hyperforin was removed from the SJW preparation.<sup>16</sup><br><br>The likely mechanism of this interaction is SJW induction of CYP3A4 mediated metabolism and P-glycoprotein mediated transport of cyclosporine.<sup>17,18</sup> Hyperforin may play a central role in this induction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yue QY, Bergquist C, and Gerden B, “Safety of St John’s Wort,” <i>Lancet</i>, 2000, 355(9203):576-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683030\">[PubMed 10683030]</a></p>\n<p>2. Barone GW, Gurley BJ, Ketel BL, et al, “Drug Interaction Between St John's Wort and Cyclosporine,” <i>Ann Pharmacother</i>, 2000, 34(9):1013-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10981246\">[PubMed 10981246]</a></p>\n<p>3. Mai I, Kruger H, Budde K, et al, “Hazardous Pharmacokinetic Interaction of Saint John's Wort (Hypericum perforatum) With the Immunosuppressant Cyclosporine,” <i>Int J Clin Pharmacol Ther</i>, 2000, 38(10):500-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11073292\">[PubMed 11073292]</a></p>\n<p>4. Ruschitzka F, Meier PJ, Turina M, et al, “Acute Heart Transplant Rejection Due to Saint John's Wort,” <i>Lancet</i>, 2000, 355:548-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683008\">[PubMed 10683008]</a></p>\n<p>5. Breidenbach T, Hoffmann MW, Becker T, et al, “Drug Interaction of St John's Wort With Cyclosporin,” <i>Lancet</i>, 2000, 355(9218):1912. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10866469\">[PubMed 10866469]</a></p>\n<p>6. Breidenbach T, Kliem V, Burg M, et al, “Profound Drop of Cyclosporin A Whole Blood Trough Levels Caused by St. John's Wort (Hypericum Perforatum),” <i>Transplantation</i>, 2000, 69(10):2229-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10852634\">[PubMed 10852634]</a></p>\n<p>7. Mandelbaum A, Pertzborn F, Martin-Facklam M, et al, “Unexplained Decrease of Cyclosporin Trough Levels in a Compliant Renal Transplant Patient,” <i>Nephrol Dial Transplant</i>, 2000, 15(9):1473-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10978415\">[PubMed 10978415]</a></p>\n<p>8. Mai I, Kruger H, Budde K, et al, “Hazardous Pharmacokinetic Interaction of Saint John's Wort (Hypericum Perforatum) With the Immunosuppressant Cyclosporin,” <i>Int J Clin Pharmacol Ther</i>, 2000, 38(10):500-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11073292\">[PubMed 11073292]</a></p>\n<p>9. Karliova M, Treichel U, Malago M, et al, “Interaction of Hypericum Perforatum (St. John's Wort) With Cyclosporin A Metabolism in a Patient After Liver Transplantation,” <i>J Hepatol</i>, 2000, 33(5):853-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11097498\">[PubMed 11097498]</a></p>\n<p>10. Barone GW, Gurley BJ, Ketel BL, et al, “Herbal Supplements: A Potential for Drug Interactions in Transplant Recipients,” <i>Transplantation</i>, 2001, 71(2):239-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11213066\">[PubMed 11213066]</a></p>\n<p>11. Ahmed SM, Banner NR and Dubrey SW, “Low Cyclosporin-A Level due to Saint-John's-Wort in Heart Transplant Patients,” <i>J Heart Lung Transplant</i>, 2001, 20(7):795. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11474706\">[PubMed 11474706]</a></p>\n<p>12. Moschella C and Jaber BL, “Interaction Between Cyclosporine and Hypericum Perforatum (St. John's Wort) After Organ Transplantation,” <i>Am J Kidney Dis</i>, 2001, 38(5):1105-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11684566\">[PubMed 11684566]</a></p>\n<p>13. Turton-Weeks SM, Barone GW, Gurley BJ, et al, “St John's Wort: A Hidden Risk for Transplant Patients,” <i>Prog Transplant</i>, 2001, 11(2):116-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11871046\">[PubMed 11871046]</a></p>\n<p>14. Alscher DM and Klotz U, “Drug Interaction of Herbal Tea Containing St. John's Wort With Cyclosporine,” <i>Transpl Int</i>, 2003, 16(7):543-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12677367\">[PubMed 12677367]</a></p>\n<p>15. Bauer S, Stormer E, Johne A, et al, “Alterations in Cyclosporin A Pharmacokinetics and Metabolism During Treatment With St John's Wort in Renal Transplant Patients,” <i>Br J Clin Pharmacol</i>, 2003, 55(2):203-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12580993\">[PubMed 12580993]</a></p>\n<p>16. Mai I, Bauer S, Perloff ES, et al, “Hyperforin Content Determines the Magnitude of the St John's Wort-Cyclosporine Drug Interaction,” <i>Clin Pharmacol Ther</i>, 2004, 76(4):330-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15470332\">[PubMed 15470332]</a></p>\n<p>17. Dresser GK, Schwarz UI, Wilkinson GR, et al, “Coordinate Induction of Both Cytochrome P4503A and MDR1 by St John's Wort in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 2003, 73(1):41-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12545142\">[PubMed 12545142]</a></p>\n<p>18. Durr D, Stieger B, Kullak-Ublick GA, “St John's Wort Induces Intestinal P-Glycoprotein/MDR1 and Intestinal and Hepatic CYP3A4,” <i>Clin Pharmacol Ther</i>, 2000, 68(6):598-604. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180019\">[PubMed 11180019]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5160":"<p><b>Title</b> CycloSPORINE (Systemic) / SulfaSALAzine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SulfaSALAzine may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased cyclosporine concentrations during concomitant therapy with sulfasalazine.</p> \n<p><b>Discussion</b> Mean serum cyclosporine concentrations increased approximately 75% in a kidney transplant patient within 5 days of discontinuing sulfasalazine (1.5 g daily).<sup>1</sup> The agents had been concomitantly administered for 13.5 months. The dosage of cyclosporine was decreased to maintain desired serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Du Cheyron D, Debruyne D, Lobbedez T, et al, “Effect of Sulfasalazine on Cyclosporin Blood Concentration,” <i>Eur J Clin Pharmacol</i>, 1999, 55(3):227-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5161":"<p><b>Title</b> CycloSPORINE (Systemic) / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfinpyrazone may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations closely when starting, stopping, or changing doses of sulfinpyrazone.</p> \n<p><b>Discussion</b> One study of 120 heart transplant recipients evaluated the impact of sulfinpyrazone therapy (200mg/day) on cyclosporine levels.<sup>1</sup> Despite an increase in average cyclosporine dose (approximately 8%), average cyclosporine serum concentrations decreased by 33% during therapy with sulfinpyrazone. The mechanism of this possible interaction is unclear, but an in vitro study using cultured human hepatocytes and human liver microsomes identified sulfinpyrazone as a potential inducer of cyclosporine oxidase (i.e., CYP3A).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Flanagan SD, Cummins CL, Susanto M, et al, “Comparison of Furosemide and Vinblastine Secretion from Cell Lines Overexpressing Multidrug Resistance Protein (P-glycoprotein) and Multidrug Resistance-Associated Proteins (MRP1 and MRP2),” <i>Pharmacology</i>, 2002, 64(3):126-34.</p>\n<p>2. Pichard L, Fabre I, Fabre G, et al, “Cyclosporin A Drug Interactions. Screening for Inducers and Inhibitors of Cytochrome P-450 (Cyclosporin A Oxidase) in Primary Cultures of Human Hepatocytes and in Liver Microsomes,” <i>Drug Metab Dispos</i>, 1990, 18(5):595-606.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5163":"<p><b>Title</b> CycloSPORINE (Systemic) / Temsirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Temsirolimus may enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of calcineurin inhibitor-induced thrombotic microangiopathy.</p> \n<p><b>Discussion</b> Since temsirolimus is the ester pro-drug of sirolimus, the potential for an interaction with cyclosporine is based on published data with oral sirolimus.<br><br>Concurrent use of sirolimus and cyclosporine may increase the risk of calcineurin inhibitor-induced thrombotic microangiopathy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rapamune (temsirolimus). Philadelphia, PA: Wyeth-Ayerst Pharmaceuticals, Inc, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5165":"<p><b>Title</b> CycloSPORINE (Systemic) / Ticlopidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ticlopidine may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cyclosporine if ticlopidine is initiated/dose increased, or increased serum concentrations/effects if ticlopidine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The serum cyclosporine concentrations have been demonstrated to be decreased by approximately 50% in 2 patients (one with nephrotic syndrome, the other a kidney transplant) following the initiation of ticlopidine (500 mg/day).<sup>1,2</sup> The effects subsided after discontinuing ticlopidine and manifested again upon rechallenge in each case. The clinical significance of these changes is unclear. The mechanism of these apparent interactions is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Verdejo MA, Gonzalez M, Sanchez MB, et al, “Suspected Cyclosporine-Ticlopidine Interaction in a Renal Transplant Patient,” <i>Meth Find Exp Clin Pharmacol</i>, 1996, 18(Suppl C):100.</p>\n<p>2. Birmele B, Lebranchu Y, Bagros PH, et al, “Interaction of Cyclosporine and Ticlopidine,” <i>Nephrol Dial Transplant</i>, 1991, 6:150-1.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5166":"<p><b>Title</b> CycloSPORINE (Systemic) / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to the ciprofloxacin prescribing information, concurrent administration of ciprofloxacin and cyclosporine may cause a transient elevation in serum creatinine.<sup>1</sup> In contrast, a review of published case reports and pharmacokinetic study concluded that there was no evidence to support the existence of either a pharmacokinetic or pharmacodynamic interaction between ciprofloxacin and cyclosporine.<sup>2</sup><br><br>In two of four published case reports where an elevation in serum creatinine was observed, cyclosporine concentrations remained unchanged after initiation of ciprofloxacin therapy, suggesting a possible pharmacodynamic interaction.<sup>3,4</sup> However, no additional information regarding comorbidities or concomitant medications was provided. In one case, the ciprofloxacin dose was not adjusted for renal function and may have been a contributing factor.<sup>4</sup> In addition, cyclosporine trough concentrations, though unchanged, were at the upper end of the therapeutic range (300-400 ng/mL) and could have been the primary cause of the observed elevation in serum creatinine.<br><br>In two other published case reports involving an elevation in serum creatinine, cyclosporine plasma concentrations did increase after initiating ciprofloxacin therapy, suggesting a potential pharmacokinetic interaction.<sup>5,6</sup> However, as no additional information was provided, there is not enough data to attribute this effect to a ciprofloxacin/cyclosporine interaction. Additionally, data from pharmacokinetic studies do not support this interaction.<sup>7,8</sup><br><br>The specific mechanism(s) for this potential interaction is uncertain, though the prescribing information’s warning suggests that this may represent additive nephrotoxic effects. A possible mechanism involves the competitive inhibition of creatinine secretion in the renal tubules by higher doses of ciprofloxacin.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cipro (ciprofloxacin). Wayne, NJ: Bayer HealthCare Pharmaceuticals , Inc., January 2013.</p>\n<p>2. Hoey LL and Lake KD, “Does Ciprofloxacin Interact with Cyclosporine?” <i>Ann Pharmacother</i>, 1994, 28(1):93-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8123970\">[PubMed 8123970]</a></p>\n<p>3. Avent CK, Krinsky D, Kirklin JK, et al, “Synergistic Nephrotoxicity due to Ciprofloxacin and Cyclosporine,” <i>Am J Med</i>, 1988, 85(3):452-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3046358\">[PubMed 3046358]</a></p>\n<p>4. Castelao AM, Sabate I, Gino JM, et al, “Cyclosporine-Drug Interactions,” <i>Transplant Proc</i>, 1988, 20 (5 Suppl 6):66-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3051593\">[PubMed 3051593]</a></p>\n<p>5. Elston RA and Taylor J, “Possible Interaction of Ciprofloxacin with Cyclosporin A,” <i>J Antimicrob Chemother</i>, 1988, 21(5):679-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3292498\">[PubMed 3292498]</a></p>\n<p>6. Nasir M, Rotellar C, Hand M, et al, “Interaction between Ciclosporin and Ciprofloxacin,” <i>Nephron</i>, 1991, 57(2):245-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2020359\">[PubMed 2020359]</a></p>\n<p>7. Kruger HU, Schuler U, Proksch B, et al, “Investigation of Potential Interaction of Ciprofloxacin With Cyclosporine in Bone Marrow Transplant Recipients,” <i>Antimicrob Agents Chemother</i>, 1990, 34(6):1048-52.</p>\n<p>8. Lang J, Finaz de Villaine J, Garraffo R, et al, “Cyclosporine (Cyclosporin A) Pharmacokinetics in Renal Transplant Patients Receiving Ciprofloxacin,” <i>Am J Med</i>, 1989, 87(5A):82S-85S.</p>\n<p>9. Hootkins R, Fenves AZ, Stephens MK, “Acute Renal Failure Secondary to Oral Ciprofloxacin Therapy: A Presentation of Three Cases and a Review of the Literature,” <i>Clin Nephrol</i>, 1989, 32(2):75-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2670382\">[PubMed 2670382]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5167":"<p><b>Title</b> CycloSPORINE (Systemic) / LevoFLOXacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> LevoFLOXacin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Cyclosporine pharmacokinetics (10 mg /kg single oral dose) were unaltered in 12 normal subjects when administered with levofloxacin (500 mg twice daily).<sup>1</sup> Another study demonstrated a 26% increase in the AUC of cyclosporine in 5 renal transplant patients (all with a serum creatinine &lt;1.4 mg/dL and a ClCr &gt; 45 mL/min) when administered with levofloxacin (500 mg twice daily for 6 days).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Doose DR, Walker SA, Chien SC, et al, “Levofloxacin Does Not Alter Cyclosporine Disposition,” <i>J Clin Pharmacol</i>, 1998, 38(1):90-3.</p>\n<p>2. Federico S, Carrano R, Capone D, et al, “Pharmacokinetic Interaction Between Levofloxacin and Ciclosporin or Tacrolimus in Kidney Transplant Recipients,” <i>Clin Pharmacokinet</i>, 2006, 45(1):1-7.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5168":"<p><b>Title</b> Minoxidil (Systemic) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of hypertrichosis during concomitant administration of cyclosporine and minoxidil.</p> \n<p><b>Discussion</b> Case reports. Severe hypertrichosis developed in six cyclosporine-treated, kidney transplant patients a few weeks after initiating concomitant administration of minoxidil (15 to 40 mg/day) for hypertension.<sup>1</sup> Both agents possess the potential for causing this effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sever MS, Sonmez YE, and Kocak N, “Limited Use of Minoxidil in Renal Transplant Recipients Because of the Additive Side-Effects of Cyclosporine on Hypertrichosis,” <i>Transplantation</i>, 1990, 50(3):536.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5169":"<p><b>Title</b> Minoxidil (Topical) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of hypertrichosis during concomitant administration of cyclosporine and minoxidil.</p> \n<p><b>Discussion</b> Case reports. Severe hypertrichosis developed in six cyclosporine-treated, kidney transplant patients a few weeks after initiating concomitant administration of minoxidil (15 to 40 mg/day) for hypertension.<sup>1</sup> Both agents possess the potential for causing this effect.<br><br>Based on clinical trials of topical minoxidil, hypertrichosis resulting from normal use occurs predominantly on the head and face,<sup>2</sup> although several case reports have described development of more widespread hypertrichosis.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sever MS, Sonmez YE, and Kocak N, “Limited Use of Minoxidil in Renal Transplant Recipients Because of the Additive Side-Effects of Cyclosporine on Hypertrichosis,” <i>Transplantation</i>, 1990, 50(3):536.</p>\n<p>2. Dawber RPR, Rundegren J. “Hypertrichosis in Females Applying Minoxidil Topical Solution and Normal Controls ,” <i>J Eur Acad Dermatol Venereol</i>, 2003,17(3):271-5.</p>\n<p>3. Peluso AM, Misciali C, Vincenzi C, Tosti C. “Diffuse Hypertrichosis During Treatment with 5% Topical Minoxidil,” <i>Br J Dermatol</i>, 1997,136(1):118-20.</p>\n<p>4. Gonzalez M, Landa N, Gardeazabal J, Calderon MJ, Bilbao I, Diaz Perez JL. “Generalized Hypertrichosis after Treatment with Topical Minoxidil,” <i>Clin Exp Dermatol</i>, 1994,19(2):157-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5170":"<p><b>Title</b> CycloSPORINE (Systemic) / Terbinafine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Terbinafine (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations when starting or stopping terbinafine, or when changing terbinafine doses.</p> \n<p><b>Discussion</b> A published report of four cases describes a modest reduction in cyclosporine concentrations following initiation of treatment with terbinafine (250mg/day) in renal transplant patients.<sup>1</sup> Cyclosporine concentrations declined by 20-45% in 3 of the 4 patients, requiring an 80% dose increase in one patient in order to maintain therapeutic cyclosporine concentrations. Further, in the one patient for whom the cyclosporine dose was increased, concentrations increased 85% within 1 week of stopping the terbinafine. <br><br>In vitro studies have concluded that terbinafine has little impact on the metabolism of cyclosporine by human liver microsomes.<sup>2,3</sup> In vivo data have demonstrated generally small or moderate alterations in cyclosporine pharmacokinetics during concomitant use of terbinafine. The mean peak concentration and AUC of cyclosporine (300 mg single dose) was decreased approximately 13% and 14%, respectively, in 20 normal male subjects when administered on day 7 of a 7-day course of terbinafine (250 mg daily).<sup>4</sup> In another report, 11 cyclosporine-treated transplant patients were treated with terbinafine (250 mg daily for 12 weeks) for culture-proven dermatophyte nail infection.<sup>5</sup> A statistically significant decrease in cyclosporine trough serum concentrations was observed; however, no other pharmacokinetic alterations were appreciated. The authors of each of these studies concluded that terbinafine does not interact with cyclosporine to a clinically significant degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lo ACY, Lui S-L, Lo W-K, et al, “The Interaction of Terbinafine and Cyclosporine A in Renal Transplant Patients,” <i>Br J Clin Pharmacol</i>, 1997, 43(3):340-1.</p>\n<p>2. Back DJ and Tjia JF, “Comparative Effects of the Antimycotic Drugs Ketoconazole, Fluconazole, Itraconazole and Terbinafine on the Metabolism of Cyclosporin by Human Liver Microsomes,” <i>Br J Clin Pharmacol</i>, 1991, 32(5):624-6.</p>\n<p>3. Shah IA, Whiting PH, Omar G, et al, “The Effects of Retinoids and Terbinafine on the Human Hepatic Microsomal Metabolism of Cyclosporin,” <i>Br J Dermatol</i>, 1993, 129(4):395-8.</p>\n<p>4. Long CC, Hill SA, Thomas RC, et al, “Effect of Terbinafine on the Pharmacokinetics of Cyclosporin in Humans,” <i>J Invest Dermatol</i>, 1994, 102(5):740-3.</p>\n<p>5. Jensen P, Lehne G, Fauchald P, et al, “Effect of Oral Terbinafine Treatment on Cyclosporin Pharmacokinetics in Organ Transplant Recipients with Dermatophyte Nail Infection,” <i>Acta Derm Venereol</i>, 1996, 76(4):280-1.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5172":"<p><b>Title</b> Tacrolimus (Systemic) / Serotonin Reuptake Inhibitor/Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Serotonin Reuptake Inhibitor/Antagonists may decrease the metabolism of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using an alternative to nefazodone to eliminate the risk of this interaction. Monitor for increased serum concentrations/toxic effects of tacrolimus if nefazodone (or any similar CYP3A4 inhibitor) is initiated/dose increased, or decreased effects if nefazodone is discontinued/dose decreased. Dosage adjustments to tacrolimus may be needed.</p>\n<div>\n <p><b>Serotonin Reuptake Inhibitor/Antagonists Interacting Members</b> Nefazodone*<br><b>Exception</b> TraZODone</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. A patient's trough serum tacrolimus concentration increased more than threefold, accompanied by signs and symptoms of tacrolimus toxicity, within 1 week of initiating nefazodone therapy (50 mg twice daily).<sup>1</sup> Evidence of toxicity included headache, confusion, visual disturbances, and a 47% increase in serum creatinine. The patient had been receiving tacrolimus for approximately 2 years without incident. Tacrolimus is metabolized by CYP3A4 isoenzymes. Nefazodone inhibits these same isoenzymes, and thus reduces tacrolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olyaei AJ, de Mattos AM, Norman DJ, et al, “Interaction Between Tacrolimus and Nefazodone in a Stable Renal Transplant Recipient,” <i>Pharmacotherapy</i>, 1998, 18:1356-9.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5173":"<p><b>Title</b> Tacrolimus (Systemic) / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Tacrolimus dosage reductions may be required when starting or altering therapy with a protease inhibitor. Monitor response, plasma concentrations (as appropriate), and for signs of toxicity. Some patients may be maintained on less than 1 mg/week of tacrolimus during coadministration with a protease inhibitor.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir*, Nelfinavir*, Ritonavir*, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The addition of lopinavir/ritonavir (n=7) or nelfinavir (n=2) to post-liver-transplant patients with stable liver function tests and stable tacrolimus concentrations significantly decreased tacrolimus clearance.<sup>1</sup> Tacrolimus dose requirements were also significantly altered, with lopinavir/ritonavir decreasing tacrolimus dose requirements by 99% and nelfinavir decreasing tacrolimus dose requirements by 75-93%. Efavirenz (n=4) increased tacrolimus clearance but did not substantially impact tacrolimus dose requirements. Similar cases of protease inhibitors having profound effects on tacrolimus dose requirements have been reported both for liver transplant and kidney transplant recipients involving lopinavir, nelfinavir, ritonavir and saquinavir.<sup>2,3,4,5,6</sup> Tacrolimus is metabolized via CYP3A enzymes and subject to transport by p-glycoprotein. Most protease inhibitors are potent inhibitors of CYP3A and inducers of p-glycoprotein. Conversely, efavirenz has been shown to be an inducer of hepatic CYP3A, with little effect on intestinal p-glycoprotein.<sup>7</sup><br><br>One case report describes a dual interaction where lopinavir/ritonavir significantly lowered tacrolimus dose requirement, and tacrolimus significantly increased plasma lopinavir and ritonavir concentrations.<sup>8</sup> Whether this effect is the result of impaired CYP3A metabolism or p-glycoprotein transport, or some other mechanism is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Teicher E, Vincent I, Bonhomme-Faivre L, et al, “Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study,” <i>Clin Pharmacokinet</i>, 2007, 46:941-52.</p>\n<p>2. Jain AB, Venkataramanan R, Eghtesad B, et al, “Effect of Coadministered Lopinavir and Ritonavir (Kaletra) on Tacrolimus Blood Concentration in Liver Transplantation Patients,” <i>Liver Transpl</i>, 2003, 9(9):954-60.</p>\n<p>3. Jain AK, Venkataramanan R, Shapiro R, et al, “The Interaction Between Antiretroviral Agents and Tacrolimus in Liver and Kidney Transplant Patients,” <i>Liver Transpl</i>, 2002, 8(9):841-5.</p>\n<p>4. Schvarcz R, Rudbeck G, Soderdahl G, et al, “Interaction Between Nelfinavir and Tacrolimus After Orthoptic Liver Transplantation in a Patient Coinfected With HIV and Hepatitis C virus (HCV),” <i>Transplantation</i>, 2000, 69(10):2194-5.</p>\n<p>5. Sheikh AM, Wolf DC, Lebovics E, et al, “Concomitant Human Immunodeficiency Virus Protease Inhibitor Therapy Markedly Reduces Tacrolimus Metabolism and Increases Blood Levels,” <i>Transplantation</i>, 1999, 68(2):307-9.</p>\n<p>6. Schonder KS, Shullo MA, and Okusanya O, “Tacrolimus and Lopinavir/Ritonavir Interaction in Liver Transplantation,” <i>Ann Pharmacother</i>, 2003, 37(12):1793-6.</p>\n<p>7. Mouly S, Lown KS, Kornhauser D, et al, “Hepatic but Not Intestinal Cyp3a4 Displays Dose-Dependent Induction by Efavirenz in Humans,” <i>Clin Pharmacol Ther</i>, 2002, 72:1-9.</p>\n<p>8. Guaraldi G, Cocchi S, Codeluppi M, et al, “Role of Therapeutic Drug Monitoring in a Patient with Human Immunodeficiency Virus Infection and End-Stage Liver Disease Undergoing Orthotopic Liver Transplantation,” <i>Transplant Proc</i>, 2005, 37:2609-10.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5174":"<p><b>Title</b> Tacrolimus (Systemic) / Calcium Channel Blockers (Dihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum tacrolimus concentrations/toxicity if a dihydropyridine calcium channel blocker (DHP-CCB) is initiated/dose increased, or decreased tacrolimus concentrations/effects if a DHP-CCB is discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Dihydropyridine) Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Cilnidipine, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study involving 15 healthy Chinese volunteers, amlodipine increased the tacrolimus AUC 2.4-to 4-fold in the 9 volunteers who were CYP3A5 expressers; no change in tacrolimus pharmacokinetic parameters were seen with amlodipine coadministration in 6 volunteers who did not express CYP3A5.<sup>1</sup> In a retrospective analysis (N=38), pediatric kidney transplant recipients treated with tacrolimus who received continuous infusion nicardipine were compared to transplant recipients who received alternate antihypertensive medications and then were stratified by CYP3A5 expression.<sup>2</sup> Although no differences in tacrolimus concentrations were noted between the groups, in patients receiving nicardipine, higher tacrolimus troughs were observed for the 8 CYP3A5 nonexpressers compared to the 4 CYP3A5 expressers (24.3 ng/mL vs 13.9 ng/mL; p=0.028).<sup>2</sup> An administrative database review found that the use of intravenous nicardipine in kidney transplant recipients taking tacrolimus was an independent predictor of an adverse effect from immunosuppressive therapy (OR 2.8, 95% CI [1.29-6.04]).<sup>3</sup> Another retrospective analysis of 50 liver transplant recipients found that the tacrolimus daily dose was 38% lower in patients treated with nifedipine compared to patients who did not receive nifedipine.<sup>4</sup> Several case reports also describe significant elevations in tacrolimus concentrations after the addition of amlodipine, felodipine, or nicardipine.<sup>3,5,6,7</sup><br><br>The mechanisms of these interactions have not been fully investigated. However, dihydropyridine calcium channel blockers (DHP-CCBs) are substrates of CYP3A4 and several of them exhibit some CYP3A4 inhibition. Thus, inhibition or competition for CYP3A4, an enzyme responsible for the majority of tacrolimus metabolism, may contribute to these potential interactions. Nicardipine appears to be the strongest CYP3A4 inhibitor of the DHP-CCB class.<sup>8,9</sup> CYP3A5 may also play a role in tacrolimus metabolism.<sup>10</sup> Thus, in the absence of an alternate route of metabolism by CYP3A5 (ie, nonexpressers of CYP3A5), any CYP3A4 inhibition (even weak inhibition) or competition for CYP3A4 binding by DHP-CCBs may result in clinically significant changes in tacrolimus exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zuo XC, Zhou YN, Zhang BK, et al. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. <i>Drug Metab Pharmacokinet</i>. 2013;28(5):398-405. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23438946\">[PubMed 23438946]</a></p>\n<p>2. Hooper DK, Fukuda T, Gardiner R, et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. <i>Transplantation</i>. 2012;93(8):806-812. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22491658\">[PubMed 22491658]</a></p>\n<p>3. Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. <i>Pediatr Transplant</i>. 2011;15(1):88-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21159108\">[PubMed 21159108]</a></p>\n<p>4. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins RL. Nifedipine interaction with tacrolimus in liver transplant recipients. <i>Ann Pharmacother</i>. 1997;31(5):571-575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9161650\">[PubMed 9161650]</a></p>\n<p>5. Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain E. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. <i>Transplantation</i>. 2012;93(7):e29-e30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22450597\">[PubMed 22450597]</a></p>\n<p>6. Butani L, Berg G, Makker SP. Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. <i>Transplantation</i>. 2002;73(1):159-160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11793001\">[PubMed 11793001]</a></p>\n<p>7. Leroy S, Isapof A, Farque S, et al. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. <i>Pediatr Nephrol</i>. 2010;25(5):965-969. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20091056\">[PubMed 20091056]</a></p>\n<p>8. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. <i>Eur J Clin Pharmacol</i>. 2000;55(11-12):843-852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10805063\">[PubMed 10805063]</a></p>\n<p>9. Nakamura K, Ariyoshi N, Iwatsubo T, et al. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. <i>Biol Pharm Bull</i>. 2005;28(5):882-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15863898\">[PubMed 15863898]</a></p>\n<p>10. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. <i>Transplantation</i>. 2004;78(8):1182-1187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502717\">[PubMed 15502717]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5175":"<p><b>Title</b> Tacrolimus (Systemic) / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of tacrolimus if diltiazem or verapamil is initiated/dose increased, or decreased effects if diltiazem or verapamil is discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> DilTIAZem*, Verapamil<br><b>Exception</b> Bepridil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Tacrolimus serum concentrations were increased more than fourfold within 3 days of initiating diltiazem therapy.<sup>1</sup> The increased serum concentration was accompanied by symptoms of tacrolimus toxicity (eg, delirium, agitation). Another case report of increased tacrolimus concentrations involved the use of diltiazem and protease inhibitors (agents known to decrease tacrolimus metabolism.<sup>2</sup> In contrast, a retrospective review of 64 patients receiving diltiazem and tacrolimus failed to demonstrate any clinically significant pharmacokinetic or pharmacodynamic effects.<sup>3</sup> The mechanism is likely related to the ability of diltiazem to inhibit CYP3A4 isoenzymes, thus reducing the metabolism of tacrolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hebert MF and Lam AY et al, “Diltiazem Increases Tacrolimus Concentrations,” <i>Ann Pharmacother</i>, 1999, 33(6):680-2.</p>\n<p>2. Hardy G, Stanke-Labesque F, Contamin C, et al, “Protease Inhibitors and Diltiazem Increase Tacrolimus Blood Concentration in a Patient With Renal Transplantation: A Case Report,” <i>Eur J Clin Pharmacol</i>, 2004, 60(8):603-5.</p>\n<p>3. Kothari J, Nash M, Zaltzman J, et al, “Diltiazem Use in Tacrolimus-Treated Renal Transplant Recipients,” <i>J Clin Pharm Ther</i>, 2004, 29(5):425-30.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5176":"<p><b>Title</b> Tacrolimus (Systemic) / Caspofungin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Caspofungin may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations of tacrolimus if caspofungin is initiated/dose increased, or increased concentrations if caspofungin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, the maximum concentration, minimum (12 hour) concentration, and AUC (0 to 12 hours) of tacrolimus (0.1 mg/kg every 12 hours for 2 doses) were decreased by 16%, 26%, and 20%, respectively, following a 10 day course of caspofungin (70 mg daily).<sup>1</sup> In a study of 12 heart and/or lung transplant recipients being treated for invasive aspergillosis, caspofungin (50-70 mg daily for a mean of 21 days) treatment resulted in a non-significant 9% decrease in average tacrolimus trough concentrations, without dose adjustment.<sup>2</sup> Another report of 7 tacrolimus-treated post-transplant patients describes the lack of a significant interaction following receipt of a 14 day course of caspofungin.<sup>3</sup><br><br>The mechanism of this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cancidas (caspofungin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; April 2016.</p>\n<p>2. Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. <i>J Heart Lung Transplant</i>. 2008;27(1):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18187079\">[PubMed 18187079]</a></p>\n<p>3. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. <i>Infection</i>. 2006;34(6):328-332. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17180587\">[PubMed 17180587]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5177":"<p><b>Title</b> Tacrolimus (Systemic) / Cinacalcet</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cinacalcet may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor tacrolimus concentrations in patients receiving cinacalcet, particularly when starting, stopping, or changing doses of cinacalcet.</p> \n<p><b>Discussion</b> In a study conducted in 6 renal transplant recipients who were treated with tacrolimus in combination with mycophenolate/azathioprine and steroids, the AUC of tacrolimus decreased by 14.3% (p = 0.039) following the addition of cinacalcet (30 mg once daily for 7 days).<sup>1</sup> These findings support the observations of a case report describing a 59% decrease in tacrolimus levels (6.3 to 2.6 mg/dL) within a week of starting cinacalcet (30 mg daily) therapy in a renal transplant recipient.<sup>2</sup> In this case, the observed interaction required an increase in tacrolimus dose.<br><br>The mechanism of this interaction is unclear. Cinacalcet is a known inhibitor of CYP2D6 and a substrate of several different cytochrome P450 enzymes,<sup>3</sup> but these factors would not explain the observed decrease in tacrolimus concentrations. In vitro studies have not found any evidence that cinacalcet is an inducer of drug metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. <i>Nephrol Dial Transplant</i>. 2008;23(3):1048-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17956893\">[PubMed 17956893]</a></p>\n<p>2. Maass E, Mueller GA, Heller T, Koziolek MJ. Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. <i>Transplant Proc</i>. 2007;39(10):3468-3470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18089410\">[PubMed 18089410]</a></p>\n<p>3. Sensipar (cinacalcet) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5179":"<p><b>Title</b> Tacrolimus (Systemic) / Fluconazole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Magnitude and clinical significance of this interaction are likely to be greater with higher doses of fluconazole.</p></li>\n <li><p><b>Route</b> (oral): Magnitude and clinical significance of this interaction are likely to be notably greater with oral tacrolimus.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with fluconazole. Due to the relatively long half-life of fluconazole, the prescribing information cautions that this interaction may persist for 4 to 5 days following discontinuation of fluconazole. The magnitude of this interaction is likely smaller with lower fluconazole doses, and IV tacrolimus is considerably less likely to significantly interact with even high dose fluconazole.</p> \n<p><b>Discussion</b> Several clinical studies (n=15 to 21) have shown that concurrent use of fluconazole with oral tacrolimus is associated with an approximate 40% to 60% reduction in tacrolimus dose requirement and/or with significantly increased tacrolimus blood concentrations.<sup>1,2,3</sup> A study showing that tacrolimus concentrations decreased by an average of 60% following discontinuation of concurrent fluconazole further emphasizes the significance of this interaction and the need for close monitoring with any adjustment to concurrent therapy.<sup>4</sup> These studies support the conclusions of at least one published case report on this topic, which described a post-liver transplant patient who was receiving tacrolimus and experienced an increase in serum creatinine and tacrolimus concentrations following initiation of fluconazole, both of which resolved following cessation of fluconazole treatment.<sup>5</sup><br><br>This interaction appears to be both dose- and route-dependent. One study noted a considerable difference in the magnitude of effect on tacrolimus concentrations between fluconazole 100 mg/day and 200 mg/day (1.4-fold vs. 3.1-fold increase in tacrolimus concentrations),<sup>2</sup> and in a retrospective analysis, the use of prophylactic fluconazole (50 mg daily) had no effect on tacrolimus serum concentrations.<sup>6</sup> High-dose fluconazole (400 mg/day) was only associated with a minimal impact (average 16% increase) on tacrolimus concentrations in patients receiving IV tacrolimus.<sup>7</sup> Due to the relatively long half-life of fluconazole, the prescribing information cautions that this interaction may persist for 4 to 5 days following discontinuation of fluconazole.<sup>8</sup><br><br>The likely mechanism of this interaction is inhibition of the first-pass metabolism (primarily via CYP3A in the intestine and liver) of oral tacrolimus by fluconazole, resulting in decreased metabolism and increased bioavailability of orally administered tacrolimus.<sup>3,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Toda F, Tanabe K, Ito S, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. <i>Transplant Proc</i>. 2002;34(5):1733-1735. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12176555\">[PubMed 12176555]</a></p>\n<p>2. Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. <i>Transplantation</i>. 1994;57(10):1521-1523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7515201\">[PubMed 7515201]</a></p>\n<p>3. Lumlertgul D, Noppakun K, Rojanasthien N, et al. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients. <i>J Med Assoc Thai</i>. 2006;89(suppl 2):S73-S78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17044457\">[PubMed 17044457]</a></p>\n<p>4. Hairhara Y, Makuuchi M, Kawarasaki H, et al. Effect of fluconazole on blood levels of tacrolimus. <i>Transplant Proc</i>. 1999;31(7):2767. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10578284\">[PubMed 10578284]</a></p>\n<p>5. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. <i>Diabete Metab</i>. 1994;20(1):49-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7520007\">[PubMed 7520007]</a></p>\n<p>6. Sikora MB, Truax C, Lee S, et al. Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. <i>Clin Transplant</i>. 2012;26(5):E555-E560. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23061766\">[PubMed 23061766]</a></p>\n<p>7. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. <i>Transplantation</i>. 1996;61(8):1268-1272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8610430\">[PubMed 8610430]</a></p>\n<p>8. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; January 2010.</p>\n<p>9. Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. <i>Res Commun Chem Pathol Pharmacol</i>. 1994;84(1):35-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7518966\">[PubMed 7518966]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5180":"<p><b>Title</b> Tacrolimus (Systemic) / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the metabolism of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of tacrolimus and grapefruit or grapefruit juice.</p> \n<p><b>Discussion</b> Due to the ability of grapefruit juice (GFJ) to inhibit the metabolism of tacrolimus, the manufacturer recommends avoiding consumption of grapefruit or GFJ in combination with tacrolimus.<sup>1</sup> In vivo studies have demonstrated GFJ to have a generally moderate impact on tacrolimus blood concentrations; however, study designs and results are varied. In a prospective study of liver transplant patients, blood concentration of tacrolimus was increased by 2-fold in one subgroup after one week of unprocessed GFJ (250 mL twice/day) was added to standard tacrolimus therapy.<sup>2</sup> Another subgroup administered a more processed, concentrated and diluted GFJ (250 mL twice/day) did not show a statistically significant increase in tacrolimus serum concentration.<sup>2</sup> A study involving seven patients with connective tissue diseases who had inadequate tacrolimus concentrations despite tacrolimus doses of 3 mg/day or more found that consuming approximately 200 mL of fresh GFJ for periods ranging from 4 to 10 months increased tacrolimus blood concentrations by 2.3- to 4.8-fold (average increase of 3.3-fold).<sup>3</sup> Two patients required tacrolimus dose reductions and one patient required a dose increase during concurrent GFJ. Several patients experienced fluctuations in tacrolimus blood concentrations for unknown reasons throughout the treatment period. Additionally, two published patient cases report a 10-fold and 5-fold increase in tacrolimus serum concentration after consumption of 1000 mL of GFJ (consumed over three days) and 1.5 kg of orange marmalade made with grapefruit (consumed over one week), respectively.<sup>4,5</sup><br><br>The likely mechanism for this observed interaction is grapefruit inhibition of intestinal CYP3A, resulting in decreased metabolism and greater bioavailability of oral tacrolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; February 2015.</p>\n<p>2. Liu C, Shang YF, Zhang XF, et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. <i>Eur J Clin Pharmacol</i>. 2009;65(9):881-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19629461\">[PubMed 19629461]</a></p>\n<p>3. Tsuji H, Ohmura K, Nakashima R, et al. Efficacy and safety of grapefruit juice intake accompanying tacrolimus treatment in connective tissue disease patients. <i>Intern Med</i>. 2016;55(12):1547-1552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27301503\">[PubMed 27301503]</a></p>\n<p>4. Fukatsu S, Fukudo M, Masuda S, et al. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. <i>Drug Metab Pharmacokinet</i>. 2006;21:122-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16702731\">[PubMed 16702731]</a>.</p>\n<p>5. Peynaud D, Charpiat B, Vial T, et al. Tacrolimus severe overdosage after intake of masked grapefruit in orange marmalade. <i>Eur J Clin Pharmacol</i>. 2007;63:721-722. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17530235\">[PubMed 17530235]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5182":"<p><b>Title</b> Tacrolimus (Systemic) / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased tacrolimus concentrations when phenytoin is initiated/dose increased and increased tacrolimus concentrations/toxicity if phenytoin is discontinued/dose decreased. Tacrolimus dosage requirements may be greater in patients receiving phenytoin. In addition, monitor for increased phenytoin concentrations/effects if tacrolimus is initiated/dose increased.</p> \n<p><b>Discussion</b> One case report describes 2 heart transplant recipients with tacrolimus serum concentration to dose ratios that were significantly lower during concomitant therapy with phenytoin compared with tacrolimus therapy alone.<sup>1</sup> Another report describes a 54-year-old kidney transplant recipient who required tacrolimus 0.25 mg/kg/day while on phenytoin therapy to maintain therapeutic trough levels, but only required tacrolimus 0.16 mg/kg/day to achieve therapeutic concentrations after phenytoin discontinuation.<sup>2</sup> One additional report describes a 19-year-old kidney transplant recipient who had difficulty achieving therapeutic tacrolimus concentrations while on phenytoin therapy.<sup>3</sup> Phenytoin has been used in numerous cases to enhance tacrolimus elimination in cases of tacrolimus toxicity.<sup>4,5,6,7,8</sup> In addition to high tacrolimus dose requirements while on phenytoin therapy, one case report describes a kidney transplant recipient who experienced elevated phenytoin levels after his cyclosporine was changed to tacrolimus.<sup>9</sup> <br><br>Tacrolimus prescribing information states that phenytoin may decrease tacrolimus concentrations. Increased monitoring of tacrolimus concentrations and appropriate dose increases as needed are recommended.<sup>10</sup> Because concomitant administration of phenytoin and tacrolimus may also increase phenytoin concentrations, increased monitoring of phenytoin concentrations is also recommended.<sup>10</sup><br><br>The mechanism by which phenytoin decreases tacrolimus concentrations is likely due to induction of CYP3A4, an enzyme responsible for tacrolimus metabolism. The mechanism by which tacrolimus may increase phenytoin concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wada K, Takada M, Ueda T, et al. Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports. <i>Int J Clin Pharmacol Ther</i>. 2007;45(9):524-528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17907595\">[PubMed 17907595]</a></p>\n<p>2. Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. <i>Transplant Proc</i>. 1999;31(6):2252-2253. [PubMed 10500564 ]</p>\n<p>3. Formea CM, Evans CG, Karlix JL. Altered cytochrome p450 metabolism of calcineurin inhibitors: case report and review of the literature. <i>Pharmacotherapy</i>. 2005;25(7):1021-1029. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16006281\">[PubMed 16006281]</a></p>\n<p>4. Patel SJ, Kuten SA, Musick WL, Gaber AO, Monsour HP, Knight RJ. Combination drug products for HIV - a word of caution for the transplant clinician [published online April 18, 2016. <i>Am J Transplant</i>. Doi: 10.1111/ajt.13826. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27089541\">[PubMed 27089541]</a></p>\n<p>5. El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury [published online November 27, 2015]. <i>Hematol Oncol Stem Cell Ther</i>. Doi: 10.1016/j.hemonc.2015.11.001. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26684920\">[PubMed 26684920]</a></p>\n<p>6. Bax K, Tijssen J, Rieder MJ, Filler G. Rapid resolution of tacrolimus intoxication-induced AKI with a corticosteroid and phenytoin. <i>Ann Pharmacother</i>. 2014;48(11):1525-1528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25104567\">[PubMed 25104567]</a></p>\n<p>7. Jantz AS, Patel SJ, Suki WN, Knight RJ, Bhimaraj A, Gaber AO. Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients [published online June 13, 2013]. <i>Case Rep Transplant</i>. Doi: 10.1155/2013/375263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23844312\">[PubMed 23844312]</a></p>\n<p>8. Karasu Z, Gurakar A, Carlson J, et al. Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. <i>J Okla State Med Assoc</i>. 2001;94(4):121-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11392178\">[PubMed 11392178]</a></p>\n<p>9. Thompson PA, Mosley CA. Tacrolimus-phenytoin interaction. <i>Ann Pharmacother</i>. 1996;30(5):544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8740340\">[PubMed 8740340]</a></p>\n<p>10. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5183":"<p><b>Title</b> Tacrolimus (Systemic) / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor tacrolimus concentrations closely when using a proton pump inhibitor together with tacrolimus. Tacrolimus dose adjustment may be necessary. Patients with certain CYP2C19 and/or CYP3A5 genotypes may be at greater risk. Rabeprazole or pantoprazole may be less likely to significantly interact. Selected H2-receptor antagonists (i.e., ranitidine or famotidine) also appear less likely to interact.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, RABEprazole, Revaprazan<br><b>Exception</b> Pantoprazole</p>\n</div> \n<p><b>Discussion</b> Concurrent proton pump inhibitor (PPI) therapy has been associated with increased tacrolimus concentrations (by 50-300%) in several case reports<sup>1,2,3,4,5</sup> and clinical studies.<sup>6,7,8</sup> Among the PPIs, omeprazole,<sup>1,2,3,6</sup> lanzoprazole,<sup>1,4,5,7,8</sup> and rabeprazole<sup>7</sup> have each been associated with significantly increased tacrolimus concentrations. However, several reports have presented evidence that rabeprazole may be less likely to significantly interact with tacrolimus than omeprazole or lansoprazole.<sup>1,2,5,8,9</sup> Also, one small study with the PPI pantoprazole failed to find evidence of an interaction with tacrolimus.<sup>10</sup> Many studies and case reports have suggested that the magnitude and clinical severity of this interaction may be at least partially dependent on individual patient's CYP2C19 and/or CYP3A5 genotypes, with patients having loss-of-function genotypes at higher risk for a more severe PPI-tacrolimus interaction.<sup>1,4,5,6,7,8</sup><br><br>In contrast to the many reports associating concurrent omeprazole with an increased tacrolimus concentration/dose ratio, data from a study in 51 renal transplant patients showed that the tacrolimus concentration/dose ratio was no different with concurrent omeprazole.<sup>11</sup> Also, an in vitro study employing a concentration of omeprazole 24-fold higher than the in vivo maximum concentration (achieved upon repeated dosing as reported by the manufacturer) demonstrated only a 15% inhibition of the oxidative metabolism of tacrolimus.<sup>12</sup><br><br>The mechanism of this apparent interaction is likely inhibition of tacrolimus metabolism (and/or transport by p-glycoprotein) by selected PPIs. All PPIs are metabolized by CYP2C19 and CYP3A, and all PPIs have been shown in in vitro studies to be capable of inhibiting CYP2C19 to at least some degree.<sup>13,14</sup> The dependence of this interaction on CYP2C19 and/or CYP3A5 genotypes suggests that greater PPI concentrations and/or a greater reliance on CYP3A-mediated PPI metabolism due to poor CYP2C19 activity increases the magnitude of the interaction. This was apparently demonstrated by one case report of a BMT patient who was heterozygous for CYP2C19 and CYP3A5 mutations.<sup>15</sup> The patient experienced a decrease in their serum tacrolimus concentrations after a lansoprazole dose reduction, an effect that was exacerbated by voriconazole discontinuation in the same general time period.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hosohata K, Masuda S, Ogura Y, et al, “Interaction between Tacrolimus and Lansoprazole, but Not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5,” <i>Drug Metab Pharmacokinet</i>, 2008, 23:134-8.</p>\n<p>2. Takahashi K, Yano I, Fukuhara Y, et al, “Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant Recipient,” <i>Drug Metab Pharmacokinet</i>, 2007, 22:441-4.</p>\n<p>3. Moreau C, Debray D, Loriot MA, et al, “Interaction between Tacrolimus and Omeprazole in a Pediatric Liver Transplant Recipient,” <i>Transplantation</i>, 2006, 81:487-8.</p>\n<p>4. Takahashi K, Motohashi H, Yonezawa A, et al, “Lansoprazole-Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism,” <i>Ann Pharmacother</i>, 2004, 38:791-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15010519\">[PubMed 15010519]</a></p>\n<p>5. Homma M, Itagaki F, Yuzawa K, et al, “Effects of Lansoprazole and Rabeprazole on Tacrolimus Blood Concentration: Case of a Renal Transplant Recipient with CYP2C19 Gene Mutation,” <i>Transplantation</i>, 2002, 73:303-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11821750\">[PubMed 11821750]</a></p>\n<p>6. Hosohata K, Masuda S, Katsura T, et al, “Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients,” <i>Drug Metab Dispos</i>, 2009, [Epub ahead of print]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19139162\">[PubMed 19139162]</a></p>\n<p>7. Miura M, Inoue K, Kagaya H, et al, “Influence of Rabeprazole and Lansoprazole on the Pharmacokinetics of Tacrolimus in Relation to CYP2C19, CYP3A5 and MDR1 Polymorphisms in Renal Transplant Recipients,” <i>Biopharm Drug Dispos</i>, 2007, 28:167-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17377957\">[PubMed 17377957]</a></p>\n<p>8. Itagaki F, Homma M, Yuzawa K, et al, “Effect of Lansoprazole and Rabeprazole on Tacrolimus Pharmacokinetics in Healthy Volunteers with CYP2C19 Mutations,” <i>J Pharm Pharmacol</i>, 2004, 56:1055-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15285851\">[PubMed 15285851]</a></p>\n<p>9. Itagaki F, Homma M, Yuzawa K, et al, “Drug Interaction of Tacrolimus and Proton Pump Inhibitors in Renal Transplant Recipients with CYP2C19 Gene Mutation,” <i>Transplant Proc</i>, 2002, 34:2777-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12431607\">[PubMed 12431607]</a></p>\n<p>10. Lorf T, Ramadori G, Ringe B, et al, “The Effect of Pantoprazole on Tacrolimus and Cyclosporin a Blood Concentration in Transplant Recipients,” <i>Eur J Clin Pharmacol</i>, 2000, 56:439-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11009056\">[PubMed 11009056]</a></p>\n<p>11. Pascual J, Marcen R, Orea OE, et al, “Interaction Between Omeprazole and Tacrolimus in Renal Allograft Recipients: A Clinical-Analytical Study,” <i>Transplant Proc</i>, 2005, 37(9):3752-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16386527\">[PubMed 16386527]</a></p>\n<p>12. Matsuda H, Iwasaki K, Shiraga T, et al, “Interactions of FK506 (Tacrolimus) with Clinically Important Drugs,” <i>Res Commun Mol Pathol Pharmacol</i>, 1996, 91(1):57-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8824931\">[PubMed 8824931]</a></p>\n<p>13. Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” <i>Drug Metab Dispos</i>, 2004, 32:821-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15258107\">[PubMed 15258107]</a></p>\n<p>14. Ko J, Sukhova N, Thacker D, et al, “Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms,” <i>Drug Metab Dispos</i>, 1997, 25:853-862. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9224780\">[PubMed 9224780]</a></p>\n<p>15. Iwamoto T, Monma F, Fujieda A, et al, “Hepatic Drug Interaction Between Tacrolimus and Lansoprazole in a Bone Marrow Transplant Patient Receiving Voriconazole and Harboring CYP2C19 and CYP3A4 Heterozygous Mutations,” <i>Clin Ther</i>, 2011, Jul 28 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21802143\">[PubMed 21802143]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5184":"<p><b>Title</b> Tacrolimus (Systemic) / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Due to the potential significance of this interaction (therapeutic failure), consider using a non-interacting immunosuppressive agent or antimicrobial. Monitor for decreased serum concentrations/therapeutic effects of tacrolimus if a rifamycin derivative is initiated/dose increased, or increased serum concentrations/toxic effects if a rifamycin derivative is discontinued/dose decreased. Substantial increases in tacrolimus dosage may be needed. In order of expected potency/risk: rifampin &gt; rifapentine &gt; rifabutin.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In clinical studies in healthy volunteers, coadministration of rifampin (600 mg/day for 1-2 weeks) decreased the AUCs of immediate release oral, extended release oral, and intravenous tacrolimus by 68%, 56%, and 35%, respectively.<sup>1,2</sup> The bioavailability of immediate release tacrolimus was decreased by roughly 50%.<sup>1,3</sup><br><br>A retrospective analysis and several published case reports describe decreased serum concentrations of tacrolimus in patients treated concomitantly with rifampin.<sup>4,5,6,7,8,9</sup> Based on two published case reports, substantial decreases in tacrolimus exposure may also occur with concomitant use of rifabutin, although these may not be as great as those seen with rifampin.<sup>10,11</sup> <br><br>The suspected primary mechanism of this interaction is induction of CYP3A mediated tacrolimus metabolism by the rifamycin derivatives. Rifamycin induction of other enzymes mediating tacrolimus metabolism, and/or of P-glycoprotein mediated efflux transport may also theoretically contribute. Rifabutin and rifapentine induce CYP3A4 to a lesser extent than rifampin but may also significantly affect tacrolimus concentrations.<sup>13,14</sup> The use of CYP3A inhibitors to counteract these effects in cases has yielded inconsistent results.<sup>7,10,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hebert MF, Fisher RM, and Marsh CL, “Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 1999, 39(1):91-6.</p>\n<p>2. Prescribing Information. Astagraf XL (tacrolimus extended-release). Northbrook, IL: Astellas Pharma US, Inc., 7/2013.</p>\n<p>3. Prescribing Information. Prograf (tacrolimus). Northbrook, IL: Astellas Pharma US, Inc., 8/2012.</p>\n<p>4. Furlan V, Perello L, Jacquemin E, et al, “Interactions Between FK506 and Rifampicin or Erythromycin in Pediatric Liver Recipients,” <i>Transplantation</i>, 1995, 59:1217.</p>\n<p>5. Kiuchi T, Inomata Y, Uemoto S, et al, “A Hepatic Graft Tuberculosis Transmitted From a Living-Related Donor,” <i>Transplantation</i>, 1997, 63:905-7.</p>\n<p>6. Ha YE, Joo EJ, Park SY, et al, “Tacrolimus as a Risk Factor for Tuberculosis and Outcome of Treatment With Rifampicin in Solid Organ Transplant Recipients,” <i>Transpl Infect Dis</i>, 2012, 14(6):626-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22372581\">[PubMed 22372581]</a></p>\n<p>7. Bhaloo S and Prasad GV, “Severe Reduction in Tacrolimus Levels With Rifampin Despite Multiple Cytochrome P450 Inhibitors: A Case Report,” <i>Transplant Proc</i>, 2003, 35(7):2449-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14611983\">[PubMed 14611983]</a></p>\n<p>8. Chenhsu RY, Loong CC, Chou MH, et al, “Renal Allograft Dysfunction Associated With Rifampin-Tacrolimus Interaction,” <i>Ann Pharmacothe</i>, 2000, 34(1):27-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10669182\">[PubMed 10669182]</a></p>\n<p>9. Moreno M, Latorre A, Manzanares C, et al, “Clinical Management of Tacrolimus Drug Interactions in Renal Transplant Patients,” <i>Transplant Proc</i>, 1999, 31(6):2252-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10500564\">[PubMed 10500564]</a></p>\n<p>10. Hickey MD, Quan DJ, Chin-Hong PV, et al, “Use of Rifabutin for the Treatment of a Latent Tuberculosis Infection in a Patient After Solid Organ Transplantation,” <i>Liver Transpl</i>, 2013, 19(4):457-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23526600\">[PubMed 23526600]</a></p>\n<p>11. Lopez-Montes A, Gallego E, Lopez E, et al, “Treatment of Tuberculosis With Rifabutin in a Renal Transplant Recipient,” <i>Am J Kidney Dis</i>, 2004, 44(4):e59-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15384035\">[PubMed 15384035]</a></p>\n<p>12. Mori T, Aisa Y, Kato J, et al, “Overcoming the Effect of Rifampin on the Tacrolimus Metabolism by Itraconazole Administration in an Allogeneic Hematopoietic Stem Cell Transplant Recipient,” <i>Int J Hematol</i>, 2010, 91(3):553-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20195928\">[PubMed 20195928]</a></p>\n<p>13. Prescribing Information. Mycobutin (rifabutin). New York, NY: Pharmacia and Upjohn Company, a division of Pfizer, Inc., 10/2007.</p>\n<p>14. Prescribing Information. Priftin (rifapentine). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 5/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5185":"<p><b>Title</b> Tacrolimus (Systemic) / Sirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of tacrolimus and sirolimus is not recommended. The prescribing information for the Astagraf XL brand of tacrolimus specifically states that this combination is not recommended for kidney, liver, or heart transplant patients, while the prescribing information for the Prograf brand states that this combination is not recommended in liver or heart transplant patients and that the safety and efficacy of concurrent use in kidney transplant patients has not been established.</p> \n<p><b>Discussion</b> In stable renal transplant recipients, concomitant administration of tacrolimus (dose not specified) with sirolimus (2 mg or 5 mg/day), decreased both tacrolimus AUC and minimum plasma concentration (Cmin) by 30% compared to tacrolimus monotherapy.<sup>1</sup> Both tacrolimus and sirolimus are highly protein bound and share common metabolic pathways (both are substrates for CYP3A4 and P-glycoprotein (P-gp)).<br><br>What may be of more importance than the potential pharmacokinetic interaction between these two agents is the potential for an increased risk of adverse events, including fatalities, associated with this combination. An excess in mortality, hepatic artery thrombosis (HAT), and graft loss have been observed in de novo liver transplant patients receiving both agents.<sup>1,2,3</sup> An increased risk for nephrotoxicity, impaired wound healing, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA), hyperlipidemia, and post-transplantation diabetes mellitus have also been observed with the concomitant use of these two agents.<sup>1,2,3,4,5,6,7</sup><br><br>In a small study of renal transplant patients (n=39), the authors note an alarming toxicity profile in association with the use of full dose tacrolimus (trough levels 10-15 ng/mL) and reduced dose sirolimus (trough levels 5-10 ng/mL) when compared to reduced dose tacrolimus (trough levels 5-10 ng/mL) with standard sirolimus dosing (trough levels 10-15 ng/mL).<sup>4</sup> In heart transplant recipients, administration of full dose tacrolimus with sirolimus (2 mg/day) was associated with an increased risk of renal impairment, wound healing complications, and insulin-dependent post-transplant diabetes mellitus.<sup>1</sup> In light of these toxicity/interaction concerns, the prescribing information for the Astagraf XL brand of tacrolimus specifically states that this combination is not recommended for kidney, liver, or heart transplant patients.<sup>2</sup> The prescribing information for the Prograf brand states that this combination is not recommended in liver or heart transplant patients and that the safety and efficacy of concurrent use in kidney transplant patients has not been established.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., July 2012.</p>\n<p>2. Prescribing information. Astagraf XL (tacrolimus). Northbrook, IL: Astellas Pharma US, Inc., July 2013.</p>\n<p>3. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals, Inc, July 2007.</p>\n<p>4. Lo A, Fegidi MF, Gaber LW, et al, “Observations Regarding The Use of Sirolimus and Tacrolimus in High-Risk Cadaveric Renal Transplantation,” <i>Clin Transplant</i>, 2004, 18:53-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15108771\">[PubMed 15108771]</a></p>\n<p>5. Ciancio G, Burke GW, Gaynor JJ, et al, “A Randomized Long-Term Trial of Tacrolimus/Sirolimus versus Tacrolimus/Mycophenolate versus Cyclosporine/Sirolimus in Renal Transplantation: Three-Year Analysis,” <i>Transplant</i>, 2006, 81(6)845-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16570006\">[PubMed 16570006]</a></p>\n<p>6. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al, “Mycophenolate Mofetil Vs. Sirolimus in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen,” <i>Clin Transplant</i>, 2008, 22:141-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18339132\">[PubMed 18339132]</a></p>\n<p>7. Zucker MJ, Baran DA, Arroyo LH, et al, “De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow Up Analysis,” <i>Transplant Proc</i>, 2005, 37:2231-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15964386\">[PubMed 15964386]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5186":"<p><b>Title</b> Tacrolimus (Systemic) / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients should probably avoid the use of St Johns Wort if they are receiving tacrolimus. Monitor for reduced serum concentrations of tacrolimus if St Johns Wort is initiated/dose increased, and increased serum concentrations if St Johns Wort is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of tacrolimus was decreased 58% in 10 tacrolimus-stable renal transplant patients after 2 weeks of treatment with St Johns Wort (600 mg/day).<sup>1</sup> Tacrolimus doses were approximately doubled in most patients in order to maintain adequate serum concentrations. Doses were reduced approximately 2 weeks after discontinuing St Johns Wort. The AUC of tacrolimus decreased an average of 35% in a study of 10 healthy volunteers who received single doses of tacrolimus prior to and after St Johns Wort (300 mg three times/day x 18 days).<sup>2</sup> Of note, one subject experienced a 31% increase in tacrolimus AUC following St Johns Wort, in contrast to the overall findings.<br><br>St Johns Wort induces CYP3A4 and p-glycoprotein, both of which participate in the metabolism/elimination of tacrolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mai I, Stormer E, Bauer S, et al, “Impact of St Johns Wort Treatment on the Pharmacokinetics of Tacrolimus and Mycophenolic Acid in Renal Transplant Patients,” <i>Nephrol Dial Transplant</i>, 2003, 18(4):819-22.</p>\n<p>2. Herbert M, Park J, Chen YL, et al, “Effects of St. John's Wort (Hypericum Perforatum) on Tacrolimus Pharmacokinetics in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2004, 44(1):89-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14681346\">[PubMed 14681346]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5187":"<p><b>Title</b> Temsirolimus / Tacrolimus (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tacrolimus (Systemic) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of tacrolimus with temsirolimus.</p> \n<p><b>Discussion</b> Since temsirolimus is the ester pro-drug of sirolimus, the potential for an interaction with tacrolimus is based on published data with oral sirolimus.<br><br>In stable renal transplant patients, concomitant administration of tacrolimus (dose not specified) with sirolimus (2 mg or 5 mg/day), decreased both tacrolimus AUC and minimum plasma concentration (Cmin) by 30% compared to tacrolimus monotherapy.<sup>1</sup> Both tacrolimus and sirolimus are highly protein bound and share common metabolic pathways (both are substrates for CYP3A4 and P-glycoprotein (P-gp)). <br><br>What may be of more importance than the potential pharmacokinetic interaction between these two agents, is the potential for an increased risk of adverse events including fatalities associated with their combined use. An excess in mortality, hepatic artery thrombosis (HAT), and graft loss have been observed in de novo liver transplant patients receiving both agents.<sup>2</sup> An increased risk for nephrotoxicity, impaired wound healing, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA), hyperlipidemia, and post-transplantation diabetes mellitus has also been observed with the concomitant use of these two agents.<sup>2,3,4,5,6</sup> <br><br>In a small study of renal transplant patients (n=39), the authors note an alarming toxicity profile in association with the use of full dose tacrolimus (trough levels 10-15 ng/mL) and reduced dose sirolimus (trough levels 5-10 ng/mL) when compared to reduced dose tacrolimus (trough levels 5-10 ng/mL) with standard sirolimus dosing (trough levels 10-15 ng/mL).<sup>3</sup> In heart transplant patients, administration of full dose tacrolimus with sirolimus (2 mg/day) was associated with an increased risk of renal impairment, wound healing complications, and insulin-dependent post-transplant diabetes mellitus.<sup>1</sup> In light of these toxicity/interaction concerns, tacrolimus prescribing information states that concurrent use of sirolimus with tacrolimus is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rapamune (temsirolimus). Philadelphia, PA: Wyeth-Ayerst Pharmaceuticals, Inc, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5188":"<p><b>Title</b> Tacrolimus (Systemic) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of tacrolimus with cyclosporine. Discontinue tacrolimus or cyclosporine therapy at least 24 hours prior to initiating therapy with the other agent. Obtain serum levels of discontinued agent and if serum levels are elevated further delay initiating therapy with the other agent.</p> \n<p><b>Discussion</b> Tacrolimus prescribing information specifically recommends against concomitant use with cyclosporine due to an increased risk of nephrotoxicity.<sup>1</sup> Both tacrolimus and cyclosporine can be nephrotoxic, and a synergistic effect might be anticipated with their concomitant use. Additionally, as both agents are highly bound to plasma proteins and share common metabolic pathways (both are substrates for CYP3A4 and P-glycoprotein),<sup>2,3,4</sup> elevated serum levels of either agent might be expected with concomitant therapy, possibly furthering the nephrotoxic risks.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., February 2009.</p>\n<p>2. Prescribing information. Neoral (cyclosporine). East Hanoverton, NJ: Novartis Pharmaceuticals Corp., August 2005.</p>\n<p>3. Kim RB, “Drugs as P-Glycoprotein Substrates, Inhbitors, and Inducers,” <i>Drug Metab Rev</i> 2002, 34(1&amp;2): 47-54.</p>\n<p>4. Christians U, Jacobsen W, Benet LZ, et al, “Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus,” <i>Clin Pharmacokinet</i> 2002, 41(11): 813-51.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5189":"<p><b>Title</b> Tacrolimus (Systemic) / LevoFLOXacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LevoFLOXacin (Systemic) may enhance the QTc-prolonging effect of Tacrolimus (Systemic). LevoFLOXacin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination for signs and symptoms of excessive QTc interval prolongation and arrhythmia, as well as for possibly increased systemic concentrations and toxic effects of tacrolimus.</p> \n<p><b>Discussion</b> The AUC of tacrolimus was increased 25% in 5 renal transplant patients (all with a serum creatinine &lt;1.4 mg/dL and a ClCr &gt; 45 mL/min) when administered with levofloxacin (500 mg twice daily for 6 days).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Federico S, Carrano R, Capone D, et al, “Pharmacokinetic Interaction Between Levofloxacin and Ciclosporin or Tacrolimus in Kidney Transplant Recipients,” <i>Clin Pharmacokinet</i>, 2006, 45(2):169-75.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5190":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Tacrolimus (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tacrolimus (Systemic) may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Most available data suggest a very limited effect. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> Atorvastatin pharmacokinetics were not significantly altered in a study of 13 healthy volunteers who received 4 days of tacrolimus.<sup>1</sup> In another study, adding simvastatin to tacrolimus was associated with no statistically significant increase in simvastatin concentrations (n = 20).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lemahieu WP, Hermann M, Asberg A, et al, “Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus,” <i>Am J Transplant</i>, 2005, 5(9):2236-43. [PMID: 16095503]</p>\n<p>2. Ichimaru N, Takahara S, Kokado Y, et al, “Changes in Lipid Metabolism and Effect of Simvastatin in Renal Transplant Recipients Induced by Cyclosporine or Tacrolimus,” <i>Atherosclerosis</i>, 2001, 158(2):417-23. [PMID: 11583721]</p>\n<p>3. Kohnle M, Pietruck F, Kribben A, et al, “Ezetimibe for the Treatment of Uncontrolled Hypercholesterolemia in Patients with High-dose Statin Therapy after Renal Transplantation,” <i>Am J Transplant</i>, 2006, 6(1):205-8. [PMID: 16433776]</p>\n<p>4. Hedman M, Neuvonen PJ, Neuvonen M, et al, “Pharmacokinetics and Pharmacodynamics of Pravastatin in Pediatric and Adolescent Cardiac Transplant Recipients on a Regimen of Triple Immunosuppression,” <i>Clin Pharmacol Ther</i>, 2004, 75(1):101-9. [PMID:14749696]</p>\n<p>5. Butani L, “Prospective Monitoring of Lipid Profiles in Children Receiving Pravastatin Preemptively after Renal Transplantation,” <i>Pediatr Transplant</i>, 2005, 9(6):746-53. [PMID: 16269046]</p>\n<p>6. Zachoval R, Gerbes AL, Schwandt P, et al, “Short-term Effects of Statin Therapy in Patients with Hyperlipoproteinemia after Liver Transplantation: Results of a Randomized Cross-over Trial,” <i>J Hepatol</i>, 2001, 35(1):86-91. [PMID: 11495047]</p>\n<p>7. Penson MG, Fricker FJ, Thompson JR, et al, “Safety and Efficacy of Pravastatin Therapy for the Prevention of Hyperlipidemia in Pediatric and Adolescent Cardiac Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2001, 20(6):611-8. [PMID: 11404165]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5191":"<p><b>Title</b> Alcohol (Ethyl) / Tacrolimus (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tacrolimus (Topical) may enhance the dermatologic adverse effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients using topical tacrolimus of the increased potential for experiencing facial flushing following the consumption of alcoholic beverages. Aspirin, as a prostaglandin inhibitor, may attenuate the effects if needed.</p> \n<p><b>Discussion</b> Case reports (some including rechallenge) and adverse effects reports from clinical trials describe the development of localized flushing (including redness and warm sensation) at the application sites of topical tacrolimus<sup>1,2,3,4,5</sup> and pimecrolimus<sup>2</sup> within 5-15 minutes of alcohol consumption. The overall incidence of “alcohol intolerance” (as it is described in the tacrolimus ointment package insert) is reported as 3.7-6.9%.<sup>1,5</sup> No mention of alcohol-related concerns or effects is mentioned in the pimecrolimus package insert.<sup>6</sup> The effects observed in the cited cases lasted approximately 1 hour. A mechanism for this observation is unclear. It has been postulated that aldehyde dehydrogenase inhibition by tacrolimus in the skin at the application site may lead to increase acetaldehyde concentrations and subsequent effects (mediated via either prostaglandins).<sup>2</sup> Aspirin administration has been noted to attenuate the effects in a couple of cases.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Soter NA, Fleischer AB Jr, Webster GF, et al, “Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Adult Patients: Part II, Safety,” <i>J Am Acad Dermatol</i>, 2001, 44(1 Suppl):S39-46.</p>\n<p>2. Ehst BD and Warshaw EM, “Alcohol-Induced Application Site Erythema After Topical Immunomodulator Use and Its Inhibition by Aspirin,” <i>Arch Dermatol</i>, 2004, 140(8):1014-5.</p>\n<p>3. Milingou M, Antille C, Sorg O, et al, “Alcohol Intolerance and Facial Flushing in Patients Treated With Topical Tacrolimus,” <i>Arch Dermatol</i>, 2004, 140(12):1542-4.</p>\n<p>4. Lubbe J and Milingou M, “Images in Clinical Medicine. Tacrolimus Ointment, Alcohol, and Facial Flushing,” <i>N Engl J Med</i>, 2004, 351(26):2740.</p>\n<p>5. Personal Communication. Eileen Jaracz, PharmD, Fujisawa Healthcare Inc Medical Information Department, Deerfield, IL. January 11, 2005.</p>\n<p>6. Elidel [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5192":"<p><b>Title</b> Tacrolimus (Topical) / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum concentrations/toxic effects of topical tacrolimus if an interacting macrolide antibiotic is initiated/dose increased. Azithromycin may be a safer alternative than erythromycin or clarithromycin; however, monitoring may still be warranted.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic), Clarithromycin, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Fidaxomicin, Roxithromycin, Spiramycin</p>\n</div> \n<p><b>Discussion</b> A kidney transplant patient experienced a very significant increase in tacrolimus trough serum concentrations (from 2.8-36.1 ng/mL) within 6 days of starting clarithromycin therapy (500 mg/day).<sup>1</sup> This occurred despite a 64% decrease in tacrolimus dosage. Several reports describe four- to sixfold increases in tacrolimus serum concentrations occurring within as few as 4 days of starting erythromycin therapy.<sup>2,3</sup> Signs of renal toxicity were evident in some cases. Data on the concomitant use of tacrolimus and azithromycin is scant. One case report describes a more than twofold increase in serum tacrolimus concentrations occurring within 3 day of initiating azithromycin therapy (500 mg daily).<sup>4</sup> Another report describes no pharmacokinetic changes during concomitant therapy.<sup>5</sup> The mechanism of the former interactions is unclear, but some macrolide antibiotics (as well as telithromycin, a ketolide) inhibit CYP3A4 isoenzymes. Tacrolimus also possesses an affinity for this isoenzyme. It is possible that the competition for the isoenzyme leaves a greater amount of free tacrolimus in the serum. The cause of azithromycin-associated changes in tacrolimus pharmacokinetics is unknown.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>6,7,8,9,10,11,12</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>13,14,15,16,17,18,19,20,21,22,23</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wolter K, Wagner K, Philipp T, et al, “Interaction Between FK 506 and Clarithromycin in a Renal Transplant Patient,” <i>Eur J Clin Pharmacol</i>, 1994, 47(2):207-8.</p>\n<p>2. Shaeffer MS, Collier D, and Sorrell MF, “Interaction Between FK506 and Erythromycin,” <i>Ann Pharmacother</i>, 1994, 28(2):280-1.</p>\n<p>3. Jensen C, Jordan M, Shapiro R, et al, “Interaction Between Tacrolimus and Erythromycin,” <i>Lancet</i>, 1994, 344(8925):825.</p>\n<p>4. Ibrahim RB, Abella EM, and Chandrasekar PH, “Tacrolimus-Clarithromycin Interaction in a Patient Receiving Bone Marrow Transplantation,” <i>Ann Pharmacother</i>, 2002, 36(12):1971-2.</p>\n<p>5. Mori T, Aisa Y, Nakazato T, et al, “Tacrolimus-Azithromycin Interaction in a Recipient of Allogeneic Bone Marrow Transplantation,” <i>Transpl Int</i>, 2005, 18(6):757-8.</p>\n<p>6. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>7. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 8. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>9. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>10. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>11. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>12. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>13. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>14. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>15. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>16. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>17. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>18. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>19. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>20. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>21. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>22. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>23. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5193":"<p><b>Title</b> Tacrolimus (Topical) / Serotonin Reuptake Inhibitor/Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Serotonin Reuptake Inhibitor/Antagonists may decrease the metabolism of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if nefazodone is initiated/dose increased.</p>\n<div>\n <p><b>Serotonin Reuptake Inhibitor/Antagonists Interacting Members</b> Nefazodone<br><b>Exception</b> TraZODone</p>\n</div> \n<p><b>Discussion</b> Case report. A patient's trough serum tacrolimus concentration increased more than threefold, accompanied by signs and symptoms of tacrolimus toxicity, within 1 week of initiating nefazodone therapy (50 mg twice daily).<sup>1</sup> Evidence of toxicity included headache, confusion, visual disturbances, and a 47% increase in serum creatinine. The patient had been receiving tacrolimus for approximately 2 years without incident. Tacrolimus is metabolized by CYP3A4 isoenzymes. Nefazodone inhibits these same isoenzymes, and thus reduces tacrolimus metabolism.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>2,3,4,5,6,7,8</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>9,10,11,12,13,14,15,16,17,18,19</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olyaei AJ, de Mattos AM, Norman DJ, et al, “Interaction Between Tacrolimus and Nefazodone in a Stable Renal Transplant Recipient,” <i>Pharmacotherapy</i>, 1998, 18:1356-9.</p>\n<p>2. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>3. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 4. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>5. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>6. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>7. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>8. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>9. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>10. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>11. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>12. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>13. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>14. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>15. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>16. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>17. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>18. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>19. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5194":"<p><b>Title</b> Tacrolimus (Topical) / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical). Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if azole antifungals are initiated/dose increased.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> The oral bioavailability of tacrolimus (0.1 mg/kg) was increased approximately 100% in 6 normal subjects following a 12-day course of ketoconazole (200 mg/day).<sup>1</sup> Itraconazole was similarly implicated (case details not available).<sup>2</sup> Serum tacrolimus concentrations increased more than 60% in a liver transplant patient within one day of starting clotrimazole (10 mg 4 times/day), and nearly tripled within 8 days.<sup>3</sup> Subsequent therapy rechallenge confirmed the interaction. The AUC of tacrolimus (0.12 mg/kg single dose) was increased approximately threefold in normal subjects when administered following an 7-day course of voriconazole (400 mg every 12 hours day 1, then 200 mg every 12 hours).<sup>4</sup> Case reports describe this interaction in patients, including an ability to maintain acceptable trough tacrolimus concentrations with reductions in tacrolimus dosing.<sup>5,6</sup><br><br>The systemic azole derivatives likely inhibit intestinal and hepatic CYP3A4 isoenzymes, reducing tacrolimus metabolism and increasing its bioavailability.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>7,8,9,10,11,12,13</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>14,15,16,17,18,19,20,21,22,23,24</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Floren LC, Bekersky I, Benet LZ, et al, “Tacrolimus Oral Bioavailability Doubles With Coadministration of Ketoconazole,” <i>Clin Pharmacol Ther</i>, 1997, 62:41-9.</p>\n<p>2. Katari SR, Magnone M, Shapiro R, et al, “Clinical Features of Acute Reversible Tacrolimus (FK506) Nephrotoxicity in Kidney Transplant Recipients,” <i>Clin Transplant</i>, 1997, 11:237-42.</p>\n<p>3. Mieles L, Venkataramanan R, Yokoyama I, et al, “Interaction Between FK506 and Clotrimazole in a Liver Transplant Recipient,” <i>Transplantation</i>, 1991, 52:1086-7.</p>\n<p>4. Wood N, Tan K, Allan R, et al, “Effect of Voriconazole on the Pharmacokinetics of Tacrolimus,” <i>Intersci Conf Antimicrob Agents Chemother</i>, 2001, 41:2.</p>\n<p>5. Pai MP and Allen S, “Voriconazole Inhibition of Tacrolimus Metabolism,” <i>Clin Infect Dis</i>, 2003, 36:1089-91.</p>\n<p>6. Venkataramanan R, Zang S, Gayowski T, et al, “Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes.” <i>Antimicrob Agents Chemother</i>, 2002, 46(9):3091-3.</p>\n<p>7. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>8. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 9. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>10. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>11. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>12. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>13. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>14. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>15. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>16. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>17. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>18. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>19. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>20. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>21. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>22. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>23. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>24. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5195":"<p><b>Title</b> Tacrolimus (Topical) / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if a protease inhibitor is added/dose increased.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The addition of lopinavir/ritonavir (n=7) or nelfinavir (n=2) to post-liver-transplant patients with stable liver function tests and stable tacrolimus concentrations significantly decreased tacrolimus clearance.<sup>1</sup> Tacrolimus dose requirements were also significantly altered, with lopinavir/ritonavir decreasing tacrolimus dose requirements by 99% and nelfinavir decreasing tacrolimus dose requirements by 75-93%. Efavirenz (n=4) increased tacrolimus clearance but did not substantially impact tacrolimus dose requirements. Similar cases of protease inhibitors having profound effects on tacrolimus dose requirements have been reported both for liver transplant and kidney transplant recipients involving lopinavir, nelfinavir, ritonavir and saquinavir.<sup>2,3,4,5,6</sup> Tacrolimus is metabolized via CYP3A enzymes and subject to transport by p-glycoprotein. Most protease inhibitors are potent inhibitors of CYP3A and inducers of p-glycoprotein. Conversely, efavirenz has been shown to be an inducer of hepatic CYP3A, with little effect on intestinal p-glycoprotein.<sup>7</sup><br><br>One case report describes a dual interaction where lopinavir/ritonavir significantly lowered tacrolimus dose requirement, and tacrolimus significantly increased plasma lopinavir and ritonavir concentrations.<sup>8</sup> Whether this effect is the result of impaired CYP3A metabolism or p-glycoprotein transport, or some other mechanism is unclear.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>9,10,11,12,13,14,15</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>16,17,18,19,20,21,22,23,24,25,26</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Teicher E, Vincent I, Bonhomme-Faivre L, et al, “Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study,” <i>Clin Pharmacokinet</i>, 2007, 46:941-52.</p>\n<p>2. Jain AB, Venkataramanan R, Eghtesad B, et al, “Effect of Coadministered Lopinavir and Ritonavir (Kaletra) on Tacrolimus Blood Concentration in Liver Transplantation Patients,” <i>Liver Transpl</i>, 2003, 9(9):954-60.</p>\n<p>3. Jain AK, Venkataramanan R, Shapiro R, et al, “The Interaction Between Antiretroviral Agents and Tacrolimus in Liver and Kidney Transplant Patients,” <i>Liver Transpl</i>, 2002, 8(9):841-5.</p>\n<p>4. Schvarcz R, Rudbeck G, Soderdahl G, et al, “Interaction Between Nelfinavir and Tacrolimus After Orthoptic Liver Transplantation in a Patient Coinfected With HIV and Hepatitis C virus (HCV),” <i>Transplantation</i>, 2000, 69(10):2194-5.</p>\n<p>5. Sheikh AM, Wolf DC, Lebovics E, et al, “Concomitant Human Immunodeficiency Virus Protease Inhibitor Therapy Markedly Reduces Tacrolimus Metabolism and Increases Blood Levels,” <i>Transplantation</i>, 1999, 68(2):307-9.</p>\n<p>6. Schonder KS, Shullo MA, and Okusanya O, “Tacrolimus and Lopinavir/Ritonavir Interaction in Liver Transplantation,” <i>Ann Pharmacother</i>, 2003, 37(12):1793-6.</p>\n<p>7. Mouly S, Lown KS, Kornhauser D, et al, “Hepatic but Not Intestinal Cyp3a4 Displays Dose-Dependent Induction by Efavirenz in Humans,” <i>Clin Pharmacol Ther</i>, 2002, 72:1-9.</p>\n<p>8. Guaraldi G, Cocchi S, Codeluppi M, et al, “Role of Therapeutic Drug Monitoring in a Patient with Human Immunodeficiency Virus Infection and End-Stage Liver Disease Undergoing Orthotopic Liver Transplantation,” <i>Transplant Proc</i>, 2005, 37:2609-10.</p>\n<p>9. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>10. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 11. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>12. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>13. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>14. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>15. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>16. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>17. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>18. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>19. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>20. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>21. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>22. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>23. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>24. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>25. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>26. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5196":"<p><b>Title</b> Tacrolimus (Topical) / Calcium Channel Blockers (Dihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Calcium Channel Blockers (Dihydropyridine) Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Cilnidipine, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine<br><b>Exception</b> Clevidipine</p>\n</div> \n<p><b>Discussion</b> Case reports. Tacrolimus serum concentrations were increased by 55% over the course of one month of concomitant therapy with nifedipine (30-60 mg/day).<sup>1</sup> In a separate case the dose of tacrolimus required to maintain a therapeutic trough concentration was decreased 80% within 3 weeks of initiating felodipine.<sup>2</sup> The dosage was increased following the discontinuation of felodipine. Felodipine and nifedipine are both considered weak inhibitors of CYP3A4 ([I]/Ki &lt;0.1). The mechanism of these interactions is unknown.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>3,4,5,6,7,8,9</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>10,11,12,13,14,15,16,17,18,19,20</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seifeldin RA, Marcos-Alvarez A, Gordon FD, et al, “Nifedipine Interaction With Tacrolimus in Liver Transplant Recipients,” <i>Ann Pharmacother</i>, 1997, 31:571-5.</p>\n<p>2. Butani L, Berg G, and Makker SP, “Effect of Felodipine on Tacrolimus Pharmacokinetics in a Renal Transplant Recipient,” <i>Transplantation</i>, 2002, 73(1):159-60.</p>\n<p>3. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>4. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 5. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>6. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>7. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>8. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>9. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>10. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>11. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>12. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>13. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>14. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>15. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>16. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>17. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>18. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>19. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>20. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5197":"<p><b>Title</b> Tacrolimus (Topical) / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if diltiazem or verapamil is initiated/dose increased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> DilTIAZem, Verapamil<br><b>Exception</b> Bepridil</p>\n</div> \n<p><b>Discussion</b> Case report. Tacrolimus serum concentrations were increased more than fourfold within 3 days of initiating diltiazem therapy.<sup>1</sup> The increased serum concentration was accompanied by symptoms of tacrolimus toxicity (eg, delirium, agitation). Another case report of increased tacrolimus concentrations involved the use of diltiazem and protease inhibitors (agents known to decrease tacrolimus metabolism).<sup>2</sup> In contrast, a retrospective review of 64 patients receiving diltiazem and tacrolimus failed to demonstrate any clinically significant pharmacokinetic or pharmacodynamic effects.<sup>3</sup> The mechanism is likely related to the ability of diltiazem to inhibit CYP3A4 isoenzymes, thus reducing the metabolism of tacrolimus.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>4,5,6,7,8,9,10</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>11,12,13,14,15,16,17,18,19,20,21</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hebert MF and Lam AY et al, “Diltiazem Increases Tacrolimus Concentrations,” <i>Ann Pharmacother</i>, 1999, 33(6):680-2.</p>\n<p>2. Hardy G, Stanke-Labesque F, Contamin C, et al, “Protease Inhibitors and Diltiazem Increase Tacrolimus Blood Concentration in a Patient With Renal Transplantation: A Case Report,” <i>Eur J Clin Pharmacol</i>, 2004, 60(8):603-5.</p>\n<p>3. Kothari J, Nash M, Zaltzman J, et al, “Diltiazem Use in Tacrolimus-Treated Renal Transplant Recipients,” <i>J Clin Pharm Ther</i>, 2004, 29(5):425-30.</p>\n<p>4. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>5. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 6. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>7. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>8. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>9. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>10. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>11. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>12. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>13. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>14. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>15. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>16. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>17. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>18. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>19. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>20. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>21. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5199":"<p><b>Title</b> Tacrolimus (Topical) / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Several clinical studies (n=15 to 21) have shown that concurrent use of fluconazole with oral tacrolimus is associated with an approximate 40% to 60% reduction in tacrolimus dose requirement and/or with significantly increased tacrolimus blood concentrations.<sup>1,2,3,4</sup> These studies support the conclusions of a case report that described a liver transplant patient receiving tacrolimus who experienced an increase in serum creatinine and tacrolimus concentrations following initiation of fluconazole, both of which resolved after fluconazole discontinuation.<sup>5</sup><br><br>This interaction appears to be both dose- and route-dependent. One study noted a considerable difference in the magnitude of effect on tacrolimus concentrations between fluconazole 100 mg/day and 200 mg/day (1.4-fold vs. 3.1-fold increase in tacrolimus concentrations),<sup>2</sup> and in a retrospective analysis, the use of prophylactic fluconazole (50 mg daily) had no effect on tacrolimus serum concentrations.<sup>6</sup> More importantly, when considering the risk of an interaction with topical tacrolimus, high-dose fluconazole (400 mg/day) was only associated with a minimal impact (average 16% increase) on tacrolimus concentrations in patients receiving IV tacrolimus.<sup>7</sup> Prescribing information for fluconazole suggests no significant interaction exists with IV tacrolimus.<sup>8</sup><br><br>The likely mechanism of this interaction is inhibition of the first-pass metabolism (primarily via CYP3A in the intestine and liver) of oral tacrolimus by fluconazole, resulting in decreased metabolism and increased bioavailability of orally administered tacrolimus.<sup>3,9</sup><br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>10,11,12,13,14,15,16</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>17,18,19,20,21,22,23,24,25,26,27,28</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well. However, due to the absence of intestinal CYP3A4 in the metabolism of transdermally absorbed tacrolimus, the resultant effect when combined with fluconazole is more likely to resemble that of IV tacrolimus (a significantly reduced interaction) than that of oral tacrolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Toda F, Tanabe K, Ito S, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. <i>Transplant Proc</i>. 2002;34(5):1733-1735. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12176555\">[PubMed 12176555]</a></p>\n<p>2. Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. <i>Transplantation</i>. 1994;57(10):1521-1523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7515201\">[PubMed 7515201]</a></p>\n<p>3. Lumlertgul D, Noppakun K, Rojanasthien N, et al. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients. <i>J Med Assoc Thai</i>. 2006;89(suppl 2):S73-S78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17044457\">[PubMed 17044457]</a></p>\n<p>4. Hairhara Y, Makuuchi M, Kawarasaki H, et al. Effect of fluconazole on blood levels of tacrolimus. <i>Transplant Proc</i>. 1999;31(7):2767. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10578284\">[PubMed 10578284]</a></p>\n<p>5. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. <i>Diabete Metab</i>. 1994;20(1):49-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7520007\">[PubMed 7520007]</a></p>\n<p>6. Sikora MB, Truax C, Lee S, et al. Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. <i>Clin Transplant</i>. 2012;26(5):E555-E560. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23061766\">[PubMed 23061766]</a></p>\n<p>7. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. <i>Transplantation</i>. 1996;61(8):1268-1272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8610430\">[PubMed 8610430]</a></p>\n<p>8. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p>9. Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. <i>Res Commun Chem Pathol Pharmacol</i>. 1994;84(1):35-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7518966\">[PubMed 7518966]</a></p>\n<p>10. <i>Protopic</i> (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc; January 2009.</p>\n<p>11. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatits. <i>J Drugs Dermatol</i>. 2007;6(2):185-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 12. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. <i>J Am Acad Dermatol</i>. 2005;53(4):602-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>13. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. <i>J Invest Dermatol</i>. 2005;124(4):695-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>14. Undre NA, Moloney FJ, Ahmadi S, Sevenson P, Murphy GM. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. <i>Br J Dermatol</i>. 2009;160(3):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>15. Rubins A, Gutmane R, Valdmane N, Stevenson P, Foster C, Undre N. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. <i>J Invest Dermatol</i>. 2005;125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>16. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. <i>J Am Acad Dermatol</i>. 1998;38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>17. Kameda G, Kramm C, Stege H, Hermsen D, Krutmann J, Niehues T. Unexpected high serum levels of tacrolimus after a single topical application in an infant. <i>J Pediatr</i>. 2003;143(2):280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>18. Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. <i>Br J Dermatol</i>. 2004;150(5):1052-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>19. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. <i>Lancet</i>. 1996;348(9036):1240-1241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>20. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. <i>Arch Dermatol</i>. 2002;138(9):1259-1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>21. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. <i>Arch Dermatol</i>. 2001;137(6):747-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>22. Pitarch G, Torrijos A, Mahiques L, Sanchez-Carazo JL, Fortea JM. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. <i>Acta Derm Venereol</i>. 2006;86(1):64-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>23. Prot-Labarthe S, Therrien R, Champagne MA, Duval M, Joubert C. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. <i>Bone Marrow Transplant</i>. 2007;40(3):295-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>24. Russel RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. <i>J Pediatr Gastroenterol Nutr</i>. 2001;32(2):207-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>25. Teshima D, Ikesue H, Itoh Y, Urabe K, Furue M, Oishi R. Increased topical tacrolimus absorption in generalized leukemic erythroderma. <i>Ann Pharmacother</i>. 2003;37(10):1444-1447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>26. Beyerler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. <i>Dermatology</i>. 2006;212(3):260-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>27. Conrotto D, Carrozzo M, Ubertalli AV, et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. <i>Transplantation</i>. 2006;82(8):1113-1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p>28. Olson KA, West K, McCarthy PL. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease. <i>Pharmacotherapy</i>. 2014;34(6):e60-e64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24700567\">[PubMed 24700567]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}